<SEC-DOCUMENT>0001178913-22-001678.txt : 20220428
<SEC-HEADER>0001178913-22-001678.hdr.sgml : 20220428
<ACCEPTANCE-DATETIME>20220428160442
ACCESSION NUMBER:		0001178913-22-001678
CONFORMED SUBMISSION TYPE:	DEF 14A
PUBLIC DOCUMENT COUNT:		10
CONFORMED PERIOD OF REPORT:	20220428
FILED AS OF DATE:		20220428
DATE AS OF CHANGE:		20220428

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Chemomab Therapeutics Ltd.
		CENTRAL INDEX KEY:			0001534248
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				813676773
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEF 14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38807
		FILM NUMBER:		22866439

	BUSINESS ADDRESS:	
		STREET 1:		KIRYAT ATIDIM, BUILDING 7
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6158002
		BUSINESS PHONE:		972-77-331-0156

	MAIL ADDRESS:	
		STREET 1:		KIRYAT ATIDIM, BUILDING 7
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6158002

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Anchiano Therapeutics Ltd.
		DATE OF NAME CHANGE:	20180906

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BioCancell Ltd.
		DATE OF NAME CHANGE:	20111104
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEF 14A
<SEQUENCE>1
<FILENAME>zk2227688.htm
<DESCRIPTION>DEF 14A
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: ZKG
         Document created using EDGARfilings PROfile 8.2.0.0
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div id="DSPFPageHeader">
      <div style="line-height: 1.25;">
        <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    </div>
    <div style="margin-left: 5.25pt; line-height: 1.25;"><img width="729" height="7" src="image0.jpg"></div>
    <div style="text-align: center; margin-right: 124.7pt; margin-left: 124.7pt; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">UNITED STATES</div>
    <div style="text-align: center; margin-right: 124.15pt; margin-left: 124.7pt; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">SECURITIES AND EXCHANGE COMMISSION</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; margin-right: 124.2pt; margin-left: 124.7pt; line-height: 1.25; font-weight: bold;">Washington, D.C. 20549</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; margin-right: 124.7pt; margin-left: 124.7pt; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">SCHEDULE 14A INFORMATION</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; margin-right: 124.7pt; margin-left: 124.7pt; line-height: 1.25; font-weight: bold;">Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934</div>
    <div style="text-align: center; margin-right: 124.7pt; margin-left: 124.7pt; line-height: 1.25; font-weight: bold;">(Amendment No.&#160; &#160; )</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="margin-left: 5.3pt; line-height: 1.25;">Filed by the Registrant <font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9746;</font></div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="margin-left: 5.3pt; line-height: 1.25;">Filed by a Party other than the Registrant <font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font></div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="margin-left: 5.3pt; line-height: 1.25;">Check the appropriate box:</div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

          <tr>
            <td style="width: 5.25pt;"><br>
            </td>
            <td style="width: 12.25pt; vertical-align: top; align: right; font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</td>
            <td style="width: auto; vertical-align: top;">
              <div>
                <div style="line-height: 1.25;">Preliminary Proxy Statement</div>
              </div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb49f2679799d4a2b847b43574468c1c2">

        <tr>
          <td style="width: 5.25pt;"><br>
          </td>
          <td style="width: 12.25pt; vertical-align: top; align: right; font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</td>
          <td style="width: auto; vertical-align: top;">
            <div>Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25">
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

          <tr>
            <td style="width: 5.25pt;"><br>
            </td>
            <td style="width: 12.25pt; vertical-align: top; align: right; font-family: 'Segoe UI Symbol', sans-serif;">&#9746;</td>
            <td style="width: auto; vertical-align: top;">
              <div>Definitive Proxy Statement</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z6c02b52df74e4ea082ab872ecff7cffe">

        <tr>
          <td style="width: 5.25pt;"><br>
          </td>
          <td style="width: 12.25pt; vertical-align: top; align: right; font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</td>
          <td style="width: auto; vertical-align: top;">
            <div>Definitive Additional Materials</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd8a2b27d4e044339a7cb21f3796c49b0">

        <tr>
          <td style="width: 5.25pt;"><br>
          </td>
          <td style="width: 12.25pt; vertical-align: top; align: right; font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</td>
          <td style="width: auto; vertical-align: top;">
            <div>Soliciting Material Pursuant to &#167;240.14a-12</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; margin-right: 124.2pt; margin-left: 124.7pt; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Chemomab Therapeutics Ltd.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: 400; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
    <div style="text-align: center; margin-right: 213.05pt; margin-left: 213.7pt; line-height: 1.25; font-weight: bold;">(Name of Registrant as Specified In Its Charter)</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25">
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"> </div>
    <div style="text-align: center; margin-right: 213.1pt; margin-left: 213.7pt; line-height: 1.25; font-weight: bold;">(Name of Person(s) Filing Proxy Statement, if other than the Registrant)</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="margin-left: 5.3pt; line-height: 1.25;">Payment of Filing Fee (Check the appropriate box):</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25">
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

          <tr>
            <td style="width: 5.25pt;"><br>
            </td>
            <td style="width: 12.25pt; vertical-align: top; align: right; font-family: 'Segoe UI Symbol', sans-serif;">&#9746;</td>
            <td style="width: auto; vertical-align: top;">
              <div>No fee required.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z5620eafdf44f4ba591c729366436403e">

        <tr>
          <td style="width: 5.25pt;"><br>
          </td>
          <td style="width: 12.25pt; vertical-align: top; align: right; font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</td>
          <td style="width: auto; vertical-align: top;">
            <div>Fee paid previously with preliminary materials.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z11f97f3c22f9441d9322e22e33be1757">

        <tr>
          <td style="width: 5.25pt;"><br>
          </td>
          <td style="width: 12.25pt; vertical-align: top; align: right; font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</td>
          <td style="width: auto; vertical-align: top;">
            <div>Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.</div>
          </td>
        </tr>

    </table>
    <div id="DSPFPageHeader">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="margin-left: 5.3pt; line-height: 1.25;"><img width="114" height="35" src="image1.jpg"></div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="margin-left: 5.3pt; line-height: 1.25;">April 28, 2022</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; margin-left: 5.3pt; line-height: 1.25;">Dear Shareholder,</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 25.5pt; margin-right: 10.85pt; margin-left: 5.3pt; line-height: 1.25;">You are cordially invited to attend the 2022 annual general meeting of the shareholders (the &#8220;Annual General Meeting&#8221;) of Chemomab
      Therapeutics Ltd. (&#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;Chemomab&#8221; or the &#8220;Company&#8221; or &#8220;our company&#8221;) to be held at 4:30 p.m., local time, on June 7, 2022, at Meitar | Law Offices, located at 16 Abba Hillel Road, 10th floor, Ramat Gan 5250608, Israel.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 25.5pt; margin-left: 5.3pt; line-height: 1.25;">At the Annual General Meeting, shareholders will vote on the matters listed in the enclosed Notice of Annual General Meeting of Shareholders. We look forward
      to greeting personally those shareholders who are able to be present at the Annual General Meeting; however, whether or not you plan to attend in person, it is important that your shares be represented. Holders of our American Depositary Shares
      (&#8220;ADSs&#8221;) will receive voting instruction cards either electronically or by physical mail, depending on the delivery instructions such holder has provided to its bank or broker. Please promptly vote your shares by marking, signing, dating and
      returning the voting instruction card in the enclosed envelope or by submitting your voting instructions online or by phone (if permitted to do so, as described in the voting instruction card that you receive).</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 25.5pt; margin-right: 10.85pt; margin-left: 5.3pt; line-height: 1.25;">Your vote is important, whether or not you attend the meeting in person. We encourage you to vote by proxy so that your shares will be
      represented and voted at the meeting. If you decide to attend the meeting and vote in person, your proxy may be revoked at your request.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; margin-left: 30.8pt; line-height: 1.25;">Thank you for your cooperation and continued support.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; margin-left: 5.3pt; line-height: 1.25;">Sincerely,</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="margin-right: 489.25pt; margin-left: 5.3pt; line-height: 1.25;"><u>/s/ Dale Pfost</u></div>
    <div style="margin-right: 489.25pt; margin-left: 5.3pt; line-height: 1.25;">Dale Pfost</div>
    <div style="margin-right: 489.25pt; margin-left: 5.3pt; line-height: 1.25;">Chairman of the Board, Chief Executive Officer</div>
    <div style="margin-right: 489.25pt; margin-left: 5.3pt; line-height: 1.25;"> <br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><img width="172" height="55" src="image2.jpg"></div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; text-indent: -56.35pt; margin-right: 150.8pt; margin-left: 208.85pt; line-height: 1.25; font-weight: bold;">NOTICE OF ANNUAL GENERAL MEETING OF</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; text-indent: -56.35pt; margin-right: 150.8pt; margin-left: 208.85pt; line-height: 1.25; font-weight: bold;">SHAREHOLDERS TO BE HELD ON JUNE 7, 2022</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="margin-left: 5.3pt; line-height: 1.25;">To the Shareholders of Chemomab Therapeutics Ltd.:</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="margin-left: 30.8pt; line-height: 1.25;">The Annual General Meeting of Shareholders of Chemomab Therapeutics Ltd. will be held at the following time, date and place for the following purpose:</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="margin-right: 444.6pt; margin-left: 5.3pt; line-height: 1.25;">TIME:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;4:30 p.m. local time </div>
    <div style="margin-right: 444.6pt; margin-left: 5.3pt; line-height: 1.25;"> <br>
    </div>
    <div style="margin-right: 444.6pt; margin-left: 5.3pt; line-height: 1.25;">DATE:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;June 7, 2022</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="margin-right: 224.85pt; margin-left: 5.3pt; line-height: 1.25;">PLACE:&#160;&#160;&#160;&#160;&#160;&#160;&#160; Meitar | Law Offices, located at 16 Abba Hillel Road, 10th floor, Ramat Gan 5250608, Israel</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="margin-right: 270.9pt; margin-left: 5.3pt; line-height: 1.25;">PURPOSE:</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; margin-left: 5.3pt; line-height: 1.25;">The agenda for the Annual General Meeting is as follows:</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z2c8282ea61ec4c70bf51bda89285610e">

        <tr>
          <td style="width: 56.15pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; align: right;">1.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Election of two Class I directors to serve on our board of directors for a term of three years or until their successors are elected and qualified, for which Dr. Nissim Darvish and Joel Maryles are the nominees.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z62fe1cd7a2c042d292493309e3f05b55">

        <tr>
          <td style="width: 56.15pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; align: right;">2.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Approval of an amendment to the terms of compensation of Dr. Adi Mor, the Company&#8217;s Co-Founder, Chief Scientific Officer and Class III Director.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z25c0b3fa132443fc9d0d151f62589f57">

        <tr>
          <td style="width: 56.15pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; align: right;">3.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Approval of additional equity grants to certain of the Company's directors and certain changes to the Company&#8217;s director compensation package, all in compliance with the Company's Compensation Policy.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z3561655ed6a64a308055736f1176a8ac">

        <tr>
          <td style="width: 56.15pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; align: right;">4.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Ratification of the appointment of Somekh Chaikin, a Member Firm of KPMG International, as our independent registered public accounting firm for the year ending December 31, 2022.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; margin-left: 30.8pt; line-height: 1.25;">In addition, shareholders will consider the Company&#8217;s audited financial statements for the year ended December&#160;31, 2021.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; margin-left: 30.8pt; line-height: 1.25;">The foregoing proposals are described more fully in the enclosed proxy statement, which we urge you to read in its entirety.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 25.5pt; margin-left: 5.3pt; line-height: 1.25;">The affirmative vote of the holders of a majority of the voting power represented at the Annual General Meeting in person or by proxy and voting thereon is
      necessary for the approval of each proposal.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 25.5pt; margin-right: 10.85pt; margin-left: 5.3pt; line-height: 1.25;">Shareholders of record at the close of business on April 28, 2022 are entitled to vote at the Annual General Meeting. A list of
      shareholders of record will be available at the Annual General Meeting and, during the 10 days prior to the Annual General Meeting, at the office of our Corporate Secretary (or, in the absence thereof, by the Chief Executive Officer of the Company)
      at our registered office in Israel, Kiryat Atidim, Building 7, Tel Aviv, 6158002, Israel.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 15.4pt; margin-right: 6.3pt; margin-left: 5.3pt; line-height: 1.25; font-weight: bold;">Please sign, date and promptly return the enclosed voting instruction card or proxy card in the enclosed envelope or
      submit your voting instructions online or by phone (if permitted to do so, as described in the voting instruction card that you receive) so that your shares will be represented whether or not you attend the Annual General Meeting.</div>
    <div style="line-height: 1.25"> <br>
    </div>
    <div style="line-height: 1.25;">
      <table cellspacing="0" cellpadding="0" border="0" id="z11083920734b4f2fa36997f387d84878" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;">

          <tr>
            <td style="width: 50%; font-family: 'Times New Roman',Times,serif; text-align: left;">
              <div>&#160;
                <div><u>/s/ Dale Pfost</u></div>
                <div>Dale Pfost</div>
                <div>Chairman of the Board, </div>
                <div>Chief Executive Officer</div>
              </div>
            </td>
            <td style="width: 50%; text-align: left; vertical-align: top;">
              <div>BY ORDER OF THE BOARD OF DIRECTORS</div>
              <div> <br>
              </div>
              <div>April 28, 2022 </div>
            </td>
          </tr>

      </table>
    </div>
    <br>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="margin-left: 279pt; line-height: 1.25;"><br>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: center; margin-right: 124.2pt; margin-left: 124.7pt; line-height: 1.25; font-weight: bold;">CHEMOMAB THERAPEUTICS LTD.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; margin-right: 241.7pt; margin-left: 242.3pt; line-height: 1.25; font-weight: bold;">Kiryat Atidim, </div>
      <div style="text-align: center; margin-right: 241.7pt; margin-left: 242.3pt; line-height: 1.25; font-weight: bold;">Building 7 Tel Aviv, </div>
      <div style="text-align: center; margin-right: 241.7pt; margin-left: 242.3pt; line-height: 1.25; font-weight: bold;">Israel 6158002</div>
      <div style="text-align: center; margin-right: 124.2pt; margin-left: 124.7pt; line-height: 1.25; font-weight: bold;">+972-77-331-0156<br>
        <u>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </u><br>
      </div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; margin-right: 183.75pt; margin-left: 184.4pt; line-height: 1.25; font-weight: bold;">PROXY STATEMENT FOR CHEMOMAB </div>
      <div style="text-align: center; margin-right: 183.75pt; margin-left: 184.4pt; line-height: 1.25; font-weight: bold;">THERAPEUTICS LTD. ANNUAL GENERAL MEETING </div>
      <div style="text-align: center; margin-right: 183.75pt; margin-left: 184.4pt; line-height: 1.25; font-weight: bold;">OF SHAREHOLDERS</div>
      <div style="text-align: center; margin-right: 124.2pt; margin-left: 124.7pt; line-height: 1.25; font-weight: bold;">TO BE HELD ON JUNE 7, 2022</div>
      <div style="line-height: 1.25; text-align: center;">&#160;<u>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </u></div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; margin-right: 124.2pt; margin-left: 124.7pt; line-height: 1.25; font-weight: bold;">GENERAL INFORMATION ABOUT THE ANNUAL GENERAL MEETING</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="margin-left: 5.3pt; line-height: 1.25; font-weight: bold;">Why Did You Send Me this Proxy Statement?</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 25.5pt; margin-right: 5.8pt; margin-left: 5.3pt; line-height: 1.25;">We sent you this proxy statement and the enclosed proxy card because the board of directors (the &#8220;Board&#8221;) of Chemomab Therapeutics Ltd.
        (&#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; the &#8220;Company,&#8221; &#8220;our company&#8221; or &#8220;Chemomab&#8221;) is soliciting your proxy to vote at the Annual General Meeting of Shareholders (the &#8220;Annual General Meeting&#8221;) and any adjournments of the Annual General Meeting to be held at 4:30
        p.m., local time, on June 7, 2022 at Meitar | Law Offices, located at 16 Abba Hillel Road, 10th floor, Ramat Gan 5250608, Israel. This proxy statement, along with the accompanying Notice of Annual General Meeting of Shareholders, summarizes the
        purpose of the Annual General Meeting and the information you need to know to vote at the Annual General Meeting. We anticipate that on or about May 4, 2022, we will begin sending this proxy statement, the attached Notice of Annual General Meeting
        and the form of proxy enclosed to all shareholders entitled to vote at the Annual General Meeting.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; margin-left: 5.3pt; line-height: 1.25; font-weight: bold;">Who Can Vote?</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 25.5pt; margin-right: 8.9pt; margin-left: 5.3pt; line-height: 1.25;">Only holders of record of ordinary shares or ADSs representing the Company&#8217;s ordinary shares (collectively, the &#8220;Shares&#8221;) on April 28,
        2022 (the &#8220;record date&#8221;) are entitled to vote at the Annual General Meeting. On the record date, there were 228,090,300 ordinary shares (equivalent to 11,404,515 ADSs) outstanding and entitled to vote.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 25.5pt; margin-left: 5.3pt; line-height: 1.25;">You do not need to attend the Annual General Meeting to vote your Shares. Shares represented by valid proxies, received in time for the Annual General
        Meeting and not revoked prior to the Annual General Meeting, will be voted at the Annual General Meeting.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; margin-left: 5.3pt; line-height: 1.25; font-weight: bold;">How Many Votes Do I Have?</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; margin-left: 30.8pt; line-height: 1.25;">Each ordinary share that you own entitles you to one vote. Each ADS represents twenty (20) of our ordinary shares.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; margin-left: 5.3pt; line-height: 1.25; font-weight: bold;">How Do I Vote?</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 25.5pt; margin-right: 10.85pt; margin-left: 5.3pt; line-height: 1.25;">Whether you plan to attend the Annual General Meeting or not, we urge you to vote by proxy. Voting by proxy will not affect your
        right to attend the Annual General Meeting.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 25.5pt; margin-right: 10.85pt; margin-left: 5.3pt; line-height: 1.25;">If your Shares are registered directly in your name through our transfer agent, or you have share certificates, and you are a
        shareholder of record, you may vote:</div>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="ze4707537a68346a1951723c14ce75373">

          <tr>
            <td style="width: 19.6pt;"><br>
            </td>
            <td style="width: 19.15pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">By mail. </font>Complete, date, sign and mail the enclosed proxy card in the enclosed postage prepaid envelope. Your proxy will be voted in accordance with your instructions. If you sign the proxy card
                but do not specify how you want your Shares voted, they will be voted as recommended by our Board.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z971fa663acc94e8ca164da1ccdba595b">

          <tr>
            <td style="width: 19.6pt;"><br>
            </td>
            <td style="width: 19.15pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">In person at the meeting. </font>If you attend the Annual General Meeting, you may deliver your completed proxy card in person or you may vote by completing a ballot, which will be available at the
                Annual General Meeting.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 25.5pt; margin-right: 8.9pt; margin-left: 5.3pt; line-height: 1.25;">If your ADSs are held in &#8220;street name&#8221; (held in the name of a bank, broker or other nominee), you must provide the bank, broker or
        other nominee with instructions on how to vote your Shares and can generally do so as follows:</div>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z3298e59697ca41d7a48849371b2cee83">

          <tr>
            <td style="width: 19.6pt;"><br>
            </td>
            <td style="width: 19.15pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">By mail. </font>You will receive instructions from your broker or other nominee explaining how to instruct them to vote your Shares.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd96163096aa046edbc4b14bc673b7c94">

          <tr>
            <td style="width: 19.6pt;"><br>
            </td>
            <td style="width: 19.15pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-weight: bold;">By Phone and/or Online.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z1e85ae37675443bbb8b5feab851fb1eb">

          <tr>
            <td style="width: 19.6pt;"><br>
            </td>
            <td style="width: 36.7pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-style: italic;">Beneficial Holders </font>can complete and submit voting instructions online at www.ProxyVote.com, in accordance with the instructions provided on the voting instruction card that you receive, or by
                calling 1-800-454-8683.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zc02a37b5966d422586b4c550801434eb">

          <tr>
            <td style="width: 19.6pt;"><br>
            </td>
            <td style="width: 36.7pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-style: italic;">Registered Holders </font>can complete and submit voting instructions online at www.proxypush.com/CMMB in accordance with the instructions on the voting instruction card you receive.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z6d9969e2400f47ae9a6066392c67b129">

          <tr>
            <td style="width: 19.6pt;"><br>
            </td>
            <td style="width: 19.15pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">In person at the Annual General Meeting. </font>Contact the broker or other nominee who holds your Shares to obtain a broker&#8217;s proxy card and bring it with you to the Annual General Meeting. You will not
                be able to vote at the Annual General Meeting unless you have a proxy card from your broker.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="line-height: 1.25"> <br>
      </div>
      <div style="margin-left: 5.3pt; line-height: 1.25; font-weight: bold;">What am I Voting On?</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; margin-left: 5.3pt; line-height: 1.25;">You are voting on:</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zc67f68ba1e7145f0a85c40adf3c26498">

          <tr>
            <td style="width: 56.15pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right;">1.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Election of two Class I directors to serve on our Board for a term of three years or until their successors are elected and qualified, for which Nissim Darvish and Joel Maryles are the nominees.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z0e79ebed07bd4db986c6037e784da359">

          <tr>
            <td style="width: 56.15pt;"><br>
            </td>
            <td style="width: 17.85pt; vertical-align: top; align: right;">2.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Approval of an amendment to the terms of compensation of Dr. Adi Mor, the Company&#8217;s Co-Founder, Chief Scientific Officer, and Class III Director.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z5eab5d1327564610b0d50acc8850b196">

          <tr>
            <td style="width: 56.15pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right;">3.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Approval of additional equity grants to certain of the Company's directors and certain changes to the Company&#8217;s director compensation package, all in compliance with the Company's Compensation Policy.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z29d887ca009542c598ba062cc0dc8373">

          <tr>
            <td style="width: 56.15pt;"><br>
            </td>
            <td style="width: 17.85pt; vertical-align: top; align: right;">4.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Ratification of the appointment of Somekh Chaikin, a Member Firm of KPMG International, as our independent registered public accounting firm for the year ending December 31, 2022.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 25.5pt; margin-right: 10.85pt; margin-left: 5.3pt; line-height: 1.25;">You will also be voting on any other business as may properly come before the Annual General Meeting or any adjournments,
        postponements, or continuations thereof.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="margin-left: 5.3pt; line-height: 1.25; font-weight: bold;">How does the Board Recommend that I Vote at the Annual General Meeting?</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; margin-left: 5.3pt; line-height: 1.25;">The Board recommends that you vote as follows:</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z143b0fe100b742afaf6841c24334f9ca">

          <tr>
            <td style="width: 19.6pt;"><br>
            </td>
            <td style="width: 12.8pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>&#8220;<font style="font-weight: bold;">FOR</font>&#8221; the proposals to elect Messrs. Darvish and Maryles to the Board;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z7e5885ca77774037821ac346c342d5f1">

          <tr>
            <td style="width: 19.6pt;"><br>
            </td>
            <td style="width: 12.8pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">"FOR</font>&#8221; the proposal to approve an amendment to the terms of compensation of Dr. Adi Mor, the Company&#8217;s Co-Founder, Chief Scientific Officer, and Class III Director;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z4dfac21476a24d1e95211024950b5acf">

          <tr>
            <td style="width: 19.6pt;"><br>
            </td>
            <td style="width: 12.8pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">"FOR</font>&#8221; the proposal to approve additional equity grants to certain of the Company's directors and certain changes to the Company&#8217;s director compensation package, all in compliance with the Company's
                Compensation Policy;&#160; and</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb0c6515e76fe42c985f54b66638ceb42">

          <tr>
            <td style="width: 19.6pt;"><br>
            </td>
            <td style="width: 12.8pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>&#8220;<font style="font-weight: bold;">FOR</font>&#8221; the proposal to ratify the appointment of Somekh Chaikin, a Member Firm of KPMG International, as our independent registered public accounting firm for the year ending December 31, 2022.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 25.5pt; margin-right: 5.8pt; margin-left: 5.3pt; line-height: 1.25;">If any other matter is properly presented at the Annual General Meeting or any adjournment, the proxy card provides that your Shares
        will be voted by the proxy holder listed on the proxy card in accordance with his or her best judgment. At the time this proxy statement was printed, we knew of no matters that needed to be acted on at the Annual General Meeting, other than those
        discussed in this proxy statement.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="margin-left: 5.3pt; line-height: 1.25; font-weight: bold;">What Constitutes a Quorum for the Annual General Meeting?</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 25.5pt; margin-right: 16.95pt; margin-left: 5.3pt; line-height: 1.25;">
        <div style="text-indent: 36pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">Due to the Nasdaq listing rules applicable to our company, of the 228,090,300 ordinary shares (equivalent to 11,404,515 ADSs) outstanding as
          of the record date, the holders of at least 33 1/3% of those ordinary shares, or at least 76,030,100 ordinary shares (equivalent to 3,801,505 ADSs), must be present at the meeting in person or represented by proxy to hold the meeting and conduct
          business. Once a quorum is established at a meeting, it shall not be broken by the withdrawal of enough votes to leave less than a quorum. Shares held by shareholders of record who are present at the meeting in person or by proxy are counted for
          purposes of determining whether a quorum exists. Abstentions and &#8220;broker non-votes&#8221; are also counted as present for purposes of determining whether a quorum exists. If a quorum is not present, the meeting will be adjourned until a quorum is
          obtained.</div>
      </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="margin-left: 5.3pt; line-height: 1.25; font-weight: bold;">What are &#8220;broker non-votes&#8221; and what effect do they have on the proposals?</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 25.5pt; margin-right: 16.95pt; margin-left: 5.3pt; line-height: 1.25;">Broker non-votes occur when a broker, bank, or other nominee holds shares in &#8220;street name&#8221; for a beneficial owner and that nominee
        does not vote the shares because it (i) has not received voting instructions from the beneficial owner and (ii) lacks discretionary voting power to vote those shares with respect to a particular proposal. Broker non-votes are counted for purposes
        of determining whether or not a quorum exists for the transaction of business but will not be counted as votes cast &#8220;for&#8221; or &#8220;against&#8221; any proposal and will have no effect on the voting results for any proposal.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 25.5pt; margin-right: 16.95pt; margin-left: 5.3pt; line-height: 1.25;">A broker is entitled to vote shares held for a beneficial owner on &#8220;routine&#8221; matters without instructions from the beneficial owner
        of those shares, which include the proposal to ratify Somekh Chaikin, a Member Firm of KPMG International, as our independent registered public accounting firm for the year ending December 31, 2022. On the other hand, absent instructions from the
        beneficial owner of such shares, a broker is not entitled to vote shares held for a beneficial owner on &#8220;non-routine&#8221; matters, which include all other proposals described in this proxy statement.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 25.5pt; margin-right: 16.95pt; margin-left: 5.3pt; line-height: 1.25;">If you hold your shares in street name, it is critical that you provide your broker, bank, or other nominee with instructions on how
        to cast your vote if you want it to count in the election of directors (Proposal No. 1), the approval of the amendment to the terms of compensation of Dr. Adi Mor (Proposal No. 2), and the approval of additional equity grants to certain of our
        directors and certain changes to our directors&#8217; compensation package (Proposal No. 3) described in this proxy statement. If you hold your shares in street name, and you do not instruct your broker, bank, or other nominee how to vote, then it will
        not be voted for any of Proposals 1, 2 or 3.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 25.5pt; margin-right: 16.95pt; margin-left: 5.3pt; line-height: 1.25;">If any other routine matters are properly brought before the annual meeting in addition to Proposal No. 4, then brokers holding
        shares in street name may vote those shares in their discretion for any such routine matters.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="margin-left: 5.3pt; line-height: 1.25; font-weight: bold;">What are the Voting Requirements to Approve the Proposals?</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 25.5pt; margin-right: 27.55pt; margin-left: 5.3pt; line-height: 1.25;">You may vote &#8220;FOR,&#8221; &#8220;AGAINST&#8221; or &#8220;ABSTAIN&#8221; on the proposal to elect Messrs. Darvish and Maryles to the Board.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 25.5pt; margin-right: 27.55pt; margin-left: 5.3pt; line-height: 1.25;">You may vote &#8220;FOR,&#8221; &#8220;AGAINST&#8221; or &#8220;ABSTAIN&#8221; on the proposal to approve the amended terms of compensation of Dr. Adi Mor, the Company&#8217;s
        Chief Scientific Officer and Class III Director.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="line-height: 1.25">&#160;
        <div style="text-align: justify; text-indent: 25.5pt; margin-right: 27.55pt; margin-left: 5.3pt; line-height: 1.25;">You may vote &#8220;FOR,&#8221; &#8220;AGAINST&#8221; or &#8220;ABSTAIN&#8221; on the proposal to approve additional equity grants to certain of the Company's
          directors and certain changes to the Company&#8217;s director compensation package, all in compliance with the Company's Compensation Policy.</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-align: justify; text-indent: 25.5pt; margin-right: 27.55pt; margin-left: 5.3pt; line-height: 1.25;">You may vote &#8220;FOR,&#8221; &#8220;AGAINST&#8221; or &#8220;ABSTAIN&#8221; on the proposal to ratify the appointment of Somekh Chaikin, a Member Firm of KPMG
          International, as our independent registered public accounting firm for the year ending December 31, 2022.</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-align: justify; text-indent: 25.5pt; margin-right: 14.4pt; margin-left: 5.3pt; line-height: 1.25;">The affirmative vote of the holders of a majority of the voting power represented at the Annual General Meeting in person or by
          proxy and voting thereon is necessary for the approval of each proposal above.&#160; This means that the numbers of shares voted &#8220;For&#8221; the proposal must exceed the numbers of shares voted &#8220;Against&#8221; the proposal. Abstentions and broker&#160;non-votes&#160;are
          not considered votes cast for this purpose, and will have no effect on the vote.</div>
        <div style="text-align: justify; text-indent: 25.5pt; margin-right: 14.4pt; margin-left: 5.3pt; line-height: 1.25;"> <br>
        </div>
      </div>
      <div style="margin-left: 5.3pt; line-height: 1.25; font-weight: bold;">How are My Votes Cast when I Sign and Return a Voting Instruction Card or Proxy Card?</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 25.5pt; margin-right: 5.75pt; margin-left: 5.3pt; line-height: 1.25;">When you sign and submit a voting instruction card, you instruct your broker (or nominee that holds your ADSs of record) to vote your
        ADSs in a certain manner. When you sign a proxy card, you appoint Dale Pfost, our Chief Executive Officer, and Donald Marvin, our Chief Financial Officer, as your representatives at the Annual General Meeting. Your broker (or other nominee), in the
        case of ADSs held in street name, or Mr. Pfost and Mr. Marvin, in the case of Shares held by record shareholders, will ensure that your Shares are voted at the Annual General Meeting as you have instructed them on the voting instruction card or
        proxy card (as applicable). Each of such persons may appoint a substitute for himself.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 25.5pt; margin-right: 10.85pt; margin-left: 5.3pt; line-height: 1.25;">Even if you plan to attend the Annual General Meeting, it is a good idea to complete, sign and return your voting instruction card or
        proxy card in advance of the Annual General Meeting in case your plans change. This way, your Shares will be voted by you whether or not you actually attend the Annual General Meeting.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="margin-left: 5.3pt; line-height: 1.25; font-weight: bold;">May I Revoke My Proxy?</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 25.5pt; margin-right: 5.8pt; margin-left: 5.3pt; line-height: 1.25;">Shareholders may revoke the authority granted by their execution of proxies before the effective exercise thereof by filing with the
        Company a written notice of revocation or duly executed proxy bearing a later date, or by voting in person at the Annual General Meeting. However, if a shareholder attends the Annual General Meeting and does not elect to vote in person, his or her
        proxy will not be revoked. Unless otherwise indicated on the form of proxy, if a proxy is properly executed and received by the Company prior to the Annual General Meeting, Shares represented by the proxy will be voted in favor of the matter to be
        presented to the Annual General Meeting, as described above.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="margin-left: 5.3pt; line-height: 1.25; font-weight: bold;">What if I Receive More than One Proxy Card?</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 25.5pt; margin-right: 6.3pt; margin-left: 5.3pt; line-height: 1.25;">You may receive more than one proxy card or voting instruction form if you hold Shares in more than one account, which may be in
        registered form or held in street name. Please vote in the manner described under &#8220;How Do I Vote?&#8221; for each account to ensure that all of your Shares are voted.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="margin-left: 5.3pt; line-height: 1.25; font-weight: bold;">What if I do not Vote for the Matters Listed on My Proxy Card?</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 25.5pt; margin-left: 5.3pt; line-height: 1.25;">On all matters considered at the Annual General Meeting, abstentions of a holder of Shares will be treated as neither a vote &#8220;for&#8221; nor a vote &#8220;against&#8221; the
        matter, although they will be counted in determining if a quorum is present.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="margin-left: 5.3pt; line-height: 1.25; font-weight: bold;">Will My Shares be Voted if I do not Return My Proxy Card and do not Attend the Annual General Meeting?</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 25.5pt; margin-left: 5.3pt; line-height: 1.25;">If your Shares are registered in your name or if you have share certificates, they will not be voted if you do not return your proxy card by mail or vote at
        the meeting as described above under &#8220;How Do I Vote?&#8221;.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 25.5pt; margin-right: 5.8pt; line-height: 1.25;">&#160; If your Shares are held in street name and you do not provide voting instructions to the bank, broker or other nominee that holds your Shares as
        described above under &#8220;How Do I Vote?,&#8221; the bank, broker or other nominee has the authority to vote your Shares on certain routine matters scheduled to come before the meeting even if it does not receive instructions from you. See &#8220;What are &#8220;broker
        non-votes&#8221; and what effect do they have on the proposals?&#8221; We encourage you to provide voting instructions. This ensures your Shares will be voted at the meeting in the manner you desire.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="margin-left: 5.3pt; line-height: 1.25; font-weight: bold;">Is Voting Confidential?</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 25.5pt; margin-right: 10.85pt; margin-left: 5.3pt; line-height: 1.25;">Yes. Only the inspector of elections and our employees who have been assigned the responsibility for overseeing the legal aspects of
        the Annual General Meeting will have access to your proxy card. The inspector of elections will tabulate and certify the vote. Any comments written on the proxy card will remain confidential unless you ask that your name be disclosed.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="margin-left: 5.3pt; line-height: 1.25; font-weight: bold;">What are the Costs of Soliciting these Proxies?</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-indent: 25.5pt; margin-right: 7.15pt; margin-left: 5.3pt; line-height: 1.25;">We will pay all of the costs of soliciting these proxies. Our officers, directors and employees may solicit proxies in person or by telephone, fax or
        email. We will pay these employees and directors no additional compensation for these services. We will ask banks, brokers and other institutions, nominees and fiduciaries to forward these proxy materials to their principals and to obtain authority
        to execute proxies. We will then reimburse them for their expenses.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; margin-left: 5.3pt; line-height: 1.25; font-weight: bold;">Could other Matters be Decided at the Annual General Meeting?</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 25.5pt; margin-left: 5.3pt; line-height: 1.25;">We do not know of any other matters that will be considered at the Annual General Meeting. If any other matters arise at the Annual General Meeting at or by
        the direction of the Board, the proxies will be voted at the discretion of the proxy holders.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; margin-left: 5.3pt; line-height: 1.25; font-weight: bold;">What Happens if the Annual General Meeting is Postponed or Adjourned?</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; margin-left: 30.8pt; line-height: 1.25;">Your proxy will still be valid and may be voted at the postponed or adjourned meeting. You will still be able to change or revoke your proxy until it is voted.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="margin-left: 5.3pt; line-height: 1.25; font-weight: bold;">What are the Implications of the Company being an Emerging Growth Company and a Smaller Reporting Company?</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 25.5pt; margin-right: 10.85pt; margin-left: 5.3pt; line-height: 1.25;">We are an &#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;) and a &#8220;smaller
        reporting company,&#8221; as defined in Rule 12b-2 under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). As an emerging growth company and a smaller reporting company, we provide in this proxy statement the scaled disclosure
        permitted under the JOBS Act and otherwise as applicable to smaller reporting companies. In addition, as an emerging growth company, we are not required to conduct votes seeking shareholder approval on an advisory basis of (1) the compensation of
        our &#8220;named executive officers&#8221; or the frequency with which such votes must be conducted or (2) compensation arrangements and understandings in connection with merger transactions, known as &#8220;golden parachute&#8221; arrangements.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="margin-left: 5.3pt; line-height: 1.25; font-weight: bold;">Where can I find the voting results of the Annual General Meeting?</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 25.5pt; margin-right: 10.85pt; margin-left: 5.3pt; line-height: 1.25;">We will announce the results for the proposals voted upon at the Annual General Meeting and publish final detailed voting results in
        a Form&#160;8-K filed within four business days following the Annual General Meeting.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="margin-left: 5.3pt; line-height: 1.25; font-weight: bold;">Where can I find additional copies of this proxy statement?</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 25.5pt; margin-right: 10.85pt; margin-left: 5.3pt; line-height: 1.25;">Copies of this proxy statement are available on our website at https://www.chemomab.com/, under the Investor Relations tab (click on
        the &#8220;Investor Relations&#8221; link), and on the SEC website, <font style="font-style: italic;">www.sec.gov</font>.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; margin-right: 124.2pt; margin-left: 124.7pt; line-height: 1.25; font-weight: bold;">COMPANY BACKGROUND</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; margin-left: 5.3pt; line-height: 1.25; font-style: italic; font-weight: bold;">Company Overview</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 30.7pt; margin-left: 5.3pt; line-height: 1.25;">Chemomab is a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory
        diseases with high unmet needs. Based on the unique and pivotal role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody designed to bind and block CCL24 activity. CM-101 has
        demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 30.7pt; margin-left: 5.3pt; line-height: 1.25;">Chemomab has pioneered the therapeutic targeting of CCL24, a chemokine that promotes various types of cellular processes that regulate inflammatory and
        fibrotic activities through the CCR3 receptor. The chemokine is expressed in various types of cells, including immune cells, endothelial cells and epithelial cells. We have developed a novel CCL24 inhibiting product candidate with dual
        anti-fibrotic and anti-inflammatory activity that modulates the complex interplays of both of these inflammatory and fibrotic mechanisms that drive abnormal states of fibrosis and clinical fibrotic diseases. This innovative approach is being
        developed for difficult to treat rare diseases, also known as orphan indications or diseases, such as primary sclerosing cholangitis, or PSC and systemic sclerosis, or SSc, for which patients have no established disease modifying standard of care
        treatment options.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 30.7pt; margin-left: 5.3pt; line-height: 1.25;">CM-101, the Company&#8217;s lead clinical product candidate, is a first-in-class humanized monoclonal antibody that hinders the basic function of the soluble
        chemokine CCL24, also known as eotaxin-2, as a regulator of major inflammatory and fibrotic pathways. We have demonstrated that CM-101 interferes with the underlying biology of inflammation and fibrosis through a novel and differentiated mechanism
        of action. Based on these findings, Chemomab is actively advancing CM-101 into Phase 2 clinical studies directed toward two distinct clinical indications including patients with liver, skin, and/or lung fibrosis. We are currently conducting a Phase
        2 clinical study in PSC, a rare obstructive and cholestatic liver disease.&#160; The study is actively recruiting patients in Europe and Israel and is being expanded by adding additional dosing arms as well as an open label extension. The Company also
        plans to extend the trial by adding new territories with significant recruitment potential. In addition, we are planning to initiate a Phase 2 clinical trial in SSc in the second half of 2022. The trial in SSc, a rare autoimmune rheumatic disease
        characterized by fibrosis in the skin and the lung, will focus on establishing biological and clinical proof of concept in this patient population following treatment with CM-101. Although our primary focus relates to these two rare indications, an
        additional Phase 2 clinical study is currently enrolling patients with liver fibrosis derived due to non-alcoholic steatohepatitis, or NASH. This trial will provide important safety and PK data that will support the development of a CM-101
        subcutaneous formulation and results are expected by the end of the year.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 30.7pt; margin-left: 5.3pt; line-height: 1.25;">Fibrosis is the abnormal and excessive accumulation of collagen and extracellular matrix, the non-cellular component in all tissues and organs, that
        provides structural and biochemical support to surrounding cells. When present in excessive amounts, collagen and extracellular matrix lead to scarring and thickening of connective tissues, affecting tissue properties and potentially leading to
        organ failure. Fibrosis can occur in many different tissues, including lung, liver, kidney, muscle, skin, and the gastrointestinal tract, resulting in a wide array of progressive fibrotic conditions. Fibrosis and inflammation are intrinsically
        linked. While a healthy inflammatory response is necessary for efficient tissue repair; after disease or injury, an excessive, uncontrolled inflammatory response can lead to tissue fibrosis.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED SHAREHOLDER MATTERS</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="margin-left: 30.8pt; line-height: 1.25;">
        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">The following table sets forth information, as of April 18, 2022, regarding beneficial ownership of our ordinary shares&#160; represented by ADSs):</div>
      </div>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z8c9f8e50ba8d4cd69c7c4815848d7720">

          <tr>
            <td style="width: 19.6pt;"><br>
            </td>
            <td style="width: 12.8pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top;">
              <div>each person who is known by us to own beneficially more than 5% of our ordinary shares;</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z6681cbffaf45482f8a810c1ca6889f06">

          <tr>
            <td style="width: 19.6pt;"><br>
            </td>
            <td style="width: 12.8pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top;">
              <div>each director;</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z7e58ce55eabc435dbae4bf162019685c">

          <tr>
            <td style="width: 19.6pt;"><br>
            </td>
            <td style="width: 12.8pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top;">
              <div>each executive officer; and</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zcebf024a11bd46a3b0776f6cd67af93a">

          <tr>
            <td style="width: 19.6pt;"><br>
            </td>
            <td style="width: 12.8pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top;">
              <div>all of our directors and executive officers collectively.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-indent: 25.5pt; margin-right: 10.85pt; margin-left: 5.3pt; line-height: 1.25;">The percentages of ordinary shares beneficially owned are reported on the basis of regulations of the SEC governing the determination of beneficial
        ownership of securities. Under the rules of the SEC, a person is deemed to be a beneficial owner of a security if that person has or shares voting power, which includes the power to vote or to direct the voting of the security, or investment power,
        which includes the power to dispose of or to direct the disposition of the security.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="margin-left: 30.8pt; line-height: 1.25;">Unless otherwise noted, the address of each director and current and former executive officer of Chemomab is Kiryat Atidim, Building 7, Tel Aviv, Israel 6158002.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" class="cfttable" id="z1f27f7a29c594332bf35831fb801ab12" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">

          <tr>
            <td style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="line-height: 1.25;"><font style="line-height: 1.25;">&#160;</font></div>
              <div style="line-height: 1.25;"><font style="line-height: 1.25;">&#160;</font></div>
              <div style="line-height: 1.25;"><font style="line-height: 1.25;">&#160;</font></div>
              <div style="line-height: 1.25; font-weight: bold;">NAME OF BENEFICIAL OWNER</div>
            </td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
            <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">
              <div style="font-weight: bold;">Total</div>
              <div style="font-weight: bold;">Beneficial</div>
              <div style="font-weight: bold;">Ownership (American Depositary</div>
              <div style="font-weight: bold;">Shares)</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
            <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); text-align: center;">
              <div style="line-height: 1.25;"><font style="line-height: 1.25;"> </font></div>
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold; text-indent: 9pt;">Percentage of</div>
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold; text-indent: 11pt;">Ordinary Shares Beneficially</div>
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold; text-indent: 15pt;">Owned*</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25; font-weight: bold;">5% and Greater Shareholders</div>
            </td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="2" style="vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom;">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="2" style="vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top; width: 76%;">
              <div style="line-height: 1.25;">OrbiMed Israel Partners Limited Partnership(1)</div>
            </td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">2,606,991</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">22.8</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">
              <div style="line-height: 1.25;">%</div>
            </td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top; background-color: rgb(204, 238, 255); width: 76%;">
              <div style="line-height: 1.25;">The Centillion Fund(2)</div>
            </td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">661,370</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">5.8</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">
              <div style="line-height: 1.25;">%</div>
            </td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top; width: 76%;">
              <div style="line-height: 1.25;">Rivendell Investments 2017-9(3)</div>
            </td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">1,131,563</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">9.9</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">
              <div style="line-height: 1.25;">%</div>
            </td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top; background-color: rgb(204, 238, 255); width: 76%;">
              <div style="line-height: 1.25;">Kobi George(4)</div>
            </td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">1,329,468</div>
              <div style="line-height: 1.25;"><font style="line-height: 1.25;"></font></div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">11.5</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">
              <div style="line-height: 1.25;">%</div>
            </td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top; width: 76%;">
              <div style="line-height: 1.25;">Apeiron Group(5)</div>
            </td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">770,388</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">6.7</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">
              <div style="line-height: 1.25;">%</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" class="cfttable" id="z7ef38da56ed641acb6bfa7b10b520d90" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">

          <tr>
            <td style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="line-height: 1.25;"><font style="line-height: 1.25;">&#160;</font></div>
              <div style="line-height: 1.25;"><font style="line-height: 1.25;">&#160;</font></div>
              <div style="line-height: 1.25;"><font style="line-height: 1.25;">&#160;</font></div>
              <div style="line-height: 1.25; font-weight: bold;">NAME OF BENEFICIAL OWNER</div>
            </td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
            <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); text-align: center; font-family: 'Times New Roman',Times,serif;">
              <div style="font-weight: bold;">Total Beneficial</div>
              <div style="font-weight: bold;">Ownership (American Depositary</div>
              <div style="font-weight: bold;">Shares)</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
            <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); text-align: center;">
              <div style="line-height: 1.25;"><font style="line-height: 1.25;"> </font></div>
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold; text-indent: 9pt;">Percentage of</div>
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold; text-indent: 11pt;">Ordinary Shares Beneficially</div>
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold; text-indent: 15pt;">Owned*</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25; font-weight: bold;">Directors and Executive Officers</div>
            </td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="2" style="vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom;">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="2" style="vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%;">
              <div style="line-height: 1.25;">Dale Pfost (6)</div>
            </td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">2,500</div>
              <div style="line-height: 1.25;"><font style="line-height: 1.25;"></font></div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">0.02</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">
              <div style="line-height: 1.25;">%</div>
            </td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">Donald Marvin (7)</div>
            </td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">1,500</div>
              <div style="line-height: 1.25;"><font style="line-height: 1.25;"></font></div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">0.01</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">
              <div style="line-height: 1.25;">%</div>
            </td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%;">
              <div style="line-height: 1.25;">Adi Mor (8)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
            </td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">1,329,468</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">11.5</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">
              <div style="line-height: 1.25;">%</div>
            </td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">Neil Cohen (9)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
            </td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">16,161</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">0.14</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">
              <div style="line-height: 1.25;">%</div>
            </td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%;">
              <div style="line-height: 1.25;">Nissim Darvish (10)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
            </td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">16,274</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">0.14</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">
              <div style="line-height: 1.25;">%</div>
            </td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">Joel Maryles (11)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
            </td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">5,951</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">0.05</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">
              <div style="line-height: 1.25;">%</div>
            </td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%;">
              <div style="line-height: 1.25;">Alan Moses (12)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
            </td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">4,951</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">0.04</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">
              <div style="line-height: 1.25;">%</div>
            </td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">Claude Nicaise (13)</div>
            </td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">4,951</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">0.04</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">
              <div style="line-height: 1.25;">%</div>
            </td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%;">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">&#8212;</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">&#8212;</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top; background-color: rgb(204, 238, 255); width: 76%;">
              <div style="line-height: 1.25; font-weight: bold;">All current executive officers and directors as a group (8 persons)</div>
            </td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">1,381,756</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">11.91</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">
              <div style="line-height: 1.25;">%</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <div style="margin-left: 30.8pt; line-height: 1.25;">* Percentage ownership based on 11,404,515 ADSs outstanding as of April 18, 2022.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 25.5pt; margin-right: 5.75pt; margin-left: 5.3pt; line-height: 1.25;">
        <div style="line-height: 1.25; color: rgb(0, 0, 0); font-family: 'Times New Roman',serif;">
          <div style="line-height: 1.25; color: rgb(0, 0, 0);">(1)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Represents 2,578,174 ADSs, representing 51,563,480 ordinary shares, held by OrbiMed Israel Partners Limited Partnership, or OIP and 28,817 ADSs, representing 576,340 Ordinary
            Shares, issuable upon the exercise of warrants to purchase ADSs. The percentage is calculated based upon 11,404,515 ADSs outstanding, representing 228,090,300 Ordinary Shares, and giving effect to the additional 28,817 ADSs, representing
            576,340 Ordinary Shares, that would be outstanding following the exercise of the warrants held by OIP. OIP is the shareholder of record. OrbiMed Israel BioFund GP Limited Partnership, or OrbiMed BioFund, is the general partner of OIP, and
            OrbiMed Israel GP Ltd., or OrbiMed Israel GP, is the general partner of OrbiMed BioFund. By virtue of such relationships, OrbiMed BioFund and OrbiMed Israel GP may be deemed to have voting and investment power with respect to the shares held
            directly by OIP and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Israel GP exercises this investment and voting power through a management committee comprised of Carl Gordon,&#160;Anat Naschitz and Erez
            Chimovits, each of whom disclaims beneficial ownership of the shares held by OIP. The address of OIP is 89 Medinat HaYehudim St., Build E, 11th Floor, Herzliya 46766 Israel.</div>
        </div>
      </div>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z0b3c5a1b86a34edb8a7fa2b2a438cd52">

          <tr>
            <td style="width: 30.75pt;"><br>
            </td>
            <td style="width: 41.25pt; vertical-align: top; align: right;">(2)</td>
            <td style="width: auto; vertical-align: top;">
              <div>The address of Centillion Fund, Inc. is 10 Manoel Street, Castries, Saint Lucia.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 25.5pt; margin-right: 6.8pt; margin-left: 5.3pt; line-height: 1.25;">
        <div style="line-height: 1.25; color: rgb(0, 0, 0); font-family: 'Times New Roman',serif;">(3)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Represents 1,108,509 ADSs, representing 22,170,180 ordinary shares, held by Rivendell Investments 2017-9 LLC, or Rivendell, as reported by
          Rivendell on Schedule 13G filed with the SEC on March 26, 2021, and 23,054 ADSs, representing 461,080 Ordinary Shares, issuable upon the exercise of warrants to purchase ADSs. The percentage is calculated based upon 11,404,515 ADSs outstanding,
          representing 228,090,300 Ordinary Shares, and giving effect to the additional 23,054 ADSs, representing 461,080 Ordinary Shares, that would be outstanding following the exercise of the warrants held by Rivendell. Rivendell is the shareholder of
          record. Peter Thiel is the beneficial owner of Rivendell and has sole voting and investment power over the securities held by Rivendell. The address of Rivendell is 1209 Orange Street, Wilmington, Delaware 19801.</div>
      </div>
      <div style="line-height: 1.25">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 25.5pt; margin-right: 21.15pt; margin-left: 5.3pt; line-height: 1.25;">(4)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Consists of (i) 514,495 ADSs owned directly by Dr. George, (ii) 649,550 ADSs owned by Dr. Adi Mor (Dr. George&#8217;s spouse),
        (iii) 33,725 options to purchase 33,725 ADSs of the Company issued directly to Dr. George, issuable upon the exercise of options, and (iv) 131,698 options to purchase 131,698 ADSs of the Company, issued to Dr. Mor, (Dr. George&#8217;s spouse).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 25.5pt; margin-right: 14.75pt; margin-left: 5.3pt; line-height: 1.25;">
        <div style="line-height: 1.25; color: rgb(0, 0, 0); font-family: 'Times New Roman',serif;">(5)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Apeiron Group consists of (i) Apeiron SICAV Ltd. &#8211; Presight Capital Fund One, of which owns 438,993 ADSs, (ii) Apeiron Presight Capital Fund
          II, LP, of which owns 288,170ADSs and 28,817 ADSs issuable upon the exercise of warrants and (iii) Apeiron Investment Group Ltd., of which owns 14,408 ADSs issuable upon the exercise of warrants. Each of Fabian Hansen and Christian Angermayer may
          be deemed to share voting and investment power with respect to the ADSs held by the Apeiron Group.</div>
      </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-indent: 25.5pt; margin-right: 6.8pt; margin-left: 5.3pt; line-height: 1.25;">(6)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Represents 2,500 ADSs of the Company as reported by Dr. Dale Pfost on Form 4 filed with the SEC on March 15, 2022.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 25.5pt; margin-right: 11.05pt; margin-left: 5.3pt; line-height: 1.25;">(7)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Represents 1,500 ADSs of the Company as reported by Mr. Donald Marvin on Form 4 filed with the SEC on March 21, 2022.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd8771877978e43cc9111e2201f85b26e">

          <tr>
            <td style="width: 30.75pt;"><br>
            </td>
            <td style="width: 41.25pt; vertical-align: top; align: right;">(8)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Consists of (i) 649,550 ADSs owned directly by Dr. Mor, (ii) 514,495 ADSs owned by Dr. George, (Dr. Mor&#8217;s spouse), (iii) 131,698 ADSs&#160;issued to Dr. Mor, issuable upon the exercise of options within 60 days of the date hereof, and (iv)
                33,725 options to purchase 33,725 ADSs of the Company issued to Dr. George, (Dr. Mor&#8217;s spouse) issuable upon the exercise of options within 60 days of the date hereof, as reported by Dr. Adi Mor on Schedule 13D filed with the SEC on January
                20, 2022</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;"><br>
        </div>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb826fd5c7e9d4d89b951c10e9af6fd6c">

          <tr>
            <td style="width: 30.75pt;"><br>
            </td>
            <td style="width: 41.25pt; vertical-align: top; align: right;">(9)</td>
            <td style="width: auto; vertical-align: top;">
              <div>
                <div style="line-height: 1.25;">
                  <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">Includes 10,409 ADSs of the Company, and 5,752 ADSs of the Company issuable upon the exercise of options within 60 days of the date hereof, as reported
                    by Mr. Neil Cohen on Form 4 filed with the SEC on March 15, 2022.</div>
                </div>
              </div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zba53e09a3ca240a09c2511363956fe90">

          <tr>
            <td style="width: 30.75pt;"><br>
            </td>
            <td style="width: 41.25pt; vertical-align: top; align: right;">(10)</td>
            <td style="width: auto; vertical-align: top;">
              <div>
                <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">Includes 1,200 ADSs of the Company, and 15,074 ADSs of the Company issuable upon the exercise of options within 60 days of the date hereof, as reported
                  by Dr. Nissim Darvish on Form 4 filed with the SEC on March 14, 2022.</div>
              </div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z04f3275925ea4a54b3ed5ccc3fa87882">

          <tr>
            <td style="width: 30.75pt;"><br>
            </td>
            <td style="width: 41.25pt; vertical-align: top; align: right;">(11)</td>
            <td style="width: auto; vertical-align: top;">
              <div>
                <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">Represents 1,000 ADSs of the Company and 4,951 ADSs of the Company issuable upon the exercise of options within 60 days of the date hereof, as reported
                  by Mr. Joel Maryles on Form 4 filed with the SEC on March 21, 2022.</div>
              </div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za3e36e7d2bee4b1ebc9a47eb79ff1a7e">

          <tr>
            <td style="width: 30.75pt;"><br>
            </td>
            <td style="width: 41.25pt; vertical-align: top; align: right;">(12)</td>
            <td style="width: auto; vertical-align: top;">
              <div>Represents 4,951 ADSs of the Company issuable upon the exercise of options within 60 days of the date hereof, as reported by Dr. Alan Moses on Form 4 filed with the SEC on March 9, 2022.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb8095158b1634f408d687f323679b6d0">

          <tr>
            <td style="width: 30.75pt;"><br>
            </td>
            <td style="width: 41.25pt; vertical-align: top; align: right;">(13)</td>
            <td style="width: auto; vertical-align: top;">
              <div>
                <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">Represents 4,951 ADSs of the Company issuable upon the exercise of options within 60 days of the date hereof, as reported by Dr. Claude Nicaise on Form 4
                  filed with the SEC on March 9, 2022.</div>
              </div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; margin-right: 124.7pt; margin-left: 124.7pt; line-height: 1.25; font-weight: bold;">EXECUTIVE OFFICERS AND DIRECTORS</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25; font-weight: bold;">Directors</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-align: justify; text-indent: 24.5pt; line-height: 1.25;">Our Board is currently composed of seven members. Our Board consists of three classes of directors, each serving staggered three-year terms. Upon expiration of the term of a
          class of directors, directors in that class will be elected for a three-year term at the Annual General Meeting of shareholders in the year in which that term expires. Each director&#8217;s term continues until the election and qualification of his or
          her successor, or his or her earlier death, resignation or removal. Any increase or decrease in the number of directors will be distributed among the three classes so that, as nearly as possible, each class will consist of&#160;one-third&#160;of the
          directors.</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 24.5pt; line-height: 1.25;">The following table sets forth the names, ages, and certain other information for each of the directors with terms expiring at the Annual General Meeting (including those who
          are also nominees for election as a director at the Annual General Meeting) and for each of the continuing members of our Board. All information is as of the date of this proxy statement.</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;">&#160;</div>
      </div>
      <table cellspacing="0" cellpadding="0" class="cfttable" id="z89a6b785a95a447a944d55f06d02fdc0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">

          <tr>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="line-height: 1.25; font-weight: bold;">Name</div>
            </td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">Class</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">Age</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">Position</div>
            </td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">Director<br>
                Since</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">Current<br>
                Term<br>
                Expires</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">Expiration<br>
                of Term<br>
                for Which<br>
                Nominated</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF;">
              <div style="text-indent: -12pt; margin-left: 12pt; line-height: 1.25; font-style: italic; font-weight: bold;">Nominees for Director</div>
            </td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom;">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="2" style="vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom;">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="2" style="vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom;">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="2" style="vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom;">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="2" style="vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 20.2%;">
              <div style="text-indent: -12pt; margin-left: 12pt; line-height: 1.25;">Nissim Darvish<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup></div>
            </td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1.01%;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: center; width: 9.12%;">
              <div style="line-height: 1.25;">I</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1.01%;"><br>
            </td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1.01%;">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1.01%;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9.12%;">
              <div style="line-height: 1.25; text-align: center;">57</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1.01%;">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 20.2%;">
              <div style="line-height: 1.25;">Director</div>
            </td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1.01%;">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1.01%;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9.12%;">
              <div style="line-height: 1.25;">2021</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1.01%;">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1.01%;">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1.01%;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9.12%;">
              <div style="line-height: 1.25;">2022</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1.01%;">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1.01%;">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1.01%;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9.12%;">
              <div style="line-height: 1.25;">2025</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1.01%;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 20.2%;">
              <div style="text-indent: -12pt; margin-left: 12pt; line-height: 1.25;">Joel Maryles<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)(3)</sup></div>
            </td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1.01%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: center; width: 9.12%;">
              <div style="line-height: 1.25;">I</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1.01%;">
              <div style="line-height: 1.25;"><br>
              </div>
            </td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1.01%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1.01%;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.12%;">
              <div style="line-height: 1.25; text-align: center;">62</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1.01%;">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 20.2%;">
              <div style="line-height: 1.25;">Director</div>
            </td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1.01%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1.01%;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.12%;">
              <div style="line-height: 1.25;">2021</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1.01%;">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1.01%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1.01%;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.12%;">
              <div style="line-height: 1.25;">2022</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1.01%;">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1.01%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1.01%;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.12%;">
              <div style="line-height: 1.25;">2025</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1.01%;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 20.2%;">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1.01%;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9.12%;">&#160;</td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1.01%;">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1.01%;">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1.01%;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: center; width: 9.12%;">&#160;</td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1.01%;">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 20.2%;">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1.01%;">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1.01%;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9.12%;">&#160;</td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1.01%;">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1.01%;">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1.01%;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9.12%;">&#160;</td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1.01%;">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1.01%;">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1.01%;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9.12%;">&#160;</td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1.01%;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 20.2%;">
              <div style="text-indent: -12pt; margin-left: 12pt; line-height: 1.25; font-style: italic; font-weight: bold;">Continuing Directors</div>
            </td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1.01%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.12%;">&#160;</td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1.01%;">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1.01%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1.01%;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: center; width: 9.12%;">&#160;</td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1.01%;">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 20.2%;">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1.01%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1.01%;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.12%;">&#160;</td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1.01%;">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1.01%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1.01%;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.12%;">&#160;</td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1.01%;">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1.01%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1.01%;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.12%;">&#160;</td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1.01%;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom;">
              <div style="text-indent: -12pt; margin-left: 12pt; line-height: 1.25;">Neil Cohen<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)(3)</sup></div>
            </td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom;">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom;">
              <div style="text-align: center; line-height: 1.25;">II</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom;">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom;">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right;">
              <div style="line-height: 1.25; text-align: center;">58</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom;">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom;">
              <div style="line-height: 1.25;">Director</div>
            </td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom;">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right;">
              <div style="line-height: 1.25;">2020</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom;">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom;">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right;">
              <div style="line-height: 1.25;">2023</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom;">&#160;</td>
            <td valign="bottom" nowrap="nowrap" class="cftguttercell" colspan="1" style="vertical-align: bottom;">&#160;</td>
            <td valign="bottom" nowrap="nowrap" class="cftcurrcell" colspan="1" style="vertical-align: bottom;">&#160;</td>
            <td valign="bottom" nowrap="nowrap" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right;">
              <div style="line-height: 1.25;">&#8212;</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF;">
              <div style="text-indent: -12pt; margin-left: 12pt; line-height: 1.25;">Claude Nicaise<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup></div>
            </td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF;">
              <div style="text-align: center; line-height: 1.25;">II</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom;">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right;">
              <div style="line-height: 1.25; text-align: center;">69</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom;">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">Director</div>
            </td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right;">
              <div style="line-height: 1.25;">2021</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom;">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right;">
              <div style="line-height: 1.25;">2023</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom;">&#160;</td>
            <td valign="bottom" nowrap="nowrap" class="cftguttercell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" nowrap="nowrap" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom;">&#160;</td>
            <td valign="bottom" nowrap="nowrap" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right;">
              <div style="line-height: 1.25;">&#8212;</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom;">
              <div style="text-indent: -12pt; margin-left: 12pt; line-height: 1.25;">Adi Mor</div>
            </td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom;">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom;">
              <div style="text-align: center; line-height: 1.25;">III</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom;">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom;">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right;">
              <div style="line-height: 1.25; text-align: center;">41</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom;">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom;">
              <div style="line-height: 1.25;">Director, Chief Scientific Officer</div>
            </td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom;">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right;">
              <div style="line-height: 1.25;">2021</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom;">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom;">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right;">
              <div style="line-height: 1.25;">2024</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom;">&#160;</td>
            <td valign="bottom" nowrap="nowrap" class="cftguttercell" colspan="1" style="vertical-align: bottom;">&#160;</td>
            <td valign="bottom" nowrap="nowrap" class="cftcurrcell" colspan="1" style="vertical-align: bottom;">&#160;</td>
            <td valign="bottom" nowrap="nowrap" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right;">
              <div style="line-height: 1.25;">&#8212;</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF;">
              <div style="text-indent: -12pt; margin-left: 12pt; line-height: 1.25;">Alan Moses<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup></div>
            </td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF;">
              <div style="text-align: center; line-height: 1.25;">III</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom;">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right;">
              <div style="line-height: 1.25; text-align: center;">74</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom;">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">Director</div>
            </td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right;">
              <div style="line-height: 1.25;">2021</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom;">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right;">
              <div style="line-height: 1.25;">2024</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom;">&#160;</td>
            <td valign="bottom" nowrap="nowrap" class="cftguttercell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" nowrap="nowrap" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom;">&#160;</td>
            <td valign="bottom" nowrap="nowrap" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right;">
              <div style="line-height: 1.25;">&#8212;</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom;">
              <div style="text-indent: -12pt; margin-left: 12pt; line-height: 1.25;">Dale Pfost</div>
            </td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom;">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom;">
              <div style="text-align: center; line-height: 1.25;">III</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom;">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom;">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right;">
              <div style="line-height: 1.25; text-align: center;">65</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom;">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom;">
              <div style="line-height: 1.25;">Chairman of the Board, Chief Executive Officer</div>
            </td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom;">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right;">
              <div style="line-height: 1.25;">2021</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom;">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom;">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right;">
              <div style="line-height: 1.25;">2024</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom;">&#160;</td>
            <td valign="bottom" nowrap="nowrap" class="cftguttercell" colspan="1" style="vertical-align: bottom;">&#160;</td>
            <td valign="bottom" nowrap="nowrap" class="cftcurrcell" colspan="1" style="vertical-align: bottom;">&#160;</td>
            <td valign="bottom" nowrap="nowrap" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right;">
              <div style="line-height: 1.25;">&#8212;</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom;">&#160;</td>
          </tr>

      </table>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <br>
        </div>
        <u>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </u><br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z3ea342afe43343689f974974dc273066">

          <tr>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25;">(1)</div>
            </td>
            <td style="width: 96%; vertical-align: top;">
              <div style="line-height: 1.25;">Member of Audit Committee</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25;">(2)</div>
            </td>
            <td style="width: 96%; vertical-align: top;">
              <div style="line-height: 1.25;">Member of Compensation Committee</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25;">(3)</div>
            </td>
            <td style="width: 96%; vertical-align: top;">
              <div style="line-height: 1.25;">Member of Corporate Governance and Nominating Committee</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="margin-left: 5.3pt; line-height: 1.25; font-style: italic; font-weight: bold;">Nominees for Director</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 30.7pt; margin-left: 5.3pt; line-height: 1.25;"><font style="font-style: italic;">Nissim Darvish</font>, M.D., Ph.D.&#160;has served on our Board since March 16, 2021. Dr. Darvish is a General Partner at MeOhr
        Ventures, a venture capital fund. Dr. Darvish currently serves as a director of several private companies. Prior to his current position, Dr. Darvish served as a Venture Partner at OrbiMed Israel and as a member of the boards of directors of 9
        Meters Biopharma Inc. and Medigus Ltd. Previously, Dr. Darvish was employed at Pitango Venture Capital, where he was a General Partner managing life sciences investments. He was also the founder and CEO of Impulse Dynamics, where he oversaw a $250
        million realization event. Dr. Darvish obtained his M.D. and Ph.D. in Biophysics and Physiology from the Technion in Israel, and subsequently conducted his post-doctoral research at NIH. He has published over 100 patents and authored over 20
        publications.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-indent: 30.7pt; margin-left: 5.3pt; line-height: 1.25;">We believe that Mr. Darvish is qualified to serve on our Board because of his knowledge and experience in the biotech and pharmaceuticals industry and professional experience as
        a board member of various life sciences companies.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 30.7pt; margin-left: 5.3pt; line-height: 1.25;"><font style="font-style: italic;">Joel Maryles</font>&#160;has served on our Board since March 16, 2021. Mr. Maryles currently serves on the Board and as the
        Chairman of the Nominations Committee of Jefferies International Ltd., a position he has held since 2016. Mr. Maryles previously served on the board of directors of Radware Ltd. (NASDAQ: RDWR), from 2014 to 2020 and from 2014 to 2016, on the board
        of directors of EZchip Semiconductor Ltd., which was acquired by Mellanox Technologies in 2016. From 2015 to 2018, Mr. Maryles was a Partner at OurCrowd and from 2007 to 2012, he served as a Portfolio Manager at T-Cubed Investments, which he
        founded. Prior to that, Mr. Maryles served as a Managing Director in the Investment Banking division of Citigroup, Israel and of Furman Selz. Mr. Maryles holds a Bachelor of Science in Mechanical Engineering from the University of Illinois and an
        MBA from the University of Chicago, Illinois.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-indent: 30.7pt; margin-left: 5.3pt; line-height: 1.25;">We believe that Mr. Maryles is qualified to serve on our Board because of his corporate finance and business expertise, including his time spent serving on boards of directors
        of various technology companies and familiarity with Israeli companies.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="margin-left: 5.3pt; line-height: 1.25; font-style: italic; font-weight: bold;">Continuing Directors</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 30.7pt; margin-left: 5.3pt; line-height: 1.25;"><font style="font-style: italic;">Dr. Dale Pfost</font>&#160;has served as our Chief Executive Officer and a member of our Board since October 2021, and also as
        chairman of our Board since February 2022. Dr. Pfost has 35 years of experience as an entrepreneur, investor and business executive. From 2019 to 2021, Dr. Pfost served as Chief Executive Officer and Chairman of the Board of Lodo Therapeutics
        Corporation. From 2009 until 2019, Dr. Pfost served in a variety of roles at Microbiome Therapeutics, LLC, a company which he co-founded, including as a board member and Chief Executive Officer from 2009 until 2010 and again from 2016 until 2019.
        From 2010 until 2019, he served as a General Partner at Advent Life Sciences. From 2013 until 2017, Dr. Pfost served in a variety of roles at Vestagen Protective Technologies, including Chairman, Executive Chairman from 2013 until 2017, and Chief
        Executive Officer from 2015 until 2016. Prior to that, Dr. Pfost held various executive positions at the following companies: Chief Executive Officer at Receptor Biologix Inc. (from 2008 until 2009), President, Chief Executive Officer and Chairman
        at Acuity Pharmaceuticals, Inc. (from 2003 until 2007), President, Chief Executive Officer and Chairman at Orchid Biosciences, Inc. (from 1996 until 2002), President, Chief Executive Officer and Managing Director at Oxford Glycosciences Ltd. (from
        1988 until 1996) and Director of Robotics and Automated Chemistry Systems at Smithkline Beckman (1984 until 1988). In addition to the foregoing, Dr. Pfost has served on the board of directors of several companies, including Bioelectronica Corp.,
        AxoSim, Inc., JMB Companies LLC, Aura Bioscience, Louisiana BIO, CN Creative and Ancilia Biosciences. Dr. Pfost earned his BS from the University of California, Santa Barbara, and a PhD in physics from Brown University. We believe that Dr. Pfost is
        qualified to serve as Chairman of our Board because of his extensive executive experience leading life science companies.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 28.9pt; margin-left: 7.1pt; line-height: 1.25;"><font style="font-style: italic;">Dr. Adi Mor</font>&#160;is the co-founder of Chemomab Ltd. and served as Chemomab Ltd.&#8217;s Chief Executive Officer, Chief
        Scientific Officer and a member of Chemomab Ltd.&#8217;s board of directors from its formation in 2011 until the Chemomab Ltd.-Anchiano Therapeutics Ltd. merger that was consummated on March 16, 2021 (the &#8220;Merger&#8221;), and has continued to serve in those
        capacities for our company thereafter. Dr. Mor&#8217;s tenure as the Company&#8217;s Chief Executive Officer concluded simultaneously with the approval of Dr. Dale Pfost&#8217;s employment by the Company&#8217;s shareholders on October 25, 2021. Dr. Mor has in-depth
        knowledge in immunology focusing on rare diseases and broad experience in designing, developing and patenting a novel class of monoclonal antibodies to treat inflammatory and fibrotic diseases. Dr. Mor received her Ph.D. in immunology from Tel Aviv
        University in the Department of Neurobiochemistry in Israel and is the lead author of numerous scientific journal publications in immunology and inflammatory disorders. We believe that Dr. Mor is qualified to serve on our Board because of her
        scientific background and experience in the life sciences industry.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 30.7pt; margin-left: 5.3pt; line-height: 1.25;"><font style="font-style: italic;">Alan Moses, MD, FACP</font>&#160;has served on our Board since March 16, 2021. Dr. Moses is board certified by the ABIM with
        subspecialty certification in Endocrinology and Metabolism and is a Fellow of the American College of Physicians. Dr. Moses currently serves on the board of directors of BioFabUSA, a position he has held since 2018. Prior to that time, from 2008 to
        2018, Dr. Moses served as the Global Chief Medical Officer of Novo Nordisk A/S (CPH: NOVO-B), a company he joined in 2004. Dr. Moses served as a Professor of Medicine at Harvard Medical School from 2002 to 2006, and in collaboration with MIT, he
        co-founded and co-directed the Clinical Investigator Training Program, which focused on training physician-scientists in translational research. Dr. Moses previously served as the Senior Vice President and Chief Medical Officer of the Joslin
        Diabetes Center from 1998 to 2004. Dr. Moses holds a BS from Duke University, North Carolina and an MD from Washington University School of Medicine, Missouri. We believe that Dr. Moses is qualified to serve on our Board because of his scientific
        background and experience in the life sciences industry.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><font style="font-style: italic;">Claude Nicaise, MD</font>&#160;has served on our Board since March 16, 2021. Dr. Nicaise is a physician with extensive U.S. and international
        experience in clinical drug development, strategic management, worldwide regulatory strategy, pharmaceuticals, biotechnology, including clinical cancer research, infectious diseases and neuroscience. Dr. Nicaise is the owner and founder of Clinical
        Regulatory Services, which provides consulting services to the life science and biotechnology industry in support of all aspects of clinical and regulatory development. Since 2015, Dr. Nicaise has served on the board of directors and as the
        Chairman of the Compensation Committee of Sarepta Therapeutics, Inc. (NASDAQ: SRPT). Dr Nicaise has also served on the board of directors of Mynoryx Therapeutics since 2017. Prior to that time, from 2008 to 2014, Dr. Nicaise served as the Senior
        Vice President of Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), and between 1984 and 2008, he held numerous senior management roles at Bristol Myers Squibb (NYSE: BMY). Dr. Nicaise holds an MD and a degree in Internal Medicine, Clinical Oncology,
        from Brussels University, Belgium. We believe that Dr. Nicaise is qualified to serve on our Board because of his scientific background and experience in the life sciences industry.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-style: italic;">Neil Cohen</font>&#160;has served as a member of our Board since April 2020 and served as our interim Chief Executive Officer from October 2020 until the
        consummation of the Merger. Mr. Cohen has served as the Chairman and Chief Executive Officer of Castel Partners Ltd. since January 2012. In 1994, he co-founded Israel Seed Partners, a leading venture capital firm, and managed the firm until 2019.
        Mr. Cohen has invested in and served on the boards of directors of many private technology companies, including a large number which were acquired or completed successful initial public offerings, including Compugen (Nasdaq: CGEN), Shopping.com
        (Nasdaq: SHOP, acquired by EBAY), Broadlight (acquired by Broadcom, Nasdaq: AVGO) and Cyota (acquired by RSA). He is a venture partner at SKY, an Israeli middle-market private equity firm, Hetz Ventures Management Ltd., an early-stage Israeli
        venture capital fund, and Shavit Capital. Mr. Cohen was previously the Business Editor of The Jerusalem Post and began his career in the private equity group at N M Rothschild &amp; Sons Limited in London. Mr. Cohen received a B.A. and M.A. in
        Oriental Studies, with first class honors, from Oxford University. We believe that Mr. Cohen is qualified to serve on our Board because of his extensive experience serving as a director of both private and public companies.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Executive Officers</div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-indent: 36pt; line-height: 1.25;">The following table provides information regarding our executive officers as of the date of this proxy statement:</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;">&#160;</div>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z614977c00b4e4aa9b6a9277be55e1854">

          <tr>
            <td nowrap="nowrap" style="width: 38.7%; vertical-align: bottom; border-bottom: #000000 2px solid;">
              <div style="line-height: 1.25; font-weight: bold;">Name</div>
            </td>
            <td style="width: 1.96%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;&#160;</div>
            </td>
            <td style="width: 5%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Age</div>
            </td>
            <td style="width: 0.38%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 1.96%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;&#160;</div>
            </td>
            <td style="width: 40%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="line-height: 1.25; font-weight: bold;">Position</div>
            </td>
          </tr>
          <tr>
            <td style="width: 38.7%; vertical-align: top; background-color: #CCEEFF;">
              <div style="text-indent: -12pt; margin-left: 12pt; line-height: 1.25; font-weight: bold;">Executive Officers:</div>
            </td>
            <td style="width: 1.96%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">&#160;&#160;</div>
            </td>
            <td style="width: 5%; vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: center;">&#160;</td>
            <td style="width: 0.38%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
            <td style="width: 1.96%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">&#160;&#160;</div>
            </td>
            <td style="width: 40%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
          </tr>
          <tr>
            <td style="width: 38.7%; vertical-align: top;">
              <div style="text-indent: -12pt; margin-left: 12pt; line-height: 1.25;">Dale Pfost</div>
            </td>
            <td style="width: 1.96%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;&#160;</div>
            </td>
            <td style="width: 5%; vertical-align: bottom;">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">65</div>
            </td>
            <td nowrap="nowrap" style="width: 0.38%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 1.96%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;&#160;</div>
            </td>
            <td style="width: 40%; vertical-align: top;">
              <div style="line-height: 1.25;">Chief Executive Officer and Chairman of the Board</div>
            </td>
          </tr>
          <tr>
            <td style="width: 38.7%; vertical-align: top; background-color: #CCEEFF;">
              <div style="text-indent: -12pt; margin-left: 12pt; line-height: 1.25;">Donald Marvin</div>
            </td>
            <td style="width: 1.96%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">&#160;&#160;</div>
            </td>
            <td style="width: 5%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">70</div>
            </td>
            <td nowrap="nowrap" style="width: 0.38%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 1.96%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">&#160;&#160;</div>
            </td>
            <td style="width: 40%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">Chief Financial Officer, Executive Vice President and Chief Operating Officer&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 38.7%; vertical-align: top;">
              <div style="text-indent: -12pt; margin-left: 12pt; line-height: 1.25;">Adi Mor</div>
            </td>
            <td style="width: 1.96%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;&#160;</div>
            </td>
            <td style="width: 5%; vertical-align: bottom;">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">41</div>
            </td>
            <td nowrap="nowrap" style="width: 0.38%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 1.96%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;&#160;</div>
            </td>
            <td style="width: 40%; vertical-align: top;">
              <div style="line-height: 1.25;">Chief Scientific Officer</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-indent: 30.7pt; margin-left: 5.3pt; line-height: 1.25;">For Dr. Pfost&#8217;s and Dr. Mor&#8217;s biographies, see &#8220;<font style="font-style: italic;">Continuing Directors&#8221;</font>.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 30.7pt; margin-left: 5.3pt; line-height: 1.25;"><font style="font-style: italic;">Donald Marvin&#160;</font>has served as our Chief Financial Officer, Executive Vice President and Chief Operating Officer since
        November 8, 2021. Mr. Marvin has more than 35 years of experience at growth enterprises in corporate finance and fundraising, strategy, corporate development, mergers and acquisitions, and operations.&#160; Mr. Marvin served as Executive Vice President
        and Chief Financial Officer of Lodo Therapeutics from 2020 until 2021. He was previously Chairman, President and CEO of Concentric from 2014 to 2021. Prior to his positions at Concentric, Mr. Marvin was Managing Partner of Cairn Associates from
        2006 until 2014. He was President and CEO of IdentiGEN from 2006 until 2009. Mr. Marvin was a co-founder of Orchid BioSciences, where he served as Chief Operating Officer, CFO and Senior Vice President of Corporate Development from 1997 to 2003,
        and President and Chief Executive Officer of Diatron Corporation from 1986 until 1994. Earlier in his career, Mr. Marvin held positions of increasing responsibility at Abbott, Boehringer Ingelheim, Bayer, and PepsiCo. Mr. Marvin earned a Bachelor
        of Science degree from The Ohio State University and an MBA from Iona College.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; margin-right: 124.7pt; margin-left: 124.7pt; line-height: 1.25; font-weight: bold;">CORPORATE GOVERNANCE</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="margin-left: 5.3pt; line-height: 1.25; font-weight: bold;">Overall Role of the Board and Board Leadership Structure</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 25.5pt; margin-left: 5.3pt; line-height: 1.25;">Under the Israeli Companies Law, 5759-1999 (the &#8220;Companies Law&#8221;), our Board is responsible for setting our general policies and supervising the performance
        of management. Our Board may exercise all powers and may take all actions that are not specifically granted by the Companies Law or our articles of association to our shareholders or to management. Our executive officers are responsible for our
        day-to-day management and have individual responsibilities established by our Board.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 25.5pt; margin-left: 5.3pt; line-height: 1.25;">Under the Companies Law, the chief executive officer of a public company, or a relative of the chief executive officer, may not serve as the chairperson of
        the board of directors of such public company, and the chairperson of the board of directors of a public company, or a relative of the chairperson, may not be vested with authorities of the chief executive officer of such public company without
        obtaining shareholder approval pursuant to special majority requirements set forth in the Companies Law.</div>
      <div style="text-align: justify; text-indent: 25.5pt; margin-left: 5.3pt; line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; text-indent: 25.5pt; margin-left: 5.3pt; line-height: 1.25;">During a special general meeting of our shareholders held on February 10, 2022, our shareholders approved the appointment of Dr. Dale Pfost as Chairperson
        of our board of directors in addition to his role as our Chief Executive Officer. According to the Companies Law and the regulations promulgated thereunder, such appointment is valid for a three-year term and such re-appointment shall be subject to
        shareholder approval.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 25.5pt; margin-left: 5.3pt; line-height: 1.25;">Our Board is currently composed of seven members. Our Board consists of three classes of directors, each serving staggered three-year terms. Upon expiration
        of the term of a class of directors, directors in that class will be elected for a three-year term at the Annual General Meeting of shareholders in the year in which that term expires. Each director&#8217;s term continues until the election and
        qualification of his or her successor, or his or her earlier death, resignation or removal. Any increase or decrease in the number of directors will be distributed among the three classes so that, as nearly as possible, each class will consist
        of&#160;one-third&#160;of the directors.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; margin-left: 5.3pt; line-height: 1.25; font-weight: bold;">Board Leadership Structure</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 25.5pt; margin-left: 5.3pt; line-height: 1.25;">The Company is led by Dr. Dale Pfost, who has served as our Chief Executive Officer and Chairman of the Board since October 2021 and February 2022,
        respectively. <font style="font-weight: bold;">&#160;</font>Although the Board does not have a formal policy on whether the roles of Chief Executive Officer and Chairman of the Board should be separated, we believe that our current board leadership
        structure is suitable for us.&#160; The Chief Executive Officer is the individual selected by the Board to manage our company on a day to day basis, and his direct involvement in our business operations makes him best positioned to lead productive Board
        strategic planning sessions and determine the time allocated to each agenda item in discussions of our company&#8217;s short- and long-term objectives.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="margin-left: 5.3pt; line-height: 1.25; font-weight: bold;">Role of the Board in Risk Oversight</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 25.5pt; margin-left: 5.3pt; line-height: 1.25;">Our Board is responsible for overseeing our risk management process. Our Board focuses on our general risk management strategy, the most significant risks
        facing us, and oversees the implementation of risk mitigation strategies by management. Our Board is also apprised by management of particular risk management matters in connection with its general oversight and approval of corporate matters and
        significant transactions.&#160; The Board&#8217;s independent oversight function is further enhanced by the fact that all of the Board&#8217;s Committees are composed entirely of independent directors, the directors have complete access to management and the Board
        and its committees may retain their own respective advisors.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Corporate Governance Guidelines</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 30.7pt; margin-left: 5.3pt; line-height: 1.25;">Our Board strongly supports effective corporate governance and has developed and followed a program of strong corporate governance. Our Corporate Governance
        and Nominating Committee is responsible for overseeing our guidelines and reporting and making recommendations to the Board concerning corporate governance matters. Our guidelines are published on our website at
        https://investors.chemomab.com/documents and are available in print to any shareholder who requests them from our Corporate Secretary (or, in the absence thereof, by the Chief Executive Officer of the Company).</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25; font-weight: bold;">Director Independence</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Based upon information requested from and provided by each director concerning their background, employment and affiliations, including family relationships, our Board has
        determined that each of the directors is independent as defined under Nasdaq listing standards, with the exceptions of Dr. Mor and Dr. Pfost. Our Board also determined that Nissim Darvish and Neil Cohen, who comprise the Compensation Committee and
        Neil Cohen and Joel Maryles, who comprise the Corporate Governance and Nominating Committee, all satisfy the independence standards for such committees established by the SEC and Nasdaq listing standards, as applicable. With respect to the Audit
        Committee, our Board has determined that Joel Maryles, Alan Moses and Claude Nicaise satisfy the independence standards for such committee established by Rule 10A-3 under the Exchange Act, the SEC and Nasdaq listing standards, as applicable, and
        that Joel Maryles is a financial expert under the rules of the SEC. The Board considered the relationships between such directors and certain of the investors of the Registrant and determined that such relationships did not affect such directors&#8217;
        independence under the standards of Nasdaq, or, where applicable, under SEC rules.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25; font-weight: bold;">Code of Business Conduct and Ethics</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We have adopted a Code of Business Conduct and Ethics that includes provisions ranging from restrictions on gifts to conflicts of interest. All of our employees and directors are
        bound by this Code of Business Conduct and Ethics. Violations of our Code of Business Conduct and Ethics may be reported to the Audit Committee. The Code of Business Conduct and Ethics includes provisions applicable to all of our employees,
        including senior financial officers and members of our Board and is posted on our website. We intend to post amendments to or waivers from any such Code of Business Conduct and Ethics.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25; font-weight: bold;">Other Policies</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-indent: 36pt; line-height: 1.25;">Our insider trading and blackout policy prohibits directors, officers and employees from engaging in transactions in publicly traded options, such as puts and calls, and other derivative securities
        with respect to our securities. This prohibition extends to any hedging or similar transactions designed to decrease the risks associated with holding our securities.</div>
      <div style="margin-left: 5.3pt; line-height: 1.25; font-weight: bold;">&#160;</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Board Meetings</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The Board meets regularly during the year and holds special meetings and acts by unanimous written consent whenever circumstances require. Independent directors meet at regular
        executive sessions without management present. During fiscal year 2021, the Board held 13 meetings and conducted certain business by unanimous consent. All of our directors are encouraged to attend our Annual Meeting of shareholders. Each of our
        directors attended at least 75% of the aggregate of the total number of meetings of the Board and the total number of meetings held by all committees of the Board on which such director served. Directors are expected to attend the Annual General
        Meeting.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Board Committees</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Our Board has established the following committees. Each committee operates in accordance with a written charter that sets forth the committee&#8217;s structure, operations, membership
        requirements, responsibilities and authority to engage advisors.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Audit Committee</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Under the Companies Law, the Exchange Act and Nasdaq rules, we are required to establish an Audit Committee, and we have a separately-designated standing audit committee
        established in accordance with section 3(a)(58)(A) of the Exchange Act.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The responsibilities of an Audit Committee under the Companies Law include identifying and addressing flaws in the business management of the company, reviewing and approving
        related party transactions, establishing whistleblower procedures, overseeing the company&#8217;s internal audit system and the performance of its internal auditor, and assessing the scope of the work and recommending the fees of the company&#8217;s
        independent accounting firm. In addition, the Audit Committee is required to determine whether certain related party actions and transactions are &#8220;material&#8221; or &#8220;extraordinary&#8221; for the purpose of the requisite approval procedures under the Companies
        Law and to establish procedures for considering proposed transactions with a controlling shareholder.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In accordance with U.S. law and Nasdaq requirements, our Audit Committee is also responsible for the appointment, compensation and oversight of the work of our independent
        auditors and for assisting our Board in monitoring our financial statements, the effectiveness of our internal controls and our compliance with legal and regulatory requirements.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Under the Companies Law and related regulations, the Audit Committee must consist of at least three directors who meet certain independence criteria. Under the Nasdaq rules, we
        are required to maintain an Audit Committee consisting of at least three independent directors, all of whom are financially literate and one of whom has accounting or related financial management expertise. Each of the members of the Audit
        Committee is required to be &#8220;independent&#8221; as such term is defined in Rule 10A-3(b)(1) under the Exchange Act.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The members of the Audit Committee are Joel Maryles, Alan Moses and Claude Nicaise. Joel Maryles is the chairperson of the Audit Committee and is a financial expert under the
        rules of the SEC. Our Board has concluded that the composition of the Audit Committee meets the requirements for independence under the rules and regulations of Nasdaq and the SEC.&#160;During fiscal year 2021, the Audit Committee held three meetings.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="line-height: 1.25; font-style: italic; font-weight: bold;">Compensation Committee</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Under both the Companies Law and Nasdaq rules, we are required to establish a Compensation Committee.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The responsibilities of a Compensation Committee under the Companies Law include recommending to the Board, for ultimate shareholder approval by a special majority, a policy
        governing the compensation of directors and officers based on specified criteria, reviewing modifications to and implementing such compensation policy from time to time, and approving the actual compensation terms of directors and officers prior to
        approval by the Board.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In accordance with U.S. law and Nasdaq requirements, our Compensation Committee is also responsible for the appointment, compensation and oversight of the work of any
        compensation consultant, independent legal counsel and other advisors retained by the Compensation Committee.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The Companies Law and related regulations require the appointment of a Compensation Committee that complies with the requirements of Nasdaq. Under Nasdaq rules, we are required
        to maintain a Compensation Committee consisting of at least two independent directors; each of the members of the Compensation Committee is required to be independent under Nasdaq rules relating to Compensation Committee members, which are
        different from the general test for independence of board and committee members. The members of the Compensation Committee are Nissim Darvish and Neil Cohen. Nissim Darvish is the chairperson of the Compensation Committee. Our Board has determined
        that each member of the Compensation Committee is independent within the meaning of the independent director guidelines of Nasdaq and under Rule 10C-1 under the Exchange Act. During fiscal year 2021, the Compensation Committee held four meetings
        and conducted certain business by unanimous consent.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="line-height: 1.25; font-style: italic; font-weight: bold;">Corporate Governance and Nominating Committee</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We have established a Corporate Governance and Nominating Committee, responsible for making recommendations to the Board regarding candidates for directorships and the size and
        composition of the board. In addition, the committee is responsible for overseeing our corporate governance guidelines and reporting and making recommendations to the board concerning corporate governance matters. Under the Companies Law,
        nominations for director may also, under certain circumstances, be made by shareholders in accordance with the conditions prescribed by applicable law and our articles of association. The members of the Corporate Governance and Nominating Committee
        are Neil Cohen and Joel Maryles. Neil Cohen is the chairperson of the Corporate Governance and Nominating Committee. Our Board has determined that each member of the Corporate Governance and Nominating Committee is independent within the meaning of
        the independent director guidelines of Nasdaq.&#160;During fiscal year 2021, the Compensation Committee held one meeting and conducted certain business by unanimous consent.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="line-height: 1.25"> <br>
      </div>
      <div style="line-height: 1.25; font-weight: bold;">Board Diversity</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">
        <div style="text-indent: 36pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">While we do not currently have a formal diversity policy with respect to Board composition, the Board believes it is important for the Board
          to have gender, race and ethnicity diversity along with diversity of knowledge base, professional experience and skills. The Corporate Governance and Nominating Committee takes these qualities into account when considering director nominees for
          recommendation to the Board. We believe diversity enhances our effectiveness. Our Board currently has one female director and two members with racial diversity. However, the Board remains committed to achieving a Board composition that represents
          a diversity of background and experience, inclusive of race, ethnicity, gender and sexual orientation. The following matrix provides additional information about our board diversity as of April 28, 2022.</div>
      </div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="line-height: 1.25;">
        <table cellspacing="0" cellpadding="0" align="center" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 70%; text-align: left; color: rgb(0, 0, 0);" id="z58bec304bcd04e5994793226c0a781d1">

            <tr>
              <td colspan="9" style="vertical-align: top; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;">TOTAL NUMBER OF DIRECTORS &#8211; 7</div>
              </td>
            </tr>
            <tr>
              <td style="width: 47.74%; vertical-align: middle;">&#160;</td>
              <td colspan="2" style="vertical-align: middle;">&#160;</td>
              <td colspan="2" style="vertical-align: middle;">&#160;</td>
              <td colspan="2" style="vertical-align: middle;">&#160;</td>
              <td colspan="2" style="vertical-align: middle;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 47.74%; vertical-align: top; border-bottom: #000000 2px solid;">
                <div style="line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 9pt;">&#160;</div>
              </td>
              <td style="width: 0.64%; vertical-align: bottom; border-bottom: #000000 2px solid;">
                <div style="line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 9pt;">&#160;</div>
              </td>
              <td nowrap="nowrap" style="width: 7.54%; vertical-align: bottom; border-bottom: #000000 2px solid;">
                <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 9pt;">Female</div>
              </td>
              <td style="width: 0.64%; vertical-align: bottom; border-bottom: #000000 2px solid;">
                <div style="line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 9pt;">&#160;</div>
              </td>
              <td nowrap="nowrap" style="width: 5.26%; vertical-align: bottom; border-bottom: #000000 2px solid;">
                <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 9pt;">Male</div>
              </td>
              <td style="width: 0.64%; vertical-align: bottom; border-bottom: #000000 2px solid;">
                <div style="line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 9pt;">&#160;</div>
              </td>
              <td nowrap="nowrap" style="width: 10.95%; vertical-align: bottom; border-bottom: #000000 2px solid;">
                <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 9pt;">Nonbinary</div>
              </td>
              <td style="width: 0.64%; vertical-align: bottom; border-bottom: #000000 2px solid;">
                <div style="line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 9pt;">&#160;</div>
              </td>
              <td nowrap="nowrap" style="width: 25.95%; vertical-align: bottom; border-bottom: #000000 2px solid;">
                <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 9pt;">Did Not Disclose Gender</div>
              </td>
            </tr>
            <tr>
              <td style="width: 47.74%; vertical-align: middle;">&#160;</td>
              <td colspan="2" style="vertical-align: middle;">&#160;</td>
              <td colspan="2" style="vertical-align: middle;">&#160;</td>
              <td colspan="2" style="vertical-align: middle;">&#160;</td>
              <td colspan="2" style="vertical-align: middle;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 47.74%; vertical-align: top; background-color: #CCEEFF; border-bottom: #000000 2px solid;">
                <div style="text-indent: -12pt; margin-left: 12pt; line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 9pt;">PART 1:&#160;<font style="font-weight: bold; font-style: italic;">Gender Identity</font></div>
              </td>
              <td style="width: 0.64%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;">
                <div style="line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 9pt;">&#160;</div>
              </td>
              <td style="width: 7.54%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;">
                <div style="line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 9pt;">&#160;</div>
              </td>
              <td style="width: 0.64%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;">
                <div style="line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 9pt;">&#160;</div>
              </td>
              <td style="width: 5.26%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;">
                <div style="line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 9pt;">&#160;</div>
              </td>
              <td style="width: 0.64%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;">
                <div style="line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 9pt;">&#160;</div>
              </td>
              <td style="width: 10.95%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;">
                <div style="line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 9pt;">&#160;</div>
              </td>
              <td style="width: 0.64%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;">
                <div style="line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 9pt;">&#160;</div>
              </td>
              <td style="width: 25.95%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;">
                <div style="line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 9pt;">&#160;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 47.74%; vertical-align: middle;">&#160;</td>
              <td colspan="2" style="vertical-align: middle;">&#160;</td>
              <td colspan="2" style="vertical-align: middle;">&#160;</td>
              <td colspan="2" style="vertical-align: middle;">&#160;</td>
              <td colspan="2" style="vertical-align: middle;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 47.74%; vertical-align: top; border-bottom: #000000 2px solid;">
                <div style="text-indent: -12pt; margin-left: 24pt; line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 9pt;">Directors</div>
              </td>
              <td style="width: 0.64%; vertical-align: bottom; border-bottom: #000000 2px solid;">
                <div style="line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 9pt;">&#160;</div>
              </td>
              <td nowrap="nowrap" style="width: 7.54%; vertical-align: bottom; border-bottom: #000000 2px solid;">
                <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 9pt;">1</div>
              </td>
              <td style="width: 0.64%; vertical-align: bottom; border-bottom: #000000 2px solid;">
                <div style="line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 9pt;">&#160;</div>
              </td>
              <td nowrap="nowrap" style="width: 5.26%; vertical-align: bottom; border-bottom: #000000 2px solid;">
                <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 9pt;">6</div>
              </td>
              <td style="width: 0.64%; vertical-align: bottom; border-bottom: #000000 2px solid;">
                <div style="line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 9pt;">&#160;</div>
              </td>
              <td style="width: 10.95%; vertical-align: bottom; border-bottom: #000000 2px solid;">
                <div style="line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 9pt;">&#160;</div>
              </td>
              <td style="width: 0.64%; vertical-align: bottom; border-bottom: #000000 2px solid;">
                <div style="line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 9pt;">&#160;</div>
              </td>
              <td style="width: 25.95%; vertical-align: bottom; border-bottom: #000000 2px solid;">
                <div style="line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 9pt;">&#160;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 47.74%; vertical-align: middle;">&#160;</td>
              <td colspan="2" style="vertical-align: middle;">&#160;</td>
              <td colspan="2" style="vertical-align: middle;">&#160;</td>
              <td colspan="2" style="vertical-align: middle;">&#160;</td>
              <td colspan="2" style="vertical-align: middle;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 47.74%; vertical-align: top; background-color: #CCEEFF; border-bottom: #000000 2px solid;">
                <div style="text-indent: -12pt; margin-left: 12pt; line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 9pt;">PART 2:&#160;<font style="font-weight: bold; font-style: italic;">Demographic Background</font></div>
              </td>
              <td style="width: 0.64%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;">
                <div style="line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 9pt;">&#160;</div>
              </td>
              <td style="width: 7.54%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;">
                <div style="line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 9pt;">&#160;</div>
              </td>
              <td style="width: 0.64%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;">
                <div style="line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 9pt;">&#160;</div>
              </td>
              <td style="width: 5.26%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;">
                <div style="line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 9pt;">&#160;</div>
              </td>
              <td style="width: 0.64%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;">
                <div style="line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 9pt;">&#160;</div>
              </td>
              <td style="width: 10.95%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;">
                <div style="line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 9pt;">&#160;</div>
              </td>
              <td style="width: 0.64%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;">
                <div style="line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 9pt;">&#160;</div>
              </td>
              <td style="width: 25.95%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;">
                <div style="line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 9pt;">&#160;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 47.74%; vertical-align: middle;">&#160;</td>
              <td colspan="2" style="vertical-align: middle;">&#160;</td>
              <td colspan="2" style="vertical-align: middle;">&#160;</td>
              <td colspan="2" style="vertical-align: middle;">&#160;</td>
              <td colspan="2" style="vertical-align: middle;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 47.74%; vertical-align: top; border-bottom: #000000 2px solid;">
                <div style="text-indent: -12pt; margin-left: 24pt; line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 9pt;">African American or Black</div>
              </td>
              <td style="width: 0.64%; vertical-align: bottom; border-bottom: #000000 2px solid;">
                <div style="line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 9pt;">&#160;</div>
              </td>
              <td nowrap="nowrap" style="width: 7.54%; vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td>
              <td style="width: 0.64%; vertical-align: bottom; border-bottom: #000000 2px solid;">
                <div style="line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 9pt;">&#160;</div>
              </td>
              <td nowrap="nowrap" style="width: 5.26%; vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td>
              <td style="width: 0.64%; vertical-align: bottom; border-bottom: #000000 2px solid;">
                <div style="line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 9pt;">&#160;</div>
              </td>
              <td style="width: 10.95%; vertical-align: bottom; border-bottom: #000000 2px solid;">
                <div style="line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 9pt;">&#160;</div>
              </td>
              <td style="width: 0.64%; vertical-align: bottom; border-bottom: #000000 2px solid;">
                <div style="line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 9pt;">&#160;</div>
              </td>
              <td style="width: 25.95%; vertical-align: bottom; border-bottom: #000000 2px solid;">
                <div style="line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 9pt;">&#160;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 47.74%; vertical-align: middle;">&#160;</td>
              <td colspan="2" style="vertical-align: middle;">&#160;</td>
              <td colspan="2" style="vertical-align: middle;">&#160;</td>
              <td colspan="2" style="vertical-align: middle;">&#160;</td>
              <td colspan="2" style="vertical-align: middle;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 47.74%; vertical-align: top; background-color: #CCEEFF; border-bottom: #000000 2px solid;">
                <div style="text-indent: -12pt; margin-left: 24pt; line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 9pt;">Alaskan Native or Native American</div>
              </td>
              <td style="width: 0.64%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;">
                <div style="line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 9pt;">&#160;</div>
              </td>
              <td nowrap="nowrap" style="width: 7.54%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;">&#160;</td>
              <td style="width: 0.64%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;">&#160;</td>
              <td nowrap="nowrap" style="width: 5.26%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;">&#160;</td>
              <td style="width: 0.64%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;">&#160;</td>
              <td nowrap="nowrap" style="width: 10.95%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;">&#160;</td>
              <td style="width: 0.64%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;">&#160;</td>
              <td nowrap="nowrap" style="width: 25.95%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 47.74%; vertical-align: middle;">&#160;</td>
              <td colspan="2" style="vertical-align: middle;">&#160;</td>
              <td colspan="2" style="vertical-align: middle;">&#160;</td>
              <td colspan="2" style="vertical-align: middle;">&#160;</td>
              <td colspan="2" style="vertical-align: middle;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 47.74%; vertical-align: top; border-bottom: #000000 2px solid;">
                <div style="text-indent: -12pt; margin-left: 24pt; line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 9pt;">Asian</div>
              </td>
              <td style="width: 0.64%; vertical-align: bottom; border-bottom: #000000 2px solid;">
                <div style="line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 9pt;">&#160;</div>
              </td>
              <td nowrap="nowrap" style="width: 7.54%; vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td>
              <td style="width: 0.64%; vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td>
              <td nowrap="nowrap" style="width: 5.26%; vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td>
              <td style="width: 0.64%; vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td>
              <td nowrap="nowrap" style="width: 10.95%; vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td>
              <td style="width: 0.64%; vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td>
              <td nowrap="nowrap" style="width: 25.95%; vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 47.74%; vertical-align: middle;">&#160;</td>
              <td colspan="2" style="vertical-align: middle;">&#160;</td>
              <td colspan="2" style="vertical-align: middle;">&#160;</td>
              <td colspan="2" style="vertical-align: middle;">&#160;</td>
              <td colspan="2" style="vertical-align: middle;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 47.74%; vertical-align: top; background-color: #CCEEFF; border-bottom: #000000 2px solid;">
                <div style="text-indent: -12pt; margin-left: 24pt; line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 9pt;">Hispanic or Latinx</div>
              </td>
              <td style="width: 0.64%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;">
                <div style="line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 9pt;">&#160;</div>
              </td>
              <td nowrap="nowrap" style="width: 7.54%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;">&#160;</td>
              <td style="width: 0.64%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;">&#160;</td>
              <td nowrap="nowrap" style="width: 5.26%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;">&#160;</td>
              <td style="width: 0.64%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;">&#160;</td>
              <td nowrap="nowrap" style="width: 10.95%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;">&#160;</td>
              <td style="width: 0.64%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;">&#160;</td>
              <td nowrap="nowrap" style="width: 25.95%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 47.74%; vertical-align: middle;">&#160;</td>
              <td colspan="2" style="vertical-align: middle;">&#160;</td>
              <td colspan="2" style="vertical-align: middle;">&#160;</td>
              <td colspan="2" style="vertical-align: middle;">&#160;</td>
              <td colspan="2" style="vertical-align: middle;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 47.74%; vertical-align: top; border-bottom: #000000 2px solid;">
                <div style="text-indent: -12pt; margin-left: 24pt; line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 9pt;">Native Hawaiian or Pacific Islander</div>
              </td>
              <td style="width: 0.64%; vertical-align: bottom; border-bottom: #000000 2px solid;">
                <div style="line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 9pt;">&#160;</div>
              </td>
              <td nowrap="nowrap" style="width: 7.54%; vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td>
              <td style="width: 0.64%; vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td>
              <td nowrap="nowrap" style="width: 5.26%; vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td>
              <td style="width: 0.64%; vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td>
              <td nowrap="nowrap" style="width: 10.95%; vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td>
              <td style="width: 0.64%; vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td>
              <td nowrap="nowrap" style="width: 25.95%; vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 47.74%; vertical-align: top;">&#160;</td>
              <td style="width: 0.64%; vertical-align: bottom;">&#160;</td>
              <td nowrap="nowrap" style="width: 7.54%; vertical-align: bottom;">&#160;</td>
              <td style="width: 0.64%; vertical-align: bottom;">&#160;</td>
              <td nowrap="nowrap" style="width: 5.26%; vertical-align: bottom;">&#160;</td>
              <td style="width: 0.64%; vertical-align: bottom;">&#160;</td>
              <td nowrap="nowrap" style="width: 10.95%; vertical-align: bottom;">&#160;</td>
              <td style="width: 0.64%; vertical-align: bottom;">&#160;</td>
              <td nowrap="nowrap" style="width: 25.95%; vertical-align: bottom;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 47.74%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
                <div style="text-indent: -12pt; margin-left: 24pt; line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 9pt;">Middle Eastern or North African</div>
              </td>
              <td style="width: 0.64%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>
              <td nowrap="nowrap" style="width: 7.54%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>
              <td style="width: 0.64%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>
              <td nowrap="nowrap" style="width: 5.26%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
                <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 9pt;">2</div>
              </td>
              <td style="width: 0.64%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>
              <td nowrap="nowrap" style="width: 10.95%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>
              <td style="width: 0.64%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>
              <td nowrap="nowrap" style="width: 25.95%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>
            </tr>
            <tr>
              <td style="width: 47.74%; vertical-align: middle;">&#160;</td>
              <td colspan="2" style="vertical-align: middle;">&#160;</td>
              <td colspan="2" style="vertical-align: middle;">&#160;</td>
              <td colspan="2" style="vertical-align: middle;">&#160;</td>
              <td colspan="2" style="vertical-align: middle;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 47.74%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-indent: -12pt; margin-left: 24pt; line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 9pt;">White</div>
              </td>
              <td style="width: 0.64%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 9pt;">&#160;</div>
              </td>
              <td nowrap="nowrap" style="width: 7.54%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 9pt;">1</div>
              </td>
              <td style="width: 0.64%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
              <td nowrap="nowrap" style="width: 5.26%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 9pt;">5</div>
              </td>
              <td style="width: 0.64%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
              <td nowrap="nowrap" style="width: 10.95%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
              <td style="width: 0.64%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
              <td nowrap="nowrap" style="width: 25.95%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            </tr>
            <tr>
              <td style="width: 47.74%; vertical-align: middle;">&#160;</td>
              <td colspan="2" style="vertical-align: middle;">&#160;</td>
              <td colspan="2" style="vertical-align: middle;">&#160;</td>
              <td colspan="2" style="vertical-align: middle;">&#160;</td>
              <td colspan="2" style="vertical-align: middle;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 47.74%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
                <div style="text-indent: -12pt; margin-left: 24pt; line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 9pt;">Two or More Races or Ethnicities</div>
              </td>
              <td style="width: 0.64%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
                <div style="line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 9pt;">&#160;</div>
              </td>
              <td nowrap="nowrap" style="width: 7.54%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>
              <td style="width: 0.64%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>
              <td nowrap="nowrap" style="width: 5.26%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
                <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 9pt;">1</div>
              </td>
              <td style="width: 0.64%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>
              <td nowrap="nowrap" style="width: 10.95%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>
              <td style="width: 0.64%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>
              <td nowrap="nowrap" style="width: 25.95%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>
            </tr>
            <tr>
              <td style="width: 47.74%; vertical-align: middle;">&#160;</td>
              <td colspan="2" style="vertical-align: middle;">&#160;</td>
              <td colspan="2" style="vertical-align: middle;">&#160;</td>
              <td colspan="2" style="vertical-align: middle;">&#160;</td>
              <td colspan="2" style="vertical-align: middle;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 47.74%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-indent: -12pt; margin-left: 24pt; line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 9pt;">LGBTQ+</div>
              </td>
              <td style="width: 0.64%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 9pt;">&#160;</div>
              </td>
              <td nowrap="nowrap" style="width: 7.54%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
              <td style="width: 0.64%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
              <td nowrap="nowrap" style="width: 5.26%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
              <td style="width: 0.64%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
              <td nowrap="nowrap" style="width: 10.95%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
              <td style="width: 0.64%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
              <td nowrap="nowrap" style="width: 25.95%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            </tr>
            <tr>
              <td style="width: 47.74%; vertical-align: middle;">&#160;</td>
              <td colspan="2" style="vertical-align: middle;">&#160;</td>
              <td colspan="2" style="vertical-align: middle;">&#160;</td>
              <td colspan="2" style="vertical-align: middle;">&#160;</td>
              <td colspan="2" style="vertical-align: middle;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 47.74%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
                <div style="text-indent: -12pt; margin-left: 24pt; line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 9pt;">Did Not Disclose Demographic Background</div>
              </td>
              <td style="width: 0.64%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
                <div style="line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 9pt;">&#160;</div>
              </td>
              <td nowrap="nowrap" style="width: 7.54%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>
              <td style="width: 0.64%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>
              <td nowrap="nowrap" style="width: 5.26%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>
              <td style="width: 0.64%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>
              <td nowrap="nowrap" style="width: 10.95%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>
              <td style="width: 0.64%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>
              <td nowrap="nowrap" style="width: 25.95%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>
            </tr>

        </table>
      </div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="line-height: 1.25; font-weight: bold;">Communication with our Board</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Shareholders may communicate with the Board by directing their communications in a hard copy (i.e., non-electronic) written form to the attention of one or more members of the
        Board, or to the Board collectively, at our principal executive offices located at Kiryat Atidim, Building 7, Tel Aviv, Israel 6158002. Any communications received from interested parties in the manner described above will be collected and
        organized by our Corporate Secretary (or, in the absence thereof, by the Chief Executive Officer of the Company) and will be periodically, but in any event prior to each regularly-scheduled Board meeting, reported and/or delivered to the
        appropriate director or directors.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; margin-right: 124.2pt; margin-left: 124.7pt; line-height: 1.25; font-weight: bold;">EXECUTIVE COMPENSATION</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">
        <div style="text-align: justify; text-indent: 18pt; line-height: 1.25;">As approved by our shareholders, and as required by the Companies Law, we have adopted a compensation policy (the "Compensation Policy") regarding the terms of office and
          employment of its &#8220;office holders&#8221; (as defined in the Companies Law), including cash compensation, equity-based awards, releases from liability, indemnification and insurance, severance and other benefits. Each of the named executive officers is
          an &#8220;office holder&#8221; within the meaning of the Companies Law. The Compensation Policy is reviewed from time to time by our Compensation Committee and our Board to ensure its appropriateness.</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
      <div style="line-height: 1.25;">
        <div style="text-align: justify; text-indent: 18pt; line-height: 1.25;">Our Compensation Policy is designed to promote retention and motivation of directors and executive officers, incentivize superior individual excellence, align the interests of
          our directors and executive officers with our long-term performance, and provide a risk management tool. To that end, a portion of an executive officer&#8217;s compensation package is targeted to reflect our short and long-term goals, as well as the
          executive officer&#8217;s individual performance. On the other hand, our Compensation Policy includes measures designed to reduce the executive officer&#8217;s incentives to take excessive risks that may harm us in the long-term, such as limits on the value
          of cash bonuses and equity-based compensation, limitations on the ratio between the variable and the total compensation of an executive officer, and minimum vesting periods for equity-based compensation.</div>
        <div style="text-align: justify; text-indent: 18pt; line-height: 1.25;">&#160;</div>
        <div style="text-align: justify; text-indent: 18pt; line-height: 1.25;">Our Compensation Policy also addresses our executive officers&#8217; individual characteristics (such as his or her respective position, education, scope of responsibilities, and
          contribution to the attainment of our goals) as the basis for compensation variation among our executive officers and considers the internal ratios between compensation of our executive officers and directors and other employees. Pursuant to our
          Compensation Policy, the compensation that may be granted to an executive officer may include: base salary, annual bonuses, and other cash bonuses (such as a signing bonus and special bonuses with respect to any special achievements, such as
          outstanding personal achievement, outstanding personal effort, or outstanding company performance), equity-based compensation, benefits, and retirement and termination of service arrangements. All cash bonuses are limited to a maximum amount
          linked to the executive officer&#8217;s base salary.</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 18pt; line-height: 1.25;">An annual cash bonus may be awarded to executive officers upon the attainment&#160;of&#160;pre-set&#160;periodic&#160;objectives and individual targets. The annual cash bonus that may be granted
          to our executive officers other than our chief executive officer will be based on performance objectives and a discretionary evaluation of the executive officer&#8217;s overall performance by our chief executive officer and subject to minimum
          thresholds. The annual cash bonus that may be granted to executive officers other than our chief executive officer may alternatively be based entirely on a discretionary evaluation. Furthermore, our chief executive officer will be entitled to
          approve performance objectives for executive officers who report to him. The performance objectives and the weight to be assigned to each achievement in the overall evaluation will be based on overall company performance measures, which may be
          based on actual financial and operational results, such as (but not limited to) revenues, operating income and cash flow, and may further include divisional or personal objectives, which may include operational objectives, such as (but not
          limited to) market share, initiation of new markets and operational efficiency, customer focused objectives, project milestones objectives and investment in human capital objectives, such as employee satisfaction, employee retention and employee
          training and leadership programs.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 18pt; line-height: 1.25;">The measurable performance objectives of our chief executive officer will be determined annually by our Compensation Committee and Board. A&#160;portion of the chief executive
          officer&#8217;s annual cash bonus may be based on a discretionary evaluation of the chief executive officer&#8217;s overall performance by the Compensation Committee and the Board, based on quantitative and qualitative criteria. The measurable performance
          (which include the objectives and the weight to be assigned to each achievement in the overall evaluation) will be based on overall company performance measures and personal objectives. Company objectives may include actual financial and
          operational results, such as (but not limited to) revenues, sales, operating income, cash flow or our annual operating plan and long-term plan.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 18pt; line-height: 1.25;">The equity-based compensation under our Compensation Policy for our executive officers (including members of our Board) is designed in a manner consistent with the underlying
          objectives in determining the base salary and the annual cash bonus, with its main objectives being to enhance the alignment between the executive officers&#8217; interests with our long-term interests and those of our shareholders and to strengthen
          the retention and the motivation of executive officers in the long term. Our Compensation Policy provides for executive officer compensation in the form of equity-based awards, such as share options, restricted shares and restricted share units,
          in accordance with our share incentive plan then in place. All equity-based incentives granted to executive officers shall be subject to vesting periods in order to promote long-term retention of the awarded executive officers. The equity-based
          compensation shall be granted from time to time and be individually determined and awarded according to the performance, educational background, prior experience, qualifications, role, and the personal responsibilities of the executive officer.</div>
        <div style="line-height: 1.25">&#160;</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="text-align: justify; text-indent: 18pt; line-height: 1.25;">In addition, our Compensation Policy contains compensation recovery, or clawback provisions, in the event of an accounting restatement, provisions which allow us under certain
          conditions to recover bonuses, bonus compensation or performance-based equity compensation paid in excess, enable our Chief Executive Officer to approve an immaterial change in the terms of employment of an executive officer who reports directly
          to him (provided that the changes of the terms of employment are in accordance with our Compensation Policy) and allow us to exculpate, indemnify, and insure our executive officers and directors to the maximum extent permitted by Israeli law,
          subject to certain limitations set forth therein.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 18pt; line-height: 1.25;">Our Compensation Policy also provides for compensation to the members of our Board either (i)&#160;in accordance with the amounts provided in the Companies Regulations (Rules
          Regarding the Compensation and Expenses of an External Director) of 2000, as amended by the Companies Regulations (Relief for Public Companies Traded in Stock Exchange Outside of Israel) of 2000, as such regulations may be amended from time to
          time, or (ii)&#160;in accordance with the amounts determined in our Compensation Policy.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 18pt; line-height: 1.25;">Our Compensation Policy was amended and approved by our shareholders on July 19, 2021.</div>
        <div style="line-height: 1.25;">&#160;<br>
          <div style="line-height: 1.25; font-weight: bold;">Processes and Procedures for Compensation Decisions</div>
          <div style="line-height: 1.25">&#160;</div>
          <div style="line-height: 1.25;">
            <div style="text-align: justify; text-indent: 18pt; line-height: 1.25;">In accordance with the Companies Law, the decisions with respect to fiscal 2021 executive officer compensation, including the compensation of our named executive officers,
              are governed by our Compensation Policy for directors and officers, and made by our Compensation Committee and Board, with input from our chief executive officer (except with respect to his own compensation) and Deloitte Israel, an
              independent compensation consultant within the meaning of the rules of the SEC and Nasdaq. Deloitte Israel was engaged by our Compensation Committee pursuant to the authority delegated under its charter and serves at the discretion of the
              Compensation Committee.</div>
            <div style="line-height: 1.25">&#160;</div>
            <div style="text-align: justify; text-indent: 18pt; line-height: 1.25;">Our Compensation Committee believes our chief executive officer has valuable insight into&#160;the&#160;day-to-day&#160;contributions&#160;of our executive officers, and solicits the advice
              and input from him with respect to performance objectives under our annual bonus plan and target compensation levels for our executive officers, including our named executive officers, which are later being reviewed and approved by the Board.
              Our chief executive officer does not provide input on his own compensation, which is determined by our Compensation Committee and the Board in accordance with the Companies Law. At the request of our Compensation Committee, Deloitte Israel
              provides an assessment of the competitiveness of our executive compensation program as compared with our competitors, and our Compensation Committee uses this assessment as one of several factors in approving target levels of compensation for
              each executive officer. Other factors our Compensation Committee considers in setting executive compensation include one or more of the following: individual performance and skills, management input, internal relative alignment of
              compensation levels, anticipated future contributions to our company, and the judgment and experience of the members of our Compensation Committee.</div>
            <div style="text-align: justify; text-indent: 18pt; line-height: 1.25;"> <br>
            </div>
            <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
              <div id="DSPFPageBreak" style="page-break-after: always;">
                <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
            </div>
            <div style="line-height: 1.25">&#160;</div>
            <div style="line-height: 1.25; font-weight: bold;">Aggregate Compensation of Directors and Officers</div>
            <div style="line-height: 1.25">&#160;</div>
            <div style="line-height: 1.25;">
              <div style="text-align: justify; text-indent: 18pt; line-height: 1.25;">
                <div style="text-indent: 36pt; line-height: 1.25; font-family: 'Times New Roman',serif;">
                  <div style="line-height: 1.25; color: rgb(0, 0, 0);">The aggregate compensation we paid to our executive officers and directors (who served as executive officers and directors as of December 31, 2021) for the year ended December&#160;31, 2021
                    was approximately $950 thousand. This amount includes amounts paid, set aside or accrued to provide pension, severance, retirement or similar benefits or expenses, but does not include share-based compensation expenses, or business
                    travel, professional and business association dues and expenses reimbursed to office holders, and other benefits commonly reimbursed or paid by companies in our industry. As of December&#160;31, 2021, options to purchase 961,015 ADSs&#160;
                    granted to our officers and directors were outstanding under our share option plan at a weighted average exercise price of $9.0 per ADS.</div>
                </div>
              </div>
              <div style="line-height: 1.25;">&#160;<br>
                <div style="line-height: 1.25; font-weight: bold;">Summary Compensation Table</div>
                <div style="line-height: 1.25">&#160;</div>
                <div style="line-height: 1.25;">
                  <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The table and summary below outlines the compensation granted to individuals who served in the role of chief executive officer during the previous fiscal year and our
                    three most highly compensated executive officers with respect to the year ended December&#160;31, 2021. For purposes of the table and the summary below, &#8220;compensation&#8221; includes base salary, bonuses, equity-based compensation, retirement or
                    termination payments, benefits and perquisites such as car, phone and social benefits and any undertaking to provide such compensation.</div>
                  <div style="text-align: justify; text-indent: 18pt; line-height: 1.25;"> <br>
                  </div>
                </div>
              </div>
            </div>
          </div>
        </div>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="ze96b984867344b81b25a676cfe0b1818">

          <tr>
            <td style="width: 41.97%; vertical-align: bottom; border-bottom: #000000 2px solid;">
              <div style="line-height: 1.25;">Name and Principal Position</div>
            </td>
            <td style="width: 0.98%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 8.97%; vertical-align: bottom; border-bottom: #000000 2px solid;">
              <div style="text-align: center; line-height: 1.25;">Year</div>
            </td>
            <td style="width: 0.98%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td colspan="2" style="width: 9.95%; vertical-align: bottom; border-bottom: #000000 2px solid;">
              <div style="text-align: center; line-height: 1.25;">Salary<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup>&#160;(USD in<br>
                thousands)</div>
            </td>
            <td nowrap="nowrap" style="width: 0.98%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 0.98%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td colspan="2" style="width: 9.95%; vertical-align: bottom; border-bottom: #000000 2px solid;">
              <div style="text-align: center; line-height: 1.25;">Bonus<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup>&#160;(USD in<br>
                thousands)</div>
            </td>
            <td nowrap="nowrap" style="width: 0.98%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 0.99%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td colspan="2" style="width: 10.38%; vertical-align: bottom; border-bottom: #000000 2px solid;">
              <div style="text-align: center; line-height: 1.25;">Equity-Based<br>
                Compensation<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(3)(4)</sup><br>
                (USD in thousands)</div>
            </td>
            <td nowrap="nowrap" style="width: 0.99%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 0.99%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td colspan="2" style="width: 9.96%; vertical-align: bottom; border-bottom: #000000 2px solid;">
              <div style="text-align: center; line-height: 1.25;">Total (USD in<br>
                thousands)</div>
            </td>
            <td nowrap="nowrap" style="width: 0.99%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 41.97%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">Dale Pfost</div>
            </td>
            <td style="width: 0.98%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 8.97%; vertical-align: top; background-color: #CCEEFF;">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">2020</div>
            </td>
            <td style="width: 0.98%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 0.98%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 8.97%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="text-align: right; line-height: 1.25;">-</div>
            </td>
            <td nowrap="nowrap" style="width: 0.98%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 0.98%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 0.98%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 8.97%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="text-align: right; line-height: 1.25;">-</div>
            </td>
            <td nowrap="nowrap" style="width: 0.98%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 0.99%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 1.04%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 9.34%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="text-align: right; line-height: 1.25;">-</div>
            </td>
            <td nowrap="nowrap" style="width: 0.99%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 0.99%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 0.99%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 8.98%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="text-align: right; line-height: 1.25;">-</div>
            </td>
            <td nowrap="nowrap" style="width: 0.99%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 41.97%; vertical-align: bottom;">
              <div style="line-height: 1.25;"><font style="font-style: italic;">Chief Executive Officer and Chairman</font>&#160;(5)</div>
            </td>
            <td style="width: 0.98%; vertical-align: top;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 8.97%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">2021</div>
            </td>
            <td style="width: 0.98%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 0.98%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 8.97%; vertical-align: bottom;">
              <div style="text-align: right; line-height: 1.25;">192</div>
            </td>
            <td nowrap="nowrap" style="width: 0.98%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 0.98%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 0.98%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 8.97%; vertical-align: bottom;">
              <div style="text-align: right; line-height: 1.25;">-</div>
            </td>
            <td nowrap="nowrap" style="width: 0.98%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 0.99%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 1.04%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 9.34%; vertical-align: bottom;">
              <div style="text-align: right; line-height: 1.25;">300</div>
            </td>
            <td nowrap="nowrap" style="width: 0.99%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 0.99%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 0.99%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 8.98%; vertical-align: bottom;">
              <div style="text-align: right; line-height: 1.25;">492</div>
            </td>
            <td nowrap="nowrap" style="width: 0.99%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 41.97%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 0.98%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 8.97%; vertical-align: top; background-color: #CCEEFF;">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
            </td>
            <td style="width: 0.98%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 0.98%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 8.97%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="text-align: right; line-height: 1.25;">&#160;</div>
            </td>
            <td nowrap="nowrap" style="width: 0.98%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 0.98%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 0.98%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 8.97%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="text-align: right; line-height: 1.25;">&#160;</div>
            </td>
            <td nowrap="nowrap" style="width: 0.98%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 0.99%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 1.04%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 9.34%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="text-align: right; line-height: 1.25;">&#160;</div>
            </td>
            <td nowrap="nowrap" style="width: 0.99%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 0.99%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 0.99%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 8.98%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="text-align: right; line-height: 1.25;">&#160;</div>
            </td>
            <td nowrap="nowrap" style="width: 0.99%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 41.97%; vertical-align: bottom;">
              <div style="line-height: 1.25;">Adi Mor</div>
            </td>
            <td style="width: 0.98%; vertical-align: top;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 8.97%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">2020</div>
            </td>
            <td style="width: 0.98%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 0.98%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 8.97%; vertical-align: bottom;">
              <div style="text-align: right; line-height: 1.25;">229</div>
            </td>
            <td nowrap="nowrap" style="width: 0.98%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 0.98%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 0.98%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 8.97%; vertical-align: bottom;">
              <div style="text-align: right; line-height: 1.25;">75</div>
            </td>
            <td nowrap="nowrap" style="width: 0.98%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 0.99%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 1.04%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 9.34%; vertical-align: bottom;">
              <div style="text-align: right; line-height: 1.25;">21</div>
            </td>
            <td nowrap="nowrap" style="width: 0.99%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 0.99%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 0.99%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 8.98%; vertical-align: bottom;">
              <div style="text-align: right; line-height: 1.25;">325</div>
            </td>
            <td nowrap="nowrap" style="width: 0.99%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 41.97%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;"><font style="font-style: italic;">Chief Scientific Officer, Director and Previous Chief Executive Officer&#160;</font>(6)</div>
            </td>
            <td style="width: 0.98%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 8.97%; vertical-align: top; background-color: #CCEEFF;">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">2021</div>
            </td>
            <td style="width: 0.98%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 0.98%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 8.97%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="text-align: right; line-height: 1.25;">313</div>
            </td>
            <td nowrap="nowrap" style="width: 0.98%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 0.98%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 0.98%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 8.97%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="text-align: right; line-height: 1.25;">167</div>
            </td>
            <td nowrap="nowrap" style="width: 0.98%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 0.99%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 1.04%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 9.34%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="text-align: right; line-height: 1.25;">8</div>
            </td>
            <td nowrap="nowrap" style="width: 0.99%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 0.99%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 0.99%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 8.98%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="text-align: right; line-height: 1.25;">519</div>
            </td>
            <td nowrap="nowrap" style="width: 0.99%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 41.97%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 0.98%; vertical-align: top;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 8.97%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
            </td>
            <td style="width: 0.98%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 0.98%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 8.97%; vertical-align: bottom;">
              <div style="text-align: right; line-height: 1.25;">&#160;</div>
            </td>
            <td nowrap="nowrap" style="width: 0.98%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 0.98%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 0.98%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 8.97%; vertical-align: bottom;">
              <div style="text-align: right; line-height: 1.25;">&#160;</div>
            </td>
            <td nowrap="nowrap" style="width: 0.98%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 0.99%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 1.04%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 9.34%; vertical-align: bottom;">
              <div style="text-align: right; line-height: 1.25;">&#160;</div>
            </td>
            <td nowrap="nowrap" style="width: 0.99%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 0.99%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 0.99%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 8.98%; vertical-align: bottom;">
              <div style="text-align: right; line-height: 1.25;">&#160;</div>
            </td>
            <td nowrap="nowrap" style="width: 0.99%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 41.97%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">Donald Marvin</div>
            </td>
            <td style="width: 0.98%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 8.97%; vertical-align: top; background-color: #CCEEFF;">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">2020</div>
            </td>
            <td style="width: 0.98%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 0.98%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 8.97%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="text-align: right; line-height: 1.25;">-</div>
            </td>
            <td nowrap="nowrap" style="width: 0.98%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 0.98%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 0.98%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 8.97%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="text-align: right; line-height: 1.25;">-</div>
            </td>
            <td nowrap="nowrap" style="width: 0.98%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 0.99%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 1.04%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 9.34%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="text-align: right; line-height: 1.25;">-</div>
            </td>
            <td nowrap="nowrap" style="width: 0.99%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 0.99%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 0.99%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 8.98%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="text-align: right; line-height: 1.25;">-</div>
            </td>
            <td nowrap="nowrap" style="width: 0.99%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 41.97%; vertical-align: bottom;">
              <div style="line-height: 1.25;"><font style="font-style: italic;">Chief Financial Officer, Executive Vice President and Chief Operating Officer</font>&#160;(7)</div>
            </td>
            <td style="width: 0.98%; vertical-align: top;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 8.97%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">2021</div>
            </td>
            <td style="width: 0.98%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 0.98%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 8.97%; vertical-align: bottom;">
              <div style="text-align: right; line-height: 1.25;">94</div>
            </td>
            <td nowrap="nowrap" style="width: 0.98%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 0.98%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 0.98%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 8.97%; vertical-align: bottom;">
              <div style="text-align: right; line-height: 1.25;">-</div>
            </td>
            <td nowrap="nowrap" style="width: 0.98%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 0.99%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 1.04%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 9.34%; vertical-align: bottom;">
              <div style="text-align: right; line-height: 1.25;">102</div>
            </td>
            <td nowrap="nowrap" style="width: 0.99%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 0.99%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 0.99%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 8.98%; vertical-align: bottom;">
              <div style="text-align: right; line-height: 1.25;">196</div>
            </td>
            <td nowrap="nowrap" style="width: 0.99%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 41.97%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 0.98%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 8.97%; vertical-align: top; background-color: #CCEEFF;">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
            </td>
            <td style="width: 0.98%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 0.98%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 8.97%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="text-align: right; line-height: 1.25;">&#160;</div>
            </td>
            <td nowrap="nowrap" style="width: 0.98%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 0.98%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 0.98%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 8.97%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="text-align: right; line-height: 1.25;">&#160;</div>
            </td>
            <td nowrap="nowrap" style="width: 0.98%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 0.99%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 1.04%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 9.34%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="text-align: right; line-height: 1.25;">&#160;</div>
            </td>
            <td nowrap="nowrap" style="width: 0.99%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 0.99%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 0.99%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 8.98%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="text-align: right; line-height: 1.25;">&#160;</div>
            </td>
            <td nowrap="nowrap" style="width: 0.99%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 41.97%; vertical-align: bottom;">
              <div style="line-height: 1.25;">Sigal Fattal</div>
            </td>
            <td style="width: 0.98%; vertical-align: top;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 8.97%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">2020</div>
            </td>
            <td style="width: 0.98%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 0.98%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 8.97%; vertical-align: bottom;">
              <div style="text-align: right; line-height: 1.25;">-</div>
            </td>
            <td nowrap="nowrap" style="width: 0.98%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 0.98%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 0.98%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 8.97%; vertical-align: bottom;">
              <div style="text-align: right; line-height: 1.25;">-</div>
            </td>
            <td nowrap="nowrap" style="width: 0.98%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 0.99%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 1.04%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 9.34%; vertical-align: bottom;">
              <div style="text-align: right; line-height: 1.25;">-</div>
            </td>
            <td nowrap="nowrap" style="width: 0.99%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 0.99%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 0.99%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 8.98%; vertical-align: bottom;">
              <div style="text-align: right; line-height: 1.25;">-</div>
            </td>
            <td nowrap="nowrap" style="width: 0.99%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 41.97%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;"><font style="font-style: italic;">Previous Interim Chief Financial Officer</font>&#160;(8)</div>
            </td>
            <td style="width: 0.98%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 8.97%; vertical-align: top; background-color: #CCEEFF;">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">2021</div>
            </td>
            <td style="width: 0.98%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 0.98%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 8.97%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="text-align: right; line-height: 1.25;">136</div>
            </td>
            <td nowrap="nowrap" style="width: 0.98%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 0.98%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 0.98%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 8.97%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="text-align: right; line-height: 1.25;">122</div>
            </td>
            <td nowrap="nowrap" style="width: 0.98%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 0.99%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 1.04%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 9.34%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="text-align: right; line-height: 1.25;">616</div>
            </td>
            <td nowrap="nowrap" style="width: 0.99%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 0.99%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 0.99%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 8.98%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="text-align: right; line-height: 1.25;">906</div>
            </td>
            <td nowrap="nowrap" style="width: 0.99%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 41.97%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 0.98%; vertical-align: top;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 8.97%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
            </td>
            <td style="width: 0.98%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 0.98%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 8.97%; vertical-align: bottom;">
              <div style="text-align: right; line-height: 1.25;">&#160;</div>
            </td>
            <td nowrap="nowrap" style="width: 0.98%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 0.98%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 0.98%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 8.97%; vertical-align: bottom;">
              <div style="text-align: right; line-height: 1.25;">&#160;</div>
            </td>
            <td nowrap="nowrap" style="width: 0.98%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 0.99%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 1.04%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 9.34%; vertical-align: bottom;">
              <div style="text-align: right; line-height: 1.25;">&#160;</div>
            </td>
            <td nowrap="nowrap" style="width: 0.99%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 0.99%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 0.99%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 8.98%; vertical-align: bottom;">
              <div style="text-align: right; line-height: 1.25;">&#160;</div>
            </td>
            <td nowrap="nowrap" style="width: 0.99%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 41.97%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">Arnon Aharon</div>
            </td>
            <td style="width: 0.98%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 8.97%; vertical-align: top; background-color: #CCEEFF;">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">2020</div>
            </td>
            <td style="width: 0.98%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 0.98%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 8.97%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="text-align: right; line-height: 1.25;">261</div>
            </td>
            <td nowrap="nowrap" style="width: 0.98%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 0.98%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 0.98%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 8.97%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="text-align: right; line-height: 1.25;">38</div>
            </td>
            <td nowrap="nowrap" style="width: 0.98%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 0.99%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 1.04%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 9.34%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="text-align: right; line-height: 1.25;">51</div>
            </td>
            <td nowrap="nowrap" style="width: 0.99%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 0.99%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 0.99%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 8.98%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="text-align: right; line-height: 1.25;">375</div>
            </td>
            <td nowrap="nowrap" style="width: 0.99%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 41.97%; vertical-align: bottom;">
              <div style="line-height: 1.25;"><font style="font-style: italic;">Previous Chief Medical Officer</font>&#160;(9)</div>
            </td>
            <td style="width: 0.98%; vertical-align: top;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 8.97%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">2021</div>
            </td>
            <td style="width: 0.98%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 0.98%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 8.97%; vertical-align: bottom;">
              <div style="text-align: right; line-height: 1.25;">264</div>
            </td>
            <td nowrap="nowrap" style="width: 0.98%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 0.98%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 0.98%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 8.97%; vertical-align: bottom;">
              <div style="text-align: right; line-height: 1.25;">91</div>
            </td>
            <td nowrap="nowrap" style="width: 0.98%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 0.99%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 1.04%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 9.34%; vertical-align: bottom;">
              <div style="text-align: right; line-height: 1.25;">15</div>
            </td>
            <td nowrap="nowrap" style="width: 0.99%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 0.99%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 0.99%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 8.98%; vertical-align: bottom;">
              <div style="text-align: right; line-height: 1.25;">370</div>
            </td>
            <td nowrap="nowrap" style="width: 0.99%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="line-height: 1.25;">(1)&#160;&#160;&#160;&#160;&#160;&#160;&#160;Salary includes gross salary plus payment by us of social benefits on behalf of the officer. Such benefits may include, to the extent applicable, payments, contributions and/or allocations for risk
          insurance (e.g., life, or work disability insurance), payments for social security, vacation, medical insurance and benefits, and other benefits and perquisites consistent with our policies.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="line-height: 1.25;">(2)&#160;&#160;&#160;&#160;&#160;&#160;&#160;Represents bonuses granted with respect to 2020 and 2021.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="line-height: 1.25;">
          <div style="line-height: 1.25; color: rgb(0, 0, 0); font-family: 'Times New Roman',serif;">(3)&#160;&#160;&#160;&#160;&#160;&#160;&#160;Represents the equity-based compensation expenses recorded in our consolidated financial statements for the year ended December&#160;31, 2021, based
            on the options&#8217; fair value on the grant date, calculated in accordance with applicable accounting guidance for equity-based compensation. For a discussion of the assumptions used in reaching this valuation, see Note 2K to our annual
            consolidated financial statements included in this Annual Report on Form&#160;10-K.</div>
        </div>
        <div style="line-height: 1.25">&#160; <br>
        </div>
        <div style="line-height: 1.25;">(4)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Represents option awards.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="line-height: 1.25;">(5)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Dr. Dale Pfost&#8217;s terms of compensation were approved by the Company&#8217;s shareholders on October 25, 2021, which includes an annual base salary of $600,000. Dr. Pfost&#8217;s compensation data set forth in the
          above table is pro-rated to reflect time served as the Company&#8217;s chief executive officer in 2021.</div>
        <div style="line-height: 1.25;"> <br>
        </div>
        <div style="line-height: 1.25;">(6)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;In addition to her current positions of Chief Scientific Officer and a member of our Board, Dr. Adi Mor previously served as our Chief Executive Officer, and resigned from such role concurrent with the
          commencement of Dr. Dale Pfost&#8217;s service as our Chief Executive Officer on October 25, 2021.</div>
        <div style="line-height: 1.25;">&#160;
          <div style="line-height: 1.25;">(7)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Mr. Donald Marvin&#8217;s employment with the Company commenced on November 4, 2021, which include an annual base salary of $460,000. The compensation data set forth in the above table is pro-rated to
            reflect time served as the Company&#8217;s Chief Financial Officer, Executive Vice President and Chief Operating Officer in 2021.</div>
          <div style="line-height: 1.25;">&#160;
            <div style="line-height: 1.25;">(8)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;In addition to her current position as Consulting VP Finance, Ms. Fattal previously served as our interim Chief Financial Officer, and resigned from such role concurrent with the commencement of Mr.
              Marvin&#8217;s service as our Chief Financial Officer on November 8, 2021. Ms. Fattal&#8217;s compensation data set forth in the above table is pro-rated to reflect time served as the Company&#8217;s interim Chief Financial Officer in 2021.</div>
            <div style="line-height: 1.25">&#160;</div>
            <div style="line-height: 1.25;">(9)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Dr. Arnon Aharon resigned from his position as our Chief Medical Officer effective on January 31, 2022.</div>
            <div style="line-height: 1.25">&#160;</div>
            <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
              <div id="DSPFPageBreak" style="page-break-after: always;">
                <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
            </div>
            <br>
            <div style="line-height: 1.25; font-weight: bold;">Outstanding Equity Awards</div>
            <div style="line-height: 1.25;">&#160;
              <div style="text-indent: 18pt; line-height: 1.25;">The table below outlines the outstanding options to purchase ADSs held by our named executive officers outstanding as of December&#160;31, 2021.</div>
              <div style="line-height: 1.25">&#160;</div>
              <div style="line-height: 1.25">
                <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z95a7069d689b4c23a9e5e31b73f5311f">

                    <tr>
                      <td style="width: 51.79%; vertical-align: bottom;">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td style="width: 1%; vertical-align: bottom;">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td colspan="14" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                        <div style="text-align: center; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-weight: bold;">Option award</div>
                      </td>
                      <td nowrap="nowrap" style="width: 0.96%; vertical-align: bottom;">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                    </tr>
                    <tr>
                      <td style="width: 51.79%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-weight: bold;">Name</div>
                      </td>
                      <td style="width: 1%; vertical-align: bottom;">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                        <div style="text-align: center; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-weight: bold;">Number of securities<br>
                          underlying<br>
                          unexercised options<br>
                          (#) exercisable</div>
                      </td>
                      <td nowrap="nowrap" style="width: 1%; vertical-align: bottom;">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td style="width: 1%; vertical-align: bottom;">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                        <div style="text-align: center; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-weight: bold;">Number of<br>
                          securities<br>
                          underlying<br>
                          unexercised options<br>
                          (#)<br>
                          unexercsiable</div>
                      </td>
                      <td nowrap="nowrap" style="width: 1.41%; vertical-align: bottom;">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td style="width: 1%; vertical-align: bottom;">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                        <div style="text-align: center; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-weight: bold;">Option<br>
                          exercise<br>
                          price ($)</div>
                      </td>
                      <td nowrap="nowrap" style="width: 1%; vertical-align: bottom;">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td style="width: 1%; vertical-align: bottom;">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                        <div style="text-align: center; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-weight: bold;">Option expiration<br>
                          date</div>
                      </td>
                      <td nowrap="nowrap" style="width: 0.96%; vertical-align: bottom;">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                    </tr>
                    <tr>
                      <td style="width: 51.79%; vertical-align: top; background-color: rgb(204, 238, 255);">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">Dale Pfost,&#160;<font style="font-style: italic;">Chief Executive Officer and Chairman of the Board</font></div>
                      </td>
                      <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td style="width: 8.97%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                        <div style="text-align: right; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">-</div>
                      </td>
                      <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td style="width: 8.97%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                        <div style="text-align: right; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">459,353</div>
                      </td>
                      <td nowrap="nowrap" style="width: 1.41%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                        <div style="line-height: 1.25; color: rgb(0, 0, 0); font-family: 'Times New Roman',serif; font-size: 7.5pt;"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup></div>
                      </td>
                      <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td style="width: 8.97%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                        <div style="text-align: right; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">10.05</div>
                      </td>
                      <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td colspan="2" style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
                        <div style="text-align: center; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">25/10/2031</div>
                      </td>
                      <td nowrap="nowrap" style="width: 0.96%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                    </tr>
                    <tr>
                      <td style="width: 51.79%; vertical-align: bottom;">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td style="width: 1%; vertical-align: bottom;">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td style="width: 1%; vertical-align: bottom;">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td style="width: 8.97%; vertical-align: bottom;">
                        <div style="text-align: right; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td nowrap="nowrap" style="width: 1%; vertical-align: bottom;">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td style="width: 1%; vertical-align: bottom;">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td style="width: 1%; vertical-align: bottom;">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td style="width: 8.97%; vertical-align: bottom;">
                        <div style="text-align: right; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td nowrap="nowrap" style="width: 1.41%; vertical-align: bottom;">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td style="width: 1%; vertical-align: bottom;">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td style="width: 1%; vertical-align: bottom;">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td style="width: 8.97%; vertical-align: bottom;">
                        <div style="text-align: right; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td nowrap="nowrap" style="width: 1%; vertical-align: bottom;">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td style="width: 1%; vertical-align: bottom;">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td colspan="2" style="vertical-align: bottom;">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td nowrap="nowrap" style="width: 0.96%; vertical-align: bottom;">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                    </tr>
                    <tr>
                      <td style="width: 51.79%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">Adi Mor,&#160;<font style="font-style: italic;">Chief Scientific Officer, Director and Previous Chief Executive Officer</font></div>
                      </td>
                      <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td style="width: 8.97%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                        <div style="text-align: right; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">123,466</div>
                      </td>
                      <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td style="width: 8.97%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                        <div style="text-align: right; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">8,232</div>
                      </td>
                      <td nowrap="nowrap" style="width: 1.41%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                        <div style="line-height: 1.25; color: rgb(0, 0, 0); font-family: 'Times New Roman',serif; font-size: 7.5pt;"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup></div>
                      </td>
                      <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td style="width: 8.97%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                        <div style="text-align: right; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">1.49</div>
                      </td>
                      <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td colspan="2" style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
                        <div style="text-align: center; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">15/03/2028</div>
                      </td>
                      <td nowrap="nowrap" style="width: 0.96%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                    </tr>
                    <tr>
                      <td style="width: 51.79%; vertical-align: bottom;">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td style="width: 1%; vertical-align: bottom;">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td style="width: 1%; vertical-align: bottom;">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td style="width: 8.97%; vertical-align: bottom;">
                        <div style="text-align: right; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td nowrap="nowrap" style="width: 1%; vertical-align: bottom;">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td style="width: 1%; vertical-align: bottom;">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td style="width: 1%; vertical-align: bottom;">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td style="width: 8.97%; vertical-align: bottom;">
                        <div style="text-align: right; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td nowrap="nowrap" style="width: 1.41%; vertical-align: bottom;">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td style="width: 1%; vertical-align: bottom;">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td style="width: 1%; vertical-align: bottom;">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td style="width: 8.97%; vertical-align: bottom;">
                        <div style="text-align: right; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td nowrap="nowrap" style="width: 1%; vertical-align: bottom;">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td style="width: 1%; vertical-align: bottom;">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td colspan="2" style="vertical-align: bottom;">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td nowrap="nowrap" style="width: 0.96%; vertical-align: bottom;">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                    </tr>
                    <tr>
                      <td style="width: 51.79%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">Donald Marvin,&#160;<font style="font-style: italic;">Chief Financial Officer, Executive Vice President and Chief Operating Officer</font>&#160;</div>
                      </td>
                      <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td style="width: 8.97%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                        <div style="text-align: right; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">-</div>
                      </td>
                      <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td style="width: 8.97%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                        <div style="text-align: right; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">196,875</div>
                      </td>
                      <td nowrap="nowrap" style="width: 1.41%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                        <div style="line-height: 1.25; color: rgb(0, 0, 0); font-family: 'Times New Roman',serif; font-size: 7.5pt;"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(3)</sup></div>
                      </td>
                      <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td style="width: 8.97%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                        <div style="text-align: right; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">9.77</div>
                      </td>
                      <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td colspan="2" style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
                        <div style="text-align: center; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">08/11/2031</div>
                      </td>
                      <td nowrap="nowrap" style="width: 0.96%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                    </tr>
                    <tr>
                      <td style="width: 51.79%; vertical-align: bottom;">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td style="width: 1%; vertical-align: bottom;">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td style="width: 1%; vertical-align: bottom;">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td style="width: 8.97%; vertical-align: bottom;">
                        <div style="text-align: right; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td nowrap="nowrap" style="width: 1%; vertical-align: bottom;">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td style="width: 1%; vertical-align: bottom;">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td style="width: 1%; vertical-align: bottom;">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td style="width: 8.97%; vertical-align: bottom;">
                        <div style="text-align: right; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td nowrap="nowrap" style="width: 1.41%; vertical-align: bottom;">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td style="width: 1%; vertical-align: bottom;">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td style="width: 1%; vertical-align: bottom;">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td style="width: 8.97%; vertical-align: bottom;">
                        <div style="text-align: right; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td nowrap="nowrap" style="width: 1%; vertical-align: bottom;">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td style="width: 1%; vertical-align: bottom;">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td colspan="2" style="vertical-align: bottom;">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td nowrap="nowrap" style="width: 0.96%; vertical-align: bottom;">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                    </tr>
                    <tr>
                      <td style="width: 51.79%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">Arnon Aharon,&#160;<font style="font-style: italic;">Previous Chief Medical Officer</font> (4)</div>
                      </td>
                      <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td style="width: 8.97%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                        <div style="text-align: right; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">13,274</div>
                      </td>
                      <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td style="width: 8.97%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                        <div style="text-align: right; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">-</div>
                      </td>
                      <td nowrap="nowrap" style="width: 1.41%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td style="width: 8.97%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                        <div style="text-align: right; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">1.49</div>
                      </td>
                      <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td style="width: 8.98%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                        <div style="text-align: right; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">3/12/2027</div>
                      </td>
                      <td nowrap="nowrap" style="width: 0.96%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                    </tr>
                    <tr>
                      <td style="width: 51.79%; vertical-align: bottom;">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td style="width: 1%; vertical-align: bottom;">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td style="width: 1%; vertical-align: bottom;">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td style="width: 8.97%; vertical-align: bottom;">
                        <div style="text-align: right; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td nowrap="nowrap" style="width: 1%; vertical-align: bottom;">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td style="width: 1%; vertical-align: bottom;">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td style="width: 1%; vertical-align: bottom;">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td style="width: 8.97%; vertical-align: bottom;">
                        <div style="text-align: right; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td nowrap="nowrap" style="width: 1.41%; vertical-align: bottom;">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td style="width: 1%; vertical-align: bottom;">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td style="width: 1%; vertical-align: bottom;">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td style="width: 8.97%; vertical-align: bottom;">
                        <div style="text-align: right; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td nowrap="nowrap" style="width: 1%; vertical-align: bottom;">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td style="width: 1%; vertical-align: bottom;">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td style="width: 1%; vertical-align: bottom;">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td style="width: 8.98%; vertical-align: bottom;">
                        <div style="text-align: right; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td nowrap="nowrap" style="width: 0.96%; vertical-align: bottom;">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                    </tr>
                    <tr>
                      <td style="width: 51.79%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">Arnon Aharon,&#160;<font style="font-style: italic;">Previous Chief Medical (4) Officer</font></div>
                      </td>
                      <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td style="width: 8.97%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                        <div style="text-align: right; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">19,362</div>
                      </td>
                      <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td style="width: 8.97%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                        <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman', serif;">
                          <div style="line-height: 1.25; font-family: 'Times New Roman',serif; font-size: 12pt;">&#160;<font style="font-size: 10pt; color: rgb(0, 0, 0);">42,596</font></div>
                        </div>
                      </td>
                      <td nowrap="nowrap" style="width: 1.41%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td style="width: 8.97%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                        <div style="text-align: right; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">1.62</div>
                      </td>
                      <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                      <td colspan="2" style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
                        <div style="text-align: center; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">16/12/2029</div>
                      </td>
                      <td nowrap="nowrap" style="width: 0.96%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
                      </td>
                    </tr>

                </table>
              </div>
              <div style="line-height: 1.25"><br>
              </div>
            </div>
          </div>
        </div>
      </div>
      <div style="line-height: 1.25;">
        <div style="text-align: justify; line-height: 1.25;">(1) The options granted to Dr. Pfost vest and become exercisable over a period of four (4) years with one quarter (1/4) of the options vesting on October 25, 2022, the first anniversary of the
          grant date, and the remainder in equal amounts over the ensuing 36 monthly periods, subject to Dr. Pfost&#8217;s continued service.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; line-height: 1.25;">(2) The options granted to Dr. Mor vest and become exercisable over a period of four (4) years with one quarter (1/4) of the options vesting on March 15, 2019 and the remainder in 12 quarterly
          equal instalments, subject to the Dr. Mor&#8217;s continued service.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; line-height: 1.25;">(3) The options granted to Mr. Marvin vest and become exercisable over a period of four (4) years, with one quarter (1/4) of the options vesting on November 8, 2022, the first anniversary of the
          grant date, and the remainder in equal amounts over the ensuing 36 monthly periods, subject to Mr. Marvin&#8217;s continued service.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; line-height: 1.25;">
          <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">(4) The options granted to Dr. Aharon&#160; vest and become exercisable over a period of four (4) years with one quarter (1/4) of the options vesting on the first
            anniversary of the grant date&#160; and the remainder in 12 quarterly equal instalments, subject to Dr. Aharon&#8217;s continued service. Dr. Aharon resigned from his position as our Chief Medical Officer effective on January 31, 2022.</div>
        </div>
        <div style="line-height: 1.25">&#160;</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25; font-weight: bold;">Director Compensation Table</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="line-height: 1.25;">
          <div style="text-align: justify; text-indent: 18pt; line-height: 1.25;">The table below outlines compensation earned by our directors for the fiscal year ended December 31, 2021, including fees earned in cash and options awarded for services
            provided as a director:</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
        </div>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z3f00f392648f4f37be6d1f7ab14b5078">

          <tr>
            <td style="width: 51.99%; vertical-align: bottom; border-bottom: #000000 2px solid;">
              <div style="line-height: 1.25; font-weight: bold;">Name</div>
            </td>
            <td style="width: 1%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td colspan="2" style="width: 9.99%; vertical-align: bottom; border-bottom: #000000 2px solid;">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">Fees earned or paid<br>
                in cash ($)</div>
            </td>
            <td nowrap="nowrap" style="width: 1%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 1%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td colspan="2" style="width: 10%; vertical-align: bottom; border-bottom: #000000 2px solid;">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">Option<br>
                awards ($)</div>
            </td>
            <td nowrap="nowrap" style="width: 1%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 1%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td colspan="2" style="width: 10%; vertical-align: bottom; border-bottom: #000000 2px solid;">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">Total ($)</div>
            </td>
            <td nowrap="nowrap" style="width: 1%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 1%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td colspan="2" style="width: 10%; vertical-align: bottom; border-bottom: #000000 2px solid;">
              <div style="text-align: center; line-height: 1.25;"><font style="font-weight: bold;">Outstanding</font><br>
                <font style="font-weight: bold;">options as of</font><br>
                <font style="font-weight: bold;">December 31,</font><br>
                <font style="font-weight: bold;">2021</font>&#160;<font style="font-weight: bold;">(ADSs)</font></div>
            </td>
            <td nowrap="nowrap" style="width: 1%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 51.99%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">Stephen Squinto<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup></div>
            </td>
            <td style="width: 1%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 1%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 9%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="text-align: right; line-height: 1.25;">49</div>
            </td>
            <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 1%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 1%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 9%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="text-align: right; line-height: 1.25;">141</div>
            </td>
            <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 1%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 1%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 9%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="text-align: right; line-height: 1.25;">190</div>
            </td>
            <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 1%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 1%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 9%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="text-align: right; line-height: 1.25;">102,858</div>
            </td>
            <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 51.99%; vertical-align: top;">
              <div style="line-height: 1.25;">Nissim Darvish&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
            </td>
            <td style="width: 1%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 1%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 9%; vertical-align: bottom;">
              <div style="text-align: right; line-height: 1.25;">36</div>
            </td>
            <td nowrap="nowrap" style="width: 1%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 1%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 1%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 9%; vertical-align: bottom;">
              <div style="text-align: right; line-height: 1.25;">118</div>
            </td>
            <td nowrap="nowrap" style="width: 1%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 1%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 1%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 9%; vertical-align: bottom;">
              <div style="text-align: right; line-height: 1.25;">154</div>
            </td>
            <td nowrap="nowrap" style="width: 1%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 1%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 1%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 9%; vertical-align: bottom;">
              <div style="text-align: right; line-height: 1.25;">22,007</div>
            </td>
            <td nowrap="nowrap" style="width: 1%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 51.99%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">Joel Maryles&#160;&#160;&#160;&#160;&#160;&#160;</div>
            </td>
            <td style="width: 1%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 1%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 9%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="text-align: right; line-height: 1.25;">43</div>
            </td>
            <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 1%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 1%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 9%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="text-align: right; line-height: 1.25;">118</div>
            </td>
            <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 1%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 1%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 9%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="text-align: right; line-height: 1.25;">161</div>
            </td>
            <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 1%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 1%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 9%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="text-align: right; line-height: 1.25;">11,884</div>
            </td>
            <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 51.99%; vertical-align: top;">
              <div style="line-height: 1.25;">Alan Moses&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
            </td>
            <td style="width: 1%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 1%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 9%; vertical-align: bottom;">
              <div style="text-align: right; line-height: 1.25;">34</div>
            </td>
            <td nowrap="nowrap" style="width: 1%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 1%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 1%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 9%; vertical-align: bottom;">
              <div style="text-align: right; line-height: 1.25;">118</div>
            </td>
            <td nowrap="nowrap" style="width: 1%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 1%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 1%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 9%; vertical-align: bottom;">
              <div style="text-align: right; line-height: 1.25;">152</div>
            </td>
            <td nowrap="nowrap" style="width: 1%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 1%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 1%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 9%; vertical-align: bottom;">
              <div style="text-align: right; line-height: 1.25;">11,884</div>
            </td>
            <td nowrap="nowrap" style="width: 1%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 51.99%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">Claude Nicaise&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
            </td>
            <td style="width: 1%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 1%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 9%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="text-align: right; line-height: 1.25;">34</div>
            </td>
            <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 1%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 1%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 9%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="text-align: right; line-height: 1.25;">118</div>
            </td>
            <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 1%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 1%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 9%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="text-align: right; line-height: 1.25;">152</div>
            </td>
            <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 1%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 1%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 9%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="text-align: right; line-height: 1.25;">11,884</div>
            </td>
            <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 51.99%; vertical-align: top;">
              <div style="line-height: 1.25;">Neil Cohen</div>
            </td>
            <td style="width: 1%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 1%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 9%; vertical-align: bottom;">
              <div style="text-align: right; line-height: 1.25;">38</div>
            </td>
            <td nowrap="nowrap" style="width: 1%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 1%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 1%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 9%; vertical-align: bottom;">
              <div style="text-align: right; line-height: 1.25;">121</div>
            </td>
            <td nowrap="nowrap" style="width: 1%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 1%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 1%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 9%; vertical-align: bottom;">
              <div style="text-align: right; line-height: 1.25;">159</div>
            </td>
            <td nowrap="nowrap" style="width: 1%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 1%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 1%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 9%; vertical-align: bottom;">
              <div style="text-align: right; line-height: 1.25;">12,572</div>
            </td>
            <td nowrap="nowrap" style="width: 1%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z20d3f0c971784e0ea827a4fb7cd0421c">

          <tr>
            <td style="width: 3.83%; vertical-align: middle;">&#160;</td>
            <td style="width: 2.52%; vertical-align: top;">
              <div style="line-height: 1.25;">(1)</div>
            </td>
            <td style="width: 93.66%; vertical-align: top;">
              <div style="line-height: 1.25;">Dr. Squinto resigned from the Company&#8217;s Board effective on December 19, 2021.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25; font-weight: bold;">Employment Agreements</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Employment Agreement with Dr. Dale Pfost, our Chief Executive Officer</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">On September 1, 2021, the Company&#8217;s Board approved the appointment of Dr. Dale Pfost as Chief Executive Officer of the Company, and on October 25, 2021, the shareholders of the
        Company approved the terms of employment of Dr. Pfost, pursuant to an Executive Employment Agreement entered into between Dr. Pfost and Chemomab Therapeutics Inc., the Company&#8217;s wholly owned subsidiary. In accordance with terms of Dr. Pfost&#8217;s
        employment agreement, Dr. Pfost receives: (i) an annual base salary of $600,000 (the &#8220;Base Salary&#8221;); (ii) an initial target annual cash incentive bonus of 50% of the Base Salary and an additional potential bonus of 10% of the Base Salary based on
        Dr. Pfost&#8217;s achievement of certain predetermined goals, which shall be determined at the discretion of the Company&#8217;s Board; (iii) options to purchase 459,353 ADSs of the Company (the &#8216;Options&#8221;), constituting 3.5% of the outstanding and issued ADSs
        of the Company (on a fully diluted basis) which will vest over a period of four (4) years with one quarter (1/4) of the Options vesting on the first anniversary of the grant date and the remainder in equal amounts over the ensuing 36 monthly
        periods, unless such options have been cancelled in accordance with the terms and conditions of the 2015 Plan (as defined below); (iv) a one-time signing bonus in an amount of $80,000; (v) a one-time bonus in an amount of $80,000 upon the
        establishment of a new office in the United State and Dr. Pfost&#8217;s domiciling in the location of the new office, which will be payable within 15 days of such domiciling; (vi) 25 days of paid time off (&#8220;PTO&#8221;) per year, capped at 50 days of accrued
        PTO; and (vii) certain severance benefits payable in the event that the Company terminates Dr. Pfost&#8217;s employment without Cause (as defined in the employment agreement), provided that the total amount of the cash portion of severance benefits will
        not exceed two hundred percent (200%) of Dr. Pfost&#8217;s annual base salary at the rate in effect on the date of termination.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Additionally, in the event of termination of Dr. Pfost&#8217;s employment without Cause as the result of a merger or sale of all or substantially all of the Company&#8217;s capital stock or
        assets, (i.e. a change in control of the Company), vesting of all unvested Options will accelerate and all unvested Options will immediately vest and become exercisable. Furthermore, in the event of termination of Dr. Pfost&#8217;s employment without
        Cause, other than as a result of a merger or sale of all or substantially all of the Company&#8217;s capital stock or assets (i.e. a change in control of the Company) or if Dr. Pfost terminates his employment for Good Reason (as defined in the employment
        agreement): (a) any time-based Options then outstanding and due to vest on the twelve (12) month anniversary of Dr. Pfost&#8217;s employment commencement date will accelerate and become exercisable if Dr. Pfost has been employed by the Company at such
        time for six (6) months or more but less than twelve (12) months; and (b) all time-based Options then outstanding will accelerate and become exercisable if Dr. Pfost has been employed by the Company at such time for twelve (12) months or longer.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The foregoing description of Dr. Pfost&#8217;s employment agreement is qualified in its entirety by reference to the full text of the employment agreement, a copy of which is filed as
        Exhibit 10.10 to the Company's Annual Report, and incorporated herein by reference.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="line-height: 1.25; font-style: italic; font-weight: bold;">Employment Agreement with Dr. Adi Mor, our Chief Scientific Officer (and former Chief Executive Officer)</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Under the employment agreement, dated April 25, 2013, as amended (most recently as of July 2021) that Chemomab Ltd. entered into with its then-Chief Executive Officer (currently
        Chief Scientific Officer), Dr. Adi Mor (which contract was assumed by our company as a result of the consummation of the Merger), Dr. Mor is entitled to a gross monthly salary of NIS 52,500 (approximately $16,881). Dr. Mor is also entitled to an
        annual performance bonus in the aggregate amount of $75,000, subject to her meeting certain performance milestones, as to be determined by our Board on an annual basis. Besides base salary and bonus, Dr. Mor is entitled to other benefits that are
        provided for by Israeli law or that are customary for senior executives in Israel, including reimbursement for reasonable expenses incurred in connection with her services, and the right to use (including certain related fixed and variable costs in
        respect of) a leased car and a cellular phone. In lieu of a leased car, Dr. Mor may elect to receive a monthly car allowance payment. Dr. Mor is furthermore entitled to company contributions equivalent to 8.33%, 2.5%, and 5% of her gross monthly
        salary towards certain severance, disability and tax-advantaged savings funds (known as a manager&#8217;s insurance policy), respectively. Dr. Mor also contributes 5.5% of her gross monthly salary towards the manager&#8217;s insurance policy. The employment
        engagement is terminable by either party upon 60 days prior written notice, and contains customary provisions regarding noncompetition, confidentiality of information and assignment of inventions. As required under Israeli law, the terms of Dr.
        Mor&#8217;s engagement with Chemomab Ltd. were approved by Chemomab Ltd.&#8217;s board of directors and shareholders.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Dr. Mor has been granted, pursuant to her employment agreement, an aggregate of 10,239 options to purchase Chemomab Ltd. shares, which were fully vested on April 18, 2022, under
        Chemomab Ltd.&#8217;s share option and incentive plan (which was assumed by our company in the Merger). The options were converted to the Company's&#160; options based on the exchange ratio in the merger agreement for the Merger (the &#8220;Merger Agreement&#8221;), with
        a reciprocal adjustment to exercise price.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">At the annual meeting of our shareholders that took place on July 19, 2021, our shareholders approved an amendment to Dr. Mor&#8217;s compensation, pursuant to which Dr. Mor will
        receive: (a) an annual base salary of $249,000; (b) certain social benefits, including <font style="font-style: italic;">keren hishtalmut</font> (advanced study fund); (c) car and car related expenses; (d) a target annual gross cash bonus of
        $100,000 that can be achieved pursuant to certain pre-determined objectives according to the discretion of the Board; and (e) a one-time cash bonus in the aggregate gross amount of $90,000 in connection with Dr. Mor&#8217;s contribution to the
        consummation of the Merger and financing transaction.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">At the Annual General Meeting, our shareholders are being asked to consider a proposal to amend certain terms of Dr. Mor&#8217;s compensation, which is more substantially set forth in
        Proposal 2 herein.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="line-height: 1.25; font-style: italic; font-weight: bold;">Employment Agreement with Mr. Donald Marvin, our Chief Financial Officer, Executive Vice President and Chief Operating Officer</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">On November 8, 2021, Chemomab Therapeutics Inc. entered into an Executive Employment Agreement with Mr. Donald Marvin. In accordance with his employment agreement, Mr. Marvin
        receives an annual base salary of $460,000, and is a part of the Company&#8217;s bonus program with a yearly bonus potential of 45% of his base annual base salary, which bonus will be based on the achievement of mutually agreeable objectives to be
        determined by Mr. Marvin and the Chief Executive Officer of the Company. Additionally, in accordance with his employment agreement, Mr. Marvin received (i) 1.5% of the outstanding equity of the Company, which exercise price is based on the average
        of Company&#8217;s ADS market value over the 30 calendar days preceding November 8, 2021, and vesting over four years, (ii) an additional 0.5% of the outstanding equity of the Company for the achievement of strategic goals as agreed upon with the
        Compensation Committee and approved by the Board, (iii) a $25,000 signing bonus, and (iv) a 12-month initial severance package, which will increase by one month every two years that Mr. Marvin is employed by the Company, provided however that such
        amount does not exceed 18 months.<br>
      </div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The foregoing description of Mr. Marvin&#8217;s employment agreement is qualified in its entirety by reference to the full text of the employment agreement, a copy of which is filed as
        Exhibit 10.11 to the Company's Annual Report, and incorporated herein by reference.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="margin-left: 30.8pt; line-height: 1.25; font-style: italic; font-weight: bold;">Share Incentive Plans</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We maintain (i) the 2011 Share Option Plan (the &#8220;2011 Plan&#8221;), (ii) the Chemomab Ltd. 2015 Share Incentive Plan (the &#8220;2015 Plan&#8221;), which was assumed by our company from Chemomab
        Ltd. upon the effectiveness of the Merger, and (iii) the 2017 Equity-Based Incentive Plan (the &#8220;2017 Plan&#8221;). Upon the effectiveness of the Merger, outstanding options under the 2015 Plan became exercisable for such number of ADSs of our company
        (formerly known as Anchiano Therapeutics Ltd.) as was determined based on the exchange ratio in the Merger Agreement, with a reciprocal adjustment to exercise price. As of the date of this proxy statement, a total of 1,422,153 of our ADSs were
        reserved for issuance under the 2015 Plan, of which 73,776 ADSs had been issued pursuant to previous exercises options, and 1,326,723 ADSs were issuable under outstanding options. Of such outstanding options, options to purchase 487,921 ADSs had
        vested and were exercisable as of that date, with a weighted average exercise price of $3.16 per ADS.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="margin-left: 30.8pt; line-height: 1.25; font-style: italic; font-weight: bold;">2011 Plan</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 25.5pt; margin-right: 5.8pt; margin-left: 5.3pt; line-height: 1.25;">On December 19, 2011, our Board adopted 2011 Plan to allocate options to purchase our ordinary shares to our directors, officers,
        employees and consultants, and those of our affiliated companies (as such term is defined under the 2011 Plan), or the Grantees. The 2011 Plan is administered by our Board or a committee that was designated by our Board for such purpose (the
        &#8220;Administrator&#8221;).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 25.5pt; margin-right: 5.2pt; margin-left: 5.3pt; line-height: 1.25;">Under the 2011 Plan, we may grant options to purchase ordinary shares (&#8220;Options&#8221;), under four tracks: (i) Approved 102 capital gains
        Options through a trustee, which was approved by the Israeli Tax Authority in accordance with Section 102(a) of the Israeli Income Tax Ordinance (&#8220;ITO&#8221;), and granted under the tax track set forth in Section 102(b)(2) of the ITO, or the Approved 102
        Capital Gains Options. The holding period under this tax track is 24 months from the date of allocation of Options to the trustee or such period as may be determined in any amendment of Section 102 of the ITO, or any applicable tax ruling or
        guidelines; (ii) Approved 102 Earned Income Options through a trustee, granted under the tax track set forth is Section 102(b)(1) of the ITO, or the Approved 102 Earned Income Options. The holding period under this tax track is 12 months from the
        date of allocation of Options to the trustee or such period as may be determined in any amendment of Section 102 of the ITO; (iii) Unapproved 102 Options (the Options will not be allocated through a trustee and will not be subject to a holding
        period), or the Unapproved 102 Options; and (iv) 3(i) Options (the Options will not be subject to a holding period). These Options shall be subject to taxation pursuant to Section 3(i) of the ITO, or Section 3(i).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 25.5pt; margin-right: 7.15pt; margin-left: 5.3pt; line-height: 1.25;">Options pursuant to the first three tax tracks (under Section 102 of the ITO) can be granted to our employees and directors and the
        grant of Options under Section 3(i) can be granted to our consultants and controlling shareholders (a controlling shareholder is defined under the Section 102 of the ITO is a person who holds, directly or indirectly, alone or together with a
        &#8220;relative,&#8221; (i) the right to at least 10% of the company&#8217;s issued capital or 10% of the voting power; (ii) the right to hold at least 10% of the company&#8217;s issued capital or 10% of the voting power, or the right to purchase such rights; (iii) the
        right to receive at least 10% of the company&#8217;s profits; or (iv) the right to appoint a company&#8217;s director). Grantees who are not Israeli residents may be granted options that are subject to the applicable tax laws in their respective jurisdictions.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 25.5pt; margin-left: 5.3pt; line-height: 1.25;">We determine, in our sole discretion, under which of the first three tax tracks above the Options are granted and we notify the Grantee in a grant letter,
        as to the elected tax track. As mentioned above, consultants and controlling shareholders can only be granted Section 3(i) Options.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 25.5pt; margin-right: 5.75pt; margin-left: 5.3pt; line-height: 1.25;">The number of ordinary shares authorized to be issued under the 2011 Plan will be proportionately adjusted for any increase or
        decrease in the number of ordinary shares issued as a result of a distribution of bonus shares, change in our capitalization (split, combination, reclassification of the shares or other capital change), or issuance of rights to purchase ordinary
        shares or payment of a dividend. We will not allocate fractions of ordinary shares and the number of ordinary shares shall be rounded up to the closest number of ordinary shares.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 25.5pt; margin-right: 7.15pt; margin-left: 5.3pt; line-height: 1.25;">Unless otherwise determined by the Administrator, the exercise price of an Option granted under the 2011 Plan will be the average of
        the market price of the Company&#8217;s ordinary shares during the 22 business days prior to the date on which our Board authorized the grant of Options; provided, however, that such exercise price cannot be lower than the market price at the close of
        the trading day at which it was granted by our Board. The exercise price will be specified in the grant letter every Grantee received from us in which the Grantee notifies of the decision to grant him/her Options under the 2011 Plan.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 25.5pt; margin-right: 10.85pt; margin-left: 5.3pt; line-height: 1.25;">Unless otherwise determined by the Administrator, the Options granted under the Plan will become vested and may be exercised in 16
        equal portions of 6.25% of the total number of Options, at the end of each quarter following the day the Options were granted. Unless otherwise determined by our Board, the Options may be exercised for ten years following the date of grant, unless
        terminated earlier, and as long as the Grantee is employed by the Company (or by an affiliated company), or provides service to the Company (or an affiliated company).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; margin-left: 30.8pt; line-height: 1.25;">The Administrator may, in its absolute discretion, accelerate the time at which Options granted under the 2011 Plan or any portion of which will vest.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 25.5pt; margin-right: 10.85pt; margin-left: 5.3pt; line-height: 1.25;">Unless otherwise determined by the Administrator, in the event that the Grantee&#8217;s employment was terminated, not for Cause (as
        defined in the 2011 Plan), the Grantee may exercise that portion of the Options that had vested as of the date of such termination until the end of the specified term in the grant letter or the 2011 Plan. The portion of the Options that had not
        vested at such date, will be forfeited and can be re-granted according to the terms of the 2011 Plan.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="margin-left: 30.8pt; line-height: 1.25; font-style: italic; font-weight: bold;">2015 Plan</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 25.5pt; margin-right: 8.9pt; margin-left: 5.3pt; line-height: 1.25;">In November 2015, Chemomab Ltd.&#8217;s board of directors adopted, and its shareholders subsequently approved, the 2015 Plan. The 2015 Plan
        provides for the grant of options, restricted shares, restricted share units and other share-based awards to Chemomab Ltd.&#8217;s (following the Merger, the Company&#8217;s or Chemomab&#8217;s) and its subsidiaries&#8217; and affiliates&#8217; directors, employees, officers,
        consultants, advisors, and any other person whose services are considered valuable to Chemomab or its affiliates. Any such grants are intended to incentivize the foregoing persons to continue as service providers, to increase their efforts on
        Chemomab&#8217;s behalf or on behalf of its subsidiaries or affiliates, and to promote the success of its business.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 25.5pt; margin-right: 6pt; margin-left: 5.3pt; line-height: 1.25;">The 2015 Plan is administered by Chemomab&#8217;s board of directors or by a committee designated by the board of directors, which determines,
        subject to Israeli law, the grantees of awards and the terms of the grant, including, exercise prices, vesting schedules, acceleration of vesting and the other matters necessary in the administration of the 2015 Plan. The 2015 Plan enables Chemomab
        to issue awards under various tax regimes, including, without limitation, pursuant to Section 102 of the Israeli Income Tax Ordinance, or the Ordinance, and under Section 3(i) of the Ordinance and Section 422 of the United States Internal Revenue
        Code of 1986, as amended, or the Code.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 25.5pt; margin-right: 10.85pt; margin-left: 5.3pt; line-height: 1.25;">The 2015 Plan provides that options granted to Chemomab&#8217;s employees, directors and officers who are not controlling shareholders and
        who are considered Israeli residents are intended to qualify for special tax treatment under the &#8220;capital gain track&#8221; provisions of Section 102(b) of the Ordinance. Chemomab&#8217;s Israeli non-employee service providers and controlling shareholders may
        only be granted options under Section 3(i) of the Ordinance, which does not provide for similar tax benefits.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 25.5pt; margin-right: 5.75pt; margin-left: 5.3pt; line-height: 1.25;">Options granted under the 2015 Plan to U.S. residents may qualify as &#8220;incentive stock options&#8221; within the meaning of Section 422 of
        the Code, or may be non-qualified. The exercise price for &#8220;incentive stock options&#8221; must not be less than the fair market value on the date on which an option is granted, or 110% of the fair market value if the option holder holds more than 10% of
        Chemomab&#8217;s share capital.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 25.5pt; margin-right: 6.3pt; margin-left: 5.3pt; line-height: 1.25;">Options and other awards granted under the 2015 Plan generally vest over four years commencing on the date of grant, such that 25%
        vests on the first anniversary of the date of grant and an additional 6.25% vests at the end of each subsequent calendar quarter over the course of the next three years, provided that the participant remains continuously employed or engaged by
        Chemomab.</div>
      <div style="text-align: justify; text-indent: 25.5pt; margin-right: 6.3pt; margin-left: 5.3pt; line-height: 1.25;"> <br>
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 25.5pt; margin-right: 6.85pt; margin-left: 5.3pt; line-height: 1.25;">Options, other than certain incentive share options, that are not exercised within ten years from the grant date expire, unless
        otherwise determined by Chemomab&#8217;s board of directors or its designated committee, as applicable. Share options that qualify as &#8220;incentive stock options&#8221; and are granted to a person holding more than 10% of Chemomab&#8217;s voting power will expire
        within five years from the date of the grant. In the event of the death of a grantee while employed by or performing service for Chemomab or its subsidiary or within three months after the date of the employee&#8217;s termination, or the termination of a
        grantee&#8217;s employment or services for reasons of disability, the grantee, or in the case of death, his or her legal successor, may exercise options or other awards that have vested prior to termination within a period of one year from the date of
        disability or death. If Chemomab terminates a grantee&#8217;s employment or service for cause, all of the grantee&#8217;s vested and unvested options or other awards will expire on the date of termination. If a grantee&#8217;s employment or service is terminated for
        any other reason, the grantee may generally exercise his or her vested options or other award within three months of the date of termination. Any expired or unvested options return to the pool and become available for reissuance. From time to time,
        Chemomab may consider issuing options with slightly different terms or accelerating, extending or otherwise modifying options in accordance with applicable law and regulation and the terms of the 2015 Plan.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 25.5pt; margin-right: 11.3pt; margin-left: 5.3pt; line-height: 1.25;">In the event of a merger or consolidation of Chemomab, or a sale of all, or substantially all, of Chemomab&#8217;s shares or assets or other
        transaction having a similar effect on Chemomab, then without the consent of the option holder, Chemomab&#8217;s board of directors or its designated committee, as applicable, may, but is not required, to (i) cause any outstanding award to be assumed or
        an equivalent award to be substituted by such successor corporation, or (ii) in case the successor corporation does not assume or substitute the award (a) provide the grantee with the option to exercise the award as to all or part of the shares or
        (b) cancel the options and pay in cash an amount determined by the board of directors or the committee as fair in the circumstances. Notwithstanding the foregoing, Chemomab&#8217;s board of directors or its designated committee may upon such event amend,
        modify or terminate the terms of any award, including conferring the right to purchase any other security or asset that the board of directors or the committee shall deem, in good faith, appropriate.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="margin-left: 30.8pt; line-height: 1.25;">The 2015 plan was assumed by our company from Chemomab Ltd. upon the effectiveness of the Merger.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="margin-left: 30.8pt; line-height: 1.25; font-style: italic; font-weight: bold;">2017 Plan</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 25.5pt; margin-right: 15.3pt; margin-left: 5.3pt; line-height: 1.25;">On February 22, 2017, our Board adopted the 2017 Plan to allocate a variety of share-based awards to our directors, officers,
        employees, consultants, advisors and service providers, and those of our affiliates (companies that control us, are controlled by us or are under common control with us) (the &#8220;Participants&#8221;). The 2017 Plan is currently administered by our Board,
        and may be administered by a committee designated by our Board for such purpose.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 25.5pt; margin-right: 7.9pt; margin-left: 5.3pt; line-height: 1.25;">Under the 2017 Plan, we may grant options to purchase ordinary shares or ADSs, restricted shares or ADSs, restricted share units and
        other awards based on our ordinary shares, all of which are referred to as Awards. We may grant Awards under the same four tracks as described above with respect to the 2011 Plan, subject to the same conditions as apply for the 2011 Plan. In
        addition, we may grant incentive stock options and nonqualified stock options to Participants who are residents of the United States, and we may grant awards to Participants who are residents of other countries that comply with the laws of those
        jurisdictions.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 25.5pt; margin-right: 10.85pt; margin-left: 5.3pt; line-height: 1.25;">The number of ordinary shares authorized to be issued under the 2017 Plan will be proportionately adjusted for any increase or
        decrease in the number of ordinary shares issued as a result of a distribution of bonus shares, change in our capitalization (split, combination, reclassification of the shares or other capital change), issuance of rights to purchase ordinary
        shares or payment of a dividend. We will not allocate fractions of ordinary shares and the number of ordinary shares shall be rounded down to the closest number of ordinary shares.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 25.5pt; margin-right: 10.85pt; margin-left: 5.3pt; line-height: 1.25;">In the event of a (i) merger, consolidation, amalgamation or the like with or into another corporation, (ii) an acquisition
        (including an exchange) of all or substantially all of our ordinary shares, (iii) the sale of all or substantially all of our assets, or (iv) any other event determined by the Administrator to have a similar impact, then &#8211; unless otherwise
        determined by our Board in its sole and absolute discretion &#8211; any Award then outstanding will be assumed or an equivalent Award shall be substituted by the successor corporation, under substantially the same terms as the Award.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 25.5pt; margin-right: 6.3pt; margin-left: 5.3pt; line-height: 1.25;">The exercise price of an option granted under the 2017 Plan will, in general, be no less than the fair market value of the Company&#8217;s
        ordinary shares on the date of grant, subject to any minimum exercise price prescribed by law. The Administrator determines the vesting provisions for each Award and may, in its sole discretion, accelerate the time at which options granted under
        the 2017 Plan will vest. Unless otherwise determined by the Administrator, options may be exercised for ten years (five years in the case of an incentive stock option granted to a 10% shareholder), and as long as the Participant is employed by the
        Company (or by an affiliated company) or provides services to the Company (or an affiliated company). If a Participant&#8217;s employment is terminated, other than for cause, the Participant may generally exercise vested options for a limited period
        following termination<font style="font-style: italic;">.</font></div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-indent: 25.5pt; margin-right: 10.4pt; margin-left: 5.3pt; line-height: 1.25;">In accordance with the terms of the 2017 Plan, on January 1 of each calendar year during the term of the 2017 Plan, the number of shares available for
        issuance under the 2017 Plan shall be increased by 4% of the total number of company shares outstanding on December 31 of the immediately preceding calendar year, or such lesser number as shall be determined by the administrator of the plan,
        subject to adjustments required for recapitalization events.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">PROPOSAL NUMBER 1</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">ELECTION OF CLASS I DIRECTORS</div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Background</div>
        <div style="text-align: justify; line-height: 1.25;">&#160;</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25;">Our Board currently has seven directors and is divided into three classes with staggered three-year terms as follows:</div>
      </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z1ef4e4a69a734523ab9a83451aa51988">

          <tr>
            <td style="width: 3.82%; vertical-align: middle;">&#160;</td>
            <td style="width: 3.8%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">&#8226;</div>
            </td>
            <td style="width: 92.38%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">Class I consists of Nissim Darvish and Joel Maryles, each with a term expiring at the Annual General Meeting.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;">
        <div style="text-align: justify; line-height: 1.25;">&#160;</div>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z25c5c366bf174752a88a0ae787d89202">

          <tr>
            <td style="width: 3.82%; vertical-align: middle;">&#160;</td>
            <td style="width: 3.8%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">&#8226;</div>
            </td>
            <td style="width: 92.38%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">Class II consists of Neil Cohen and Claude Nicaise, each with a term expiring at the 2023 annual meeting of shareholders.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;">
        <div style="text-align: justify; line-height: 1.25;">&#160;</div>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="ze1a2c90a79374f10b5b48d96dd7f84b2">

          <tr>
            <td style="width: 3.82%; vertical-align: middle;">&#160;</td>
            <td style="width: 3.8%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">&#8226;</div>
            </td>
            <td style="width: 92.38%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">Class III consists of Adi Mor, Alan Moses and Dale Pfost, each with a term expiring at the 2024 annual meeting of shareholders.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;">
        <div style="text-align: justify; line-height: 1.25;">&#160;</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25;">At each annual general meeting of our shareholders, the election or re-election of directors following the expiration of the term of office of the directors of that class
          will be for a term of office that expires on the date of the third annual general meeting following such election or re-election.</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="text-align: justify; line-height: 1.25;">&#160;</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25;">At the Annual General Meeting, shareholders will be asked to re-elect Dr. Nissim Darvish and Joel Maryles. Dr. Nissim Darvish and Joel Maryles each qualify as an independent
          director under the Nasdaq listing rules. Dr. Nissim Darvish serves on our Compensation Committee and qualifies as an independent director under the rules of SEC and Nasdaq relating to his membership on the Compensation Committee. Joel Maryles
          serves on our Audit Committee and Corporate Governance and Nominating Committee and qualifies an independent director under the rules of SEC and Nasdaq relating to his membership on the Audit Committee. Joel Maryles is also a financial expert
          under the rules of the SEC.</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="text-align: justify; line-height: 1.25;">&#160;</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25;">If re-elected at the Annual General Meeting, each of Dr. Nissim Darvish and Joel Maryles will serve until the 2025 annual general meeting of our shareholders, and until his
          successor has been duly elected and qualified, or until his office is vacated in accordance with our articles of association or the Companies Law.</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="text-align: justify; line-height: 1.25;">&#160;</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25;">In accordance with the Companies Law, each of Dr. Nissim Darvish and Joel Maryles has certified to us that he meets all the requirements of the Companies Law for election as
          a director of a public company, and possesses the necessary qualifications and has sufficient time&#160;to fulfill his duties as a director of Chemomab, taking into account the size and special needs of Chemomab.</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="text-align: justify; line-height: 1.25;">&#160;</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25;">During 2021, each of the directors standing for re-election at the Annual General Meeting attended 100% of our Board and committee meetings, as applicable.</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="text-align: justify; line-height: 1.25;">&#160;</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25;">The corporate governance and nominating and committee of our Board recommended that each of Dr. Nissim Darvish and Joel Maryles be re-elected at the Annual General Meeting
          as a Class I director for a term to expire at the 2025 annual general meeting of our shareholders, and until his successor has been duly elected and qualified, or until his office is vacated in accordance with our articles of association or the
          Companies Law.&#160; For more information concerning the nominees, please see the section entitled &#8220;<font style="font-style: italic;">Executive Officers and Directors&#8212;Directors&#8212;Nominees for Director.&#8221; </font>Our Board approved this recommendation.</div>
      </div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Proposed Resolution</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Shareholders are being asked to adopt the following resolutions:<font style="font-weight: bold;">&#160;</font>&#160;</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; margin-left: 36pt; line-height: 1.25;"><font style="font-weight: bold;">&#8220;RESOLVED</font>,<font style="font-weight: bold;">&#160;</font>to re-elect Dr. Nissim Darvish to serve as a director of the Company to hold office
        until our 2025 annual general meeting of shareholders or until his successor is duly elected and qualified or until his earlier death, resignation or removal.&#8221;</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; margin-left: 36pt; line-height: 1.25;"><font style="font-weight: bold;">&#8220;RESOLVED</font>,<font style="font-weight: bold;">&#160;</font>to re-elect Mr. Joel Maryles to serve as a director of the Company to hold office until
        our 2025 annual general meeting of shareholders or until his successor is duly elected and qualified or until his earlier death, resignation or removal.&#8221;</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Required Vote</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The affirmative vote of the holders of a majority of the shares represented at the Annual General Meeting in person or by proxy and voting on the foregoing resolution is
        required. Each director nominee shall be voted separately.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Board Recommendation</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Our Board recommends a vote &#8220;FOR&#8221; Proposal 1.</div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;"> <br>
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">PROPOSAL NUMBER 2</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">TO APPROVE AN AMENDMENT TO THE TERMS OF COMPENSATION OF</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">DR. ADI MOR, THE COMPANY&#8217;S CO-FOUNDER, CHIEF SCIENTIFIC OFFICER, AND CLASS III DIRECTOR</div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Background</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The Companies Law requires that the terms of service and employment of an executive officer which also serves as a director, be approved by the company&#8217;s Compensation Committee,
        board of directors, and the shareholders of the company.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The proposed amendment to Dr. Mor&#8217;s terms of compensation were approved first by our Compensation Committee and then by the Board, while considering, among other factors, Dr.
        Mor's performance and contribution to us in general, her experience, the terms of our Compensation Policy, and other factors as required by the Companies Law.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In accordance with and subject to our Compensation Policy, as part of a long-term retention plan and in light of Dr. Mor's performance and contribution to the Company since its
        founding, it is proposed to approve the following amendments to Dr. Mor's terms of compensation as our Chief Scientific Officer:</div>
      <div style="text-align: justify; line-height: 1.25;">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zffe426d448764a3a8f34d42b2d0a33a5">

          <tr>
            <td style="width: 4%; vertical-align: middle;">
              <div style="text-align: justify; line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 5%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">1.</div>
            </td>
            <td style="width: 91%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">an increase of Dr. Mor's base gross monthly salary from 67,500 NIS (approximately $21,090) to 74,250 NIS (approximately $23,200), which represents an increase of 6,750 NIS (approximately
                $2,110), effective as of March 7, 2022 (the &#8220;Dr. Mor Base Salary Increase&#8221;);</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z2aadd517438947759531d97cb2300dd3">

          <tr>
            <td style="width: 4%; vertical-align: middle;">&#160;</td>
            <td style="width: 5%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">2.</div>
            </td>
            <td style="width: 91%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">an increase in the 2021 gross annual bonus for Dr. Mor from $100,000 to $110,250, an increase of approximately 10% (the "2021 Dr. Mor Annual Bonus"); and</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: middle;">&#160;</td>
            <td style="width: 5%; vertical-align: top;">&#160;</td>
            <td style="width: 91%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: middle;">
              <div style="text-align: justify; line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 5%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">3.</div>
            </td>
            <td style="width: 91%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">an increase in the annual gross target bonus opportunity of Dr. Mor from $100,000 to 45% of Dr. Mor's annual gross base salary, effective as of January 1, 2022 (the &#8220;Dr. Mor Annual Bonus
                Increase&#8221; and collectively the "Dr. Mor Compensation Changes").</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">For the avoidance of doubt, the foregoing amendment to Dr. Mor&#8217;s terms of compensation is not related to Dr. Mor&#8217;s service as a Class III director of the Company and is
        exclusively in connection with her employment as the Company&#8217;s Chief Scientific Officer.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Furthermore, the Company and Dr. Mor have agreed to implement a change to Dr. Mor&#8217;s compensation arrangement such that, effective immediately, Dr. Mor will be compensated
        (including the Dr. Mor Compensation Changes) through an Israeli company co-owned by Dr. Mor, as opposed to the Company compensating Dr. Mor directly. The foregoing changes will have no effect on the amount of compensation owed to her, nor will it
        affect her engagement or position with the Company in any way and do not require shareholder approval.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">All other employment terms shall remain unchanged. For further information on the compensation terms of Dr. Adi Mor, please see the section entitled &#8220;<font style="font-style: italic;">Executive Compensation&#8212;Executive Employment Agreements</font>.&#8221;</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The shareholders vote on this matter is binding under Israeli law and not merely advisory. If this proposal is not approved by the affirmative vote of our shareholders, the
        Company will not be authorized to implement the Dr. Mor Compensation Changes as described in this proxy statement.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The proposed Dr. Mor Compensation Changes were approved by our Compensation Committee and Board, reflect Dr Adi Mor's experience and are based on the comprehensive compensation
        survey provided to the Compensation Committee and the Board described above and the terms of our Compensation Policy. The proposed Dr. Mor Compensation Changes are consistent with our Compensation Policy.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Proposed Resolution</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Shareholders are being asked to adopt the following resolution:<font style="font-weight: bold;">&#160;</font>&#160;</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; margin-left: 36pt; line-height: 1.25;"><font style="font-weight: bold;">&#8220;RESOLVED</font>, to approve an amendment to the terms of compensation for Dr. Adi Mor, the Company&#8217;s Chief Scientific Officer and Class III
        Director, as described in the proxy statement, dated April 28, 2022.&#8221;</div>
      <div style="text-align: justify; line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Required Vote</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The affirmative vote of the holders of a majority of the shares represented at the Annual General Meeting in person or by proxy and voting on the foregoing resolution is
        required.</div>
      <div style="text-align: justify; line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Board Recommendation</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-weight: bold;">Our Board recommends a vote &#8220;FOR&#8221; Proposal 2.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">PROPOSAL NUMBER 3</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">TO APPROVE ADDITIONAL EQUITY GRANTS TO CERTAIN OF THE DIRECTORS OF THE COMPANY AND CERTAIN CHANGES TO THE </div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">COMPANY&#8217;S DIRECTORS COMPENSATION PACKAGE, ALL IN COMPLIANCE WITH THE COMPANY'S COMPENSATION POLICY</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="line-height: 1.25; font-weight: bold;">Background</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">As approved by our shareholders, and as required by the Companies Law, we have adopted a Compensation Policy regarding the terms of office and employment of its &#8220;office holders&#8221;
        (as defined in the Companies Law), including cash compensation, equity-based awards, releases from liability, indemnification and insurance, severance and other benefits. Chemomab compensates its directors and senior management team in accordance
        with the recommendation of its Compensation Committee and, generally, subject to the approval of our Board and shareholders. That compensation will generally need to be consistent with the terms of our Compensation Policy, which will require
        periodic approval, in accordance with the requirements of the Companies Law. For a further discussion of this policy, including the cash and equity grant components specifically, see "<font style="font-style: italic;">Executive Compensation</font>"
        above.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In addition to the Compensation Policy, on March 15, 2021, our shareholders approved certain actual compensation terms applicable to our current and future directors (the
        &#8220;Director Compensation Package&#8221;), pursuant to which (and among other terms) (i) our non-employee directors are entitled to receive an annual option grant of up to 0.05% of the Company&#8217;s share capital on a fully diluted basis, (ii) the chairman of
        our Board is entitled to receive an annual option grant of up to 0.2% of the Company&#8217;s share capital on a fully diluted basis and (iii) our non-employee directors are entitled to receive an annual cash fee of $35,000. The Director Compensation
        Policy implements terms for actual equity compensation that will be granted to directors on a regular basis and determines the annual cash fee that may be paid to non-employee directors. In accordance with the Companies Law, equity grants to our
        directors that are within the limitations of the Director Compensation Package require the approval of our Compensation Committee and Board, but not our shareholders, while any contemplated compensation made in excess of the Director Compensation
        Package will require the approval of our shareholders. Furthermore, any such compensation, including the annual cash fee payable to our non-employee directors, must be limited to the framework of the Director Compensation Package.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 32.4pt; line-height: 1.25;">Our senior management has determined that it is in the best interests of the Company, and an appropriate reward for each of our non-executive director&#8217;s ongoing contributions
        to the Company&#8217;s success, to recommend that our Compensation Committee, Board and shareholders approve the following equity-based compensation grants to each of our non-executive directors, as more fully set forth below. Our senior management
        underscored in its discussion with the Compensation Committee and the Board that the current limitations of the Director Compensation Package do not adequately reflect the value provided to the Company by each of our non-executive directors. Our
        senior management specifically emphasized the Company&#8217;s reliance on each non-executive director&#8217;s expertise during the Company&#8217;s adjustment to life as a new public company, transition of new senior management (including our Chief Executive Officer
        and Chief Financial Officer) that occurred during the second half of 2021 and recent material changes to the Company&#8217;s clinical trial strategy. While the equity grants to our non-executive directors, as set forth below, are consistent with the
        limitations of the Compensation Policy, such amounts exceed the limitations of the Director Compensation Package. Accordingly, and in accordance with the Companies Law, our board of directors is seeking the approval of our shareholders for the
        following one time additional equity grants:</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z3d53423336694a86a7516e7dd40740d0">

          <tr>
            <td style="width: 46.83%; vertical-align: bottom; border-bottom: #000000 2px solid;">
              <div style="line-height: 1.25; font-weight: bold;">Name of Grantee</div>
            </td>
            <td style="width: 0.8%; vertical-align: bottom;">&#160;</td>
            <td colspan="2" style="width: 9.6%; vertical-align: bottom; border-bottom: #000000 2px solid;">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">Number of Options</div>
            </td>
            <td style="width: 2.18%; vertical-align: bottom;">&#160;</td>
            <td style="width: 0.8%; vertical-align: bottom;">&#160;</td>
            <td style="width: 39.8%; vertical-align: bottom; border-bottom: #000000 2px solid;">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">Vesting Schedule</div>
            </td>
          </tr>
          <tr>
            <td style="width: 46.83%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">Nissim Darvish</div>
            </td>
            <td style="width: 0.8%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
            <td style="width: 0.8%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
            <td style="width: 8.8%; vertical-align: top; background-color: #CCEEFF;">
              <div style="text-align: right; line-height: 1.25;">11,180</div>
            </td>
            <td style="width: 2.18%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
            <td style="width: 0.8%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
            <td style="width: 39.8%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">100% vesting upon the first anniversary of grant</div>
            </td>
          </tr>
          <tr>
            <td style="width: 46.83%; vertical-align: top;">
              <div style="line-height: 1.25;">Joel Maryles</div>
            </td>
            <td style="width: 0.8%; vertical-align: bottom;">&#160;</td>
            <td style="width: 0.8%; vertical-align: bottom;">&#160;</td>
            <td style="width: 8.8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25;">11,180</div>
            </td>
            <td style="width: 2.18%; vertical-align: top;">&#160;</td>
            <td style="width: 0.8%; vertical-align: bottom;">&#160;</td>
            <td style="width: 39.8%; vertical-align: bottom;">
              <div style="line-height: 1.25;">100% vesting upon the first anniversary of grant</div>
            </td>
          </tr>
          <tr>
            <td style="width: 46.83%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">Alan Moses</div>
            </td>
            <td style="width: 0.8%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
            <td style="width: 0.8%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
            <td style="width: 8.8%; vertical-align: top; background-color: #CCEEFF;">
              <div style="text-align: right; line-height: 1.25;">11,180</div>
            </td>
            <td style="width: 2.18%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
            <td style="width: 0.8%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
            <td style="width: 39.8%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">100% vesting upon the first anniversary of grant</div>
            </td>
          </tr>
          <tr>
            <td style="width: 46.83%; vertical-align: top;">
              <div style="line-height: 1.25;">Claude Nicaise</div>
            </td>
            <td style="width: 0.8%; vertical-align: bottom;">&#160;</td>
            <td style="width: 0.8%; vertical-align: bottom;">&#160;</td>
            <td style="width: 8.8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25;">11,180</div>
            </td>
            <td style="width: 2.18%; vertical-align: top;">&#160;</td>
            <td style="width: 0.8%; vertical-align: bottom;">&#160;</td>
            <td style="width: 39.8%; vertical-align: bottom;">
              <div style="line-height: 1.25;">100% vesting upon the first anniversary of grant</div>
            </td>
          </tr>
          <tr>
            <td style="width: 46.83%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">Neil Cohen</div>
            </td>
            <td style="width: 0.8%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
            <td style="width: 0.8%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
            <td style="width: 8.8%; vertical-align: top; background-color: #CCEEFF; border-bottom: #000000 2px solid;">
              <div style="text-align: right; line-height: 1.25;">11,180</div>
            </td>
            <td style="width: 2.18%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
            <td style="width: 0.8%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
            <td style="width: 39.8%; vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">100% vesting upon the first anniversary of grant</div>
            </td>
          </tr>
          <tr>
            <td style="width: 46.83%; vertical-align: top;">
              <div style="line-height: 1.25; font-weight: bold;">Total</div>
            </td>
            <td style="width: 0.8%; vertical-align: bottom;">&#160;</td>
            <td style="width: 0.8%; vertical-align: bottom;">&#160;</td>
            <td style="width: 8.8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-weight: bold;">55,900</div>
            </td>
            <td style="width: 2.18%; vertical-align: top;">&#160;</td>
            <td style="width: 0.8%; vertical-align: bottom;">&#160;</td>
            <td style="width: 39.8%; vertical-align: bottom;">&#160;</td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Furthermore, our Compensation Committee and Board believe it would reflect good corporate governance and be in the best interest of the Company to amend the Director Compensation
        Package such that the upper limit associated with certain equity-based and annual cash-based compensation to our current and future directors will be consistent with the limitations previously approved by our shareholders in connection with the
        Compensation Policy. In light of the foregoing, our Board recommends that our shareholders approve an amendment to the Director Compensation Package whereby (i) future annul equity grants to our directors will be limited to up to 0.4% of the
        Company&#8217;s share capital on a fully diluted basis (ii) future annual equity grants to the chairman of our Board will be limited to up to 1.0% of the Company&#8217;s share capital on a fully diluted basis and (iii) our non-employee directors (other than
        the chairman) shall be entitled to receive an annual cash fee of up to $50,000.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25; font-weight: bold;">Proposed Resolution</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-indent: 36pt; line-height: 1.25;">Shareholders are being asked to adopt the following resolutions:</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; margin-left: 36pt; line-height: 1.25;">&#8220;<font style="font-weight: bold;">RESOLVED,</font><font style="font-weight: bold; font-style: italic;">&#160;</font>to approve the grants of options to purchase an aggregate of 55,900
        ADSs to certain of the directors of the Company, and to amend the Director Compensation Package, effective immediately, such that (i) the upper limit on annual equity grants to our current and future directors shall be 0.4% of the Company&#8217;s share
        capital on a fully diluted basis,&#160; (ii) the upper limited on annual equity grants to our current and future chairman of our Board shall be 1.0% of the Company&#8217;s share capital on a fully diluted basis and (iii) the annual cash fee payable to our
        non-employee directors will be $50,000, all as described in the proxy statement, dated April 28, 2022.&#8221;</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25; font-weight: bold;">Required Vote</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-indent: 36pt; line-height: 1.25;">The affirmative vote of the holders of a majority of the shares represented at the Annual General Meeting in person or by proxy and voting on the foregoing resolution is required.</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25; font-weight: bold;">Board Recommendation</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-indent: 36pt; line-height: 1.25; font-weight: bold;">Our Board recommends a vote &#8220;FOR&#8221; Proposal 3.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">PROPOSAL NUMBER 4</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">RATIFICATION OF APPOINTMENT OF INDEPENDENT</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">REGISTERED PUBLIC ACCOUNTING FIRM</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Under the Companies Law and our articles of association, the shareholders of our Company are authorized to appoint the Company&#8217;s independent auditors. Under our articles of
        association, our Board (or a committee, if it is so authorized by the Board) is authorized to determine the independent auditor&#8217;s remuneration. In addition, the approval by our Audit Committee of the independent auditor&#8217;s re-appointment and
        remuneration is required under the listing rules of the Nasdaq. Following the recommendation by our Audit Committee and Board, it is proposed that Somekh Chaikin, Tel Aviv, Israel, a member of KPMG International ("KPMG"), be reappointed as the
        independent auditors of the Company for the fiscal year ending December 31, 2022</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">A representative of KPMG is expected to be telephonically present at the Annual General Meeting, where he or she will be available to respond to appropriate questions and, if he
        or she desires, to make a statement.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25; font-weight: bold;">Proposed Resolution</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-indent: 36pt; line-height: 1.25;">Shareholders are being asked to adopt the following resolution:</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="margin-left: 36pt; line-height: 1.25;">&#8220;<font style="font-weight: bold;">RESOLVED</font>, to approve and ratify the re-appointment of Somekh Chaikin, Tel Aviv, Israel, a member of KPMG International, as the independent auditors of the
        Company for the fiscal year ending December 31, 2022.&#8221;</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="line-height: 1.25; font-weight: bold;">Required Vote</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-indent: 36pt; line-height: 1.25;">The affirmative vote of the holders of a majority of the shares represented at the Annual General Meeting in person or by proxy and voting on the foregoing resolution is required.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="line-height: 1.25; font-weight: bold;">Board Recommendation</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-weight: bold;">Our Board recommends a vote &#8220;FOR&#8221; Proposal 4.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Fees Paid to the Independent Registered Public Accounting Firm</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The following table presents the aggregate fees billed for professional audit services and other services rendered to us by KPMG for our fiscal years ended December&#160;31, 2021 and
        2020.</div>
      <div style="text-align: justify; line-height: 1.25;">&#160;</div>
      <table cellspacing="0" cellpadding="0" class="cfttable" id="z3e7efd499c484be0b8973e5be68bdd8e" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">

          <tr>
            <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">Fiscal Year Ended</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;"> 2021</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">2020</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top; background-color: #CCEEFF; width: 76%;">
              <div style="text-indent: -10pt; margin-left: 10pt; line-height: 1.25;">Audit Fees(1)</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" nowrap="nowrap" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">
              <div style="line-height: 1.25;">$</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">173,000</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" nowrap="nowrap" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" nowrap="nowrap" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">
              <div style="line-height: 1.25;">$</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">121,000</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top; width: 76%;">
              <div style="text-indent: -10pt; margin-left: 10pt; line-height: 1.25;">Audit-related Fees</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" nowrap="nowrap" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" nowrap="nowrap" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">&#8212;</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" nowrap="nowrap" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" nowrap="nowrap" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" nowrap="nowrap" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">&#8212;</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top; background-color: #CCEEFF; width: 76%;">
              <div style="text-indent: -10pt; margin-left: 10pt; line-height: 1.25;">Tax Fees(2)</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" nowrap="nowrap" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" nowrap="nowrap" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">29,000</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" nowrap="nowrap" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" nowrap="nowrap" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" nowrap="nowrap" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">35,000</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px;">
              <div style="text-indent: -10pt; margin-left: 10pt; line-height: 1.25;">All Other Fees(3)</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" nowrap="nowrap" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td valign="bottom" nowrap="nowrap" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="line-height: 1.25;">&#8212;</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" nowrap="nowrap" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" nowrap="nowrap" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td valign="bottom" nowrap="nowrap" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="line-height: 1.25;">&#8212;</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 4px;">
              <div style="text-indent: -10pt; margin-left: 10pt; line-height: 1.25;">Total Fees</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>
            <td valign="bottom" nowrap="nowrap" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);">
              <div style="line-height: 1.25;">$</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);">
              <div style="line-height: 1.25;">202,000</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>
            <td valign="bottom" nowrap="nowrap" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>
            <td valign="bottom" nowrap="nowrap" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);">
              <div style="line-height: 1.25;">$</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);">
              <div style="line-height: 1.25;">156,000</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>
          </tr>

      </table>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;">&#160;</div>
        <div style="line-height: 1.25;"><u>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </u><br style="line-height: 1.25;">
        </div>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z5e870e9d76104b45a30653dc3d3f70e6">

          <tr>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25;">(1)</div>
            </td>
            <td style="width: 96%; vertical-align: top;">
              <div style="line-height: 1.25;">&#8220;Audit Fees&#8221; consist of professional services rendered in connection with the audit of our consolidated financial statements and review of our quarterly consolidated financial statements and services that are
                normally provided by the independent registered public accounting firm in connection with statutory and regulatory filings or engagements for those fiscal years.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25;">(2)</div>
            </td>
            <td style="width: 96%; vertical-align: top;">
              <div style="line-height: 1.25;">&#8220;Tax Fees&#8221; consist of fees for professional services for tax compliance, tax advice and tax planning.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25;">(3)</div>
            </td>
            <td style="width: 96%; vertical-align: top;">
              <div style="line-height: 1.25;">&#8220;All other fees&#8221; consists of fees for services provided in connection with the assessment and reports of our compliance programs.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <div style="line-height: 1.25; font-weight: bold;">Auditor Independence</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In 2021, there were no other professional services provided by KPMG that would have required our Audit Committee to consider their compatibility with maintaining the independence
        of KPMG.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="line-height: 1.25; font-weight: bold;">Audit and Non-Audit Services Pre-Approval Policy</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Our Audit Committee has the sole authority to approve the scope of the audit and any audit-related services, as well as all audit fees and terms. The Audit Committee must
        pre-approve any audit and non-audit services provided by our independent registered public accounting firm. The Audit Committee will not approve the engagement of the independent registered public accounting firm to perform any services that the
        independent registered public accounting firm would be prohibited from providing under applicable laws, rules&#160;and regulations, including those of self-regulating organizations. The Audit Committee will approve permitted non-audit services by our
        independent registered public accounting firm only if it determines that using a different firm to perform such services will be less efficient or cost-effective. The Audit Committee reviews and pre-approves the statutory audit fees that can be
        provided by the independent registered public accounting firm on an annual basis.</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"> <br>
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">AUDIT COMMITTEE REPORT</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic;">The following report of the Audit Committee does not constitute soliciting material and should not be deemed filed with the SEC nor shall this information be incorporated by
        reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, each as amended, except to the extent that the Company specifically incorporates it by reference into a filing.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">Our Audit Committee consists of Chair, Joel Maryles, and members, Alan Moses and Claude Nicaise. The Board has determined that each Audit Committee member is &#8220;independent,&#8221; as independence for
        Audit Committee members is defined in the applicable Nasdaq listing standards and rules of the SEC. The Board also determined that all members of the Audit Committee are financially literate, and Mr. Maryles has been designated as an Audit
        Committee financial expert, as such term is defined in Item 407 of Regulation S-K. Although designated as Audit Committee financial experts, the Audit Committee Chair and members are not accountants for the Company nor, under SEC rules, an &#8220;expert&#8221;
        for purposes of the liability provisions of the Securities Act or for any other purpose.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">The role of the Audit Committee is to (a) oversee the accounting and financial reporting processes of the Company and the audits of the Company&#8217;s financial statements; (b) oversee the Company&#8217;s
        compliance with legal and regulatory requirements; (c) oversee the performance of the Company&#8217;s internal audit function; (d) take, or recommend that the Board of the Company take, appropriate action to oversee the qualifications, independence and
        performance of the Company&#8217;s independent auditors; and (e) prepare the report required by the rules of the SEC to be included in the Company&#8217;s annual proxy statement.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">The Audit Committee influences the overall tone for quality financial reporting, sound internal controls, and ethical behavior. Management is responsible for the preparation, presentation and
        integrity of the Company&#8217;s financial statements, for the appropriateness of the accounting and reporting policies that are used by the Company, and for the establishment and effectiveness of internal controls and procedures designed to ensure
        compliance with accounting standards and applicable laws and regulations. The independent auditors are responsible for auditing the Company&#8217;s consolidated financial statements in accordance with the standards of the Public Company Accounting
        Oversight Board (&#8220;PCAOB&#8221;), expressing an opinion as to the conformity of such financial statements with generally accepted accounting principles, expressing an opinion on the effectiveness of internal control over financial reporting, and for
        reviewing the Company&#8217;s interim consolidated financial statements.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">The independent auditors report directly to the Audit Committee. The Audit Committee has the sole authority and responsibility to recommend to the Board the nomination of the independent auditors
        for approval by the stockholders on an annual basis. The Audit Committee is directly responsible for the appointment, retention, termination, compensation, retention, evaluation and oversight of the work of the independent auditors for the purpose
        of preparing or issuing an audit report or performing other audit, review or attest services for the Company.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">In 2021, the Audit Committee routinely met and held discussions with management and KPMG, the Company&#8217;s independent registered public accounting firm. The Audit Committee discussed with management
        and KPMG regarding the Company&#8217;s audited consolidated financial statements and policies and procedures designed to reduce the likelihood of events of non-compliance with rules and regulations, including discussions of the quality, not just the
        acceptability, of accounting policies and principles, significant judgments and estimates, system of internal control over financial reporting, and clarity of disclosures, including items reported as Critical Auditing Matters in the report of the
        independent auditor (if required). The Audit Committee reviewed the annual plan and scope of work to be performed by KPMG, and met outside of the presence of management with KPMG to discuss their respective audit results, evaluations of the
        Company&#8217;s internal controls, and the overall quality of the Company&#8217;s financial reporting. Consistent with the requirements of the Sarbanes-Oxley Act of 2002 and the rules promulgated thereunder, the Audit Committee discussed with the Company those
        matters required to be discussed pursuant to PCAOB Auditing Standard 1301, &#8220;Communications with Audit Committees,&#8221; and the rules of the SEC.<br>
      </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">The Audit Committee also discussed with KPMG the firm&#8217;s independence from the Company and its management team, and reviewed the written disclosures and letter from KPMG pursuant to applicable
        requirements of the PCAOB regarding the independent registered public accounting firm&#8217;s communications with the Audit Committee concerning independence, and considered the compatibility of non-audit services, if any, with KPMG&#8217;s independence.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">Based upon the reports and discussions described above, the Audit Committee, in accordance with its responsibilities, recommended to the Board that the audited consolidated financial statements be
        included in the Company&#8217;s Annual Report.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="line-height: 1.25;">The Audit Committee:</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="line-height: 1.25;">Joel Maryles (Chair)<br>
        Alan Moses<br>
        Claude Nicaise</div>
      <div style="line-height: 1.25">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; margin-right: 124.7pt; margin-left: 124.7pt; line-height: 1.25; font-weight: bold;">ANNUAL REPORT AND RELATED REPORTS TO SHAREHOLDERS</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 25.5pt; margin-right: 6.6pt; margin-left: 5.3pt; line-height: 1.25;">Our Annual Report will be distributed to all shareholders entitled to vote along with the proxy materials. Additional copies of our
        Annual Report are available on the Internet at http://www.sec.gov and http://www.chemomab.com and are also available in paper form without charge upon written request to Chemomab Therapeutics Ltd., Kiryat Atidim, Building 7, Tel-Aviv, Israel
        6158002.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; margin-right: 124.2pt; margin-left: 124.7pt; line-height: 1.25; font-weight: bold;">HOUSEHOLDING OF PROXY MATERIALS</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 25.5pt; margin-right: 6.3pt; margin-left: 5.3pt; line-height: 1.25;">The SEC has adopted rules that permit companies and intermediaries (e.g., brokers) to satisfy the delivery requirements for proxy
        statements and annual reports with respect to two or more shareholders sharing the same address by delivering a single proxy statement addressed to those shareholders. This process, which is commonly referred to as &#8220;householding,&#8221; potentially means
        extra convenience for shareholders and cost savings for companies.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 25.5pt; margin-right: 7.85pt; margin-left: 5.3pt; line-height: 1.25;">This year, a number of brokers with account holders who are shareholders of our company will be &#8220;householding&#8221; our proxy materials. A
        single proxy statement may be delivered to multiple shareholders sharing an address unless contrary instructions have been received from the affected shareholder. Once a shareholder has received notice from its broker that it will be &#8220;householding&#8221;
        communications to such shareholder&#8217;s address, &#8220;householding&#8221; will continue until such shareholder is notified otherwise or until such shareholder notifies its broker or us that it no longer wishes to participate in &#8220;householding.&#8221; If, at any time,
        a shareholder no longer wishes to participate in &#8220;householding&#8221; and would prefer to receive a separate proxy statement and annual report (for annual meetings) in the future, such shareholders may (1) notify its broker or (2) direct its written
        request to: Chemomab Therapeutics Ltd., Kiryat Atidim, Building 7, Tel-Aviv, Israel 6158002. Shareholders who currently receive multiple copies of the proxy statement at their address and would like to request &#8220;householding&#8221; of their communications
        should contact their broker. In addition, we will promptly deliver, upon written or oral request to the address or telephone number above, a separate copy of the proxy statement to such shareholders at a shared address to which a single copy of the
        documents was delivered.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; margin-right: 124.7pt; margin-left: 124.7pt; line-height: 1.25; font-weight: bold;">OTHER INFORMATION</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; margin-left: 5.3pt; line-height: 1.25; font-weight: bold;">Section 16(a) Beneficial Ownership Reporting Compliance</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 25.5pt; margin-right: 10.85pt; margin-left: 5.3pt; line-height: 1.25;">Section 16(a) of the Exchange Act requires our directors, executive officers and holders of more than 10% of our ordinary shares (the
        &#8220;Reporting Persons&#8221;) to file with the SEC reports regarding their ownership and changes in ownership of our equity securities. Based on a review of the copies of the reports furnished to us, we believe the Reporting Persons complied with all
        applicable Section 16(a) filing requirements.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; margin-left: 5.3pt; line-height: 1.25; font-weight: bold;">Other Matters</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 25.5pt; margin-right: 10.85pt; margin-left: 5.3pt; line-height: 1.25;">The board of directors currently knows of no other business to be transacted at the Annual General Meeting, other than as set forth
        in the Notice of Annual General Meeting of Shareholders; but, if any other matter is properly presented at the Annual General Meeting, the persons named in the enclosed form of proxy will vote upon such matters in accordance with their best
        judgment.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Shareholder Proposals</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Shareholders interested in submitting a proposal for inclusion in our proxy materials for our 2023 Annual General Meeting may do so by following the procedures set forth in Rule
        14a-8 promulgated by the SEC under the Exchange Act. To be eligible for inclusion in such proxy materials, our Corporate Secretary (or, in the absence thereof, by the Chief Executive Officer of the Company) must receive shareholder proposals no
        later than January 4, 2023. If a shareholder proposal is received after March 21, 2023, we may vote in our discretion as to the proposal all of the shares for which we have received proxies for the 2023 Annual General Meeting.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Furthermore, Section 66(b) of the Companies Law allows shareholders who hold at least 1% of our outstanding ordinary shares to submit a request to include a proposal on the
        agenda of a general meeting of our shareholders. Such request made by an eligible shareholder must be received by us no later than May 5, 2022.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="margin-left: 5.3pt; line-height: 1.25; font-weight: bold;">Where to Find More Information</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 25.5pt; margin-right: 6.3pt; margin-left: 5.3pt; line-height: 1.25;">Our reports on Forms 10-K, 8-K and formerly on Forms 20-F and 6-K and all amendments to those reports are available without charge
        through our website, www.chemomab.com, as soon as reasonably practicable after they are electronically filed with, or furnished to, the SEC. Our Code of Business Conduct and Code of Ethics, and our Committee Charters are also available at our
        website located at https://www.chemomab.com/. Information contained on, or accessible through, our website does not form a part of this proxy statement and is not incorporated by reference herein. You may request a copy of our SEC filings, as well
        as the foregoing corporate documents, at no cost to you, by writing to the Company address appearing in this proxy statement or by calling us at +972-77-33-10156.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="margin-left: 30.8pt; line-height: 1.25;">Our SEC filings and submissions are also available to the public from commercial document retrieval services and at the Internet at http://www.sec.gov.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="line-height: 1.25">
        <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
          <div><br>
            <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 3%; vertical-align: top; background-color: #000000;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 39%; vertical-align: top;">
                    <div style="text-align: center; line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 3%; vertical-align: top; background-color: #000000;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 55%; vertical-align: top;" colspan="3">
                    <div style="text-align: center; line-height: 1.25;">&#160;</div>
                  </td>
                </tr>
                <tr>
                  <td style="width: 45.1%; vertical-align: top;" colspan="4">
                    <div style="text-align: center; line-height: 1.25; font-weight: bold;">
                      <div style="line-height: 1.25; font-weight: bold;"><font style="font-weight: bold;">Annual General Meeting of</font>&#160;&#160;&#160; <br>
                      </div>
                    </div>
                  </td>
                  <td style="width: 9.94%; vertical-align: top;">
                    <div style="line-height: 1.25; font-weight: bold;">&#160;</div>
                  </td>
                  <td style="width: 44.96%; vertical-align: top;">
                    <div style="text-align: center; line-height: 1.25; font-weight: bold;">&#160;&#160; <font style="font-weight: bold;">Annual Meeting of Chemomab Therapeutics Ltd. </font></div>
                  </td>
                </tr>
                <tr>
                  <td style="width: 45.1%; vertical-align: top;" colspan="4">
                    <div style="text-align: center; line-height: 1.25; font-weight: bold;">
                      <div style="line-height: 1.25; font-weight: bold;">Chemomab Therapeutics Ltd.</div>
                    </div>
                  </td>
                  <td style="width: 9.94%; vertical-align: top;">
                    <div style="line-height: 1.25; font-weight: bold;">&#160;</div>
                  </td>
                  <td style="width: 44.96%; vertical-align: top;">
                    <div style="text-align: center; line-height: 1.25; font-weight: bold;">&#160;<font style="font-weight: bold;"> to be held on June 7, 2022</font></div>
                  </td>
                </tr>
                <tr>
                  <td rowspan="1" style="width: 45.1%; vertical-align: top;" colspan="4">&#160;</td>
                  <td rowspan="1" style="width: 9.94%; vertical-align: top;">&#160;</td>
                  <td rowspan="1" style="width: 44.96%; vertical-align: top;">
                    <div style="text-align: center; line-height: 1.25; font-weight: bold;">
                      <div style="line-height: 1.25"><font style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">For Holders as of April 28, 2022</font> <br>
                      </div>
                    </div>
                  </td>
                </tr>
                <tr>
                  <td style="width: 45.1%; vertical-align: top;" colspan="4">
                    <div style="line-height: 1.25; font-weight: bold;">Date:&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;"><font style="font-weight: bold;">June 7, 2022</font> <br>
                      </font></div>
                  </td>
                  <td style="width: 9.94%; vertical-align: top;">
                    <div style="line-height: 1.25; font-weight: bold;">&#160;</div>
                  </td>
                  <td style="width: 44.96%; vertical-align: top;">
                    <div style="text-align: center; line-height: 1.25; font-weight: bold;"><br>
                    </div>
                  </td>
                </tr>
                <tr>
                  <td style="width: 45.1%; vertical-align: top;" colspan="4">
                    <div style="line-height: 1.25; font-weight: bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; See Voting Instruction On Reverse Side.</div>
                  </td>
                  <td style="width: 9.94%; vertical-align: top;">
                    <div style="line-height: 1.25; font-weight: bold;">&#160;</div>
                  </td>
                  <td style="width: 44.96%; vertical-align: top;">&#160;</td>
                </tr>
                <tr>
                  <td style="width: 45.1%; vertical-align: top;" colspan="4">
                    <div style="line-height: 1.25; font-weight: bold;">Please make your marks like this: &#9746;&#160;Use pen only</div>
                  </td>
                  <td style="width: 9.94%; vertical-align: top;">
                    <div style="line-height: 1.25; font-weight: bold;">&#160;</div>
                  </td>
                  <td style="width: 44.96%; vertical-align: top;">
                    <div style="line-height: 1.25; font-weight: bold;">&#160;</div>
                  </td>
                </tr>

            </table>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 2.11%; vertical-align: middle;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 1.93%; vertical-align: middle;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 21.37%; vertical-align: middle;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 6.48%; vertical-align: middle;">
                    <div style="text-align: center; line-height: 1.25; font-weight: bold;">For</div>
                  </td>
                  <td style="width: 7.27%; vertical-align: middle;">
                    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Against</div>
                  </td>
                  <td style="width: 7.39%; vertical-align: middle;">
                    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Abstain</div>
                  </td>
                  <td style="width: 4.97%; vertical-align: middle;" rowspan="17">
                    <div style="text-align: center; line-height: 1.25;">
                      <div style="line-height: 1.25;"><img src="sc.jpg"><img width="22" height="12" src="image3.jpg"> </div>
                      <div style="line-height: 1.25">&#160;</div>
                    </div>
                  </td>
                  <td style="width: 48.48%; vertical-align: middle;" rowspan="17" colspan="7">
                    <div style="line-height: 1.25;"><font style="line-height: 1.25;">&#160;</font></div>
                    <div style="text-align: center; line-height: 1.25;">
                      <div style="line-height: 1.25;"><img width="68" height="28" src="image5.jpg"></div>
                    </div>
                    <div style="line-height: 1.25;">&#160;&#160;</div>
                    <div style="line-height: 1.25;">&#160;&#160;&#160;&#160; &#9679; Mark, sign and date your Voting Instruction Form.</div>
                    <div style="line-height: 1.25;">&#160;&#160;&#160;&#160;&#160;&#9679; Detach your Voting Instruction Form.</div>
                    <div style="line-height: 1.25;">&#160;&#160;&#160;&#160;&#160;&#9679; Return your Voting Instruction Form in the postage-paid envelope provided.</div>
                    <div style="line-height: 1.25;">&#160;</div>
                    <div style="text-align: center; line-height: 1.25; font-weight: bold;">
                      <div style="margin-left: 57.35pt; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">All votes must be received by 12:00 p.m. EST, on May 31, 2022.</div>
                    </div>
                    <div style="text-align: center; line-height: 1.25;">&#160; <br>
                    </div>
                    <div style="line-height: 1.25; font-weight: bold;">PROXY TABULATOR FOR</div>
                    <div style="line-height: 1.25; font-weight: bold;">CHEMOMAB THERAPEUTICS LTD.</div>
                    <div style="line-height: 1.25; font-weight: bold;">P.O. BOX 8016</div>
                    <div style="line-height: 1.25; font-weight: bold;">CARY, NC 27512-9903</div>
                    <div style="line-height: 1.25;">&#160;</div>
                    <div style="text-align: center; line-height: 1.25;">&#160;</div>
                    <div style="text-align: center; line-height: 1.25;">&#160;</div>
                    <div style="text-align: center; line-height: 1.25;">&#160;</div>
                    <div style="text-align: center; line-height: 1.25;">&#160;<br>
                    </div>
                    <div style="text-align: center; line-height: 1.25;">&#160;</div>
                    <div style="text-align: center; line-height: 1.25;"> <br>
                    </div>
                    <div style="text-align: center; line-height: 1.25;"> <br>
                    </div>
                    <div style="text-align: center; line-height: 1.25;"> <br>
                    </div>
                    <div style="text-align: center; line-height: 1.25;"> <br>
                    </div>
                    <div style="text-align: center; line-height: 1.25;"> <br>
                    </div>
                    <div style="text-align: center; line-height: 1.25;"> <br>
                    </div>
                    <div style="text-align: center; line-height: 1.25;"> <br>
                    </div>
                    <div style="text-align: center; line-height: 1.25;"> <br>
                    </div>
                    <div style="text-align: center; line-height: 1.25;"> <br>
                    </div>
                    <div style="text-align: center; line-height: 1.25;"> <br>
                    </div>
                    <div style="line-height: 1.25;">
                      <div style="line-height: 1.25;">
                        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
                        </div>
                        <div style="margin-left: 5.3pt; line-height: 1.25;"><img width="21" height="12" src="image4.jpg"></div>
                        <div style="line-height: 1.25">&#160; <img src="sc2.jpg"> </div>
                      </div>
                      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
                      </div>
                    </div>
                  </td>
                </tr>
                <tr>
                  <td style="width: 2.11%; vertical-align: top;">
                    <div style="line-height: 1.25;">1.</div>
                  </td>
                  <td colspan="2" style="width: 23.3%; vertical-align: top;">
                    <div style="text-align: justify; line-height: 1.25;">
                      <div>To re-elect each of Messrs. Nissim Darvish and Joel Maryles for a term of three years as a Class I director of the Company, until the Company&#8217;s annual general meeting of the shareholders to be held in 2025 and until his
                        respective successor is duly elected and qualified:</div>
                    </div>
                  </td>
                  <td style="width: 6.48%; vertical-align: top;">
                    <div style="text-align: center; line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 7.27%; vertical-align: top;">
                    <div style="text-align: center; line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 7.39%; vertical-align: top;">
                    <div style="text-align: center; line-height: 1.25; font-family: 'Segoe UI Symbol', sans-serif;"><br>
                    </div>
                  </td>
                </tr>
                <tr>
                  <td style="width: 2.11%; vertical-align: middle;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 1.93%; vertical-align: top;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 21.37%; vertical-align: top;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 6.48%; vertical-align: top;"><br>
                  </td>
                  <td style="width: 7.27%; vertical-align: top;"><br>
                  </td>
                  <td style="width: 7.39%; vertical-align: middle;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                </tr>
                <tr>
                  <td style="width: 2.11%; vertical-align: middle;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 1.93%; vertical-align: top;">
                    <div style="line-height: 1.25;"><br>
                    </div>
                  </td>
                  <td style="width: 21.37%; vertical-align: top;">
                    <div style="text-align: justify; line-height: 1.25;">
                      <div style="line-height: 1.25;">1a.&#160;&#160;&#160; Nissim Darvish</div>
                    </div>
                  </td>
                  <td style="width: 6.48%; vertical-align: top;">
                    <div style="text-align: center; line-height: 1.25; font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</div>
                  </td>
                  <td style="width: 7.27%; vertical-align: top;">
                    <div style="text-align: center; line-height: 1.25; font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</div>
                  </td>
                  <td style="width: 7.39%; vertical-align: middle;">
                    <div style="line-height: 1.25; text-align: center;">&#160;&#9744;</div>
                  </td>
                </tr>
                <tr>
                  <td style="width: 2.11%; vertical-align: middle;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 1.93%; vertical-align: middle;"> <br>
                  </td>
                  <td style="width: 21.37%; vertical-align: middle;">
                    <div style="line-height: 1.25;">&#160;2a.&#160;&#160;&#160; Joel Maryles</div>
                  </td>
                  <td style="width: 6.48%; vertical-align: middle; text-align: center;">
                    <div style="line-height: 1.25;">&#9744;</div>
                  </td>
                  <td style="width: 7.27%; vertical-align: middle; text-align: center;">
                    <div style="line-height: 1.25;">&#160;&#9744;</div>
                  </td>
                  <td style="width: 7.39%; vertical-align: middle; text-align: center;">
                    <div style="line-height: 1.25;">&#160;&#9744;</div>
                  </td>
                </tr>
                <tr>
                  <td rowspan="1" style="width: 2.11%; vertical-align: middle;">&#160;</td>
                  <td rowspan="1" style="width: 1.93%; vertical-align: middle;">&#160;</td>
                  <td rowspan="1" style="width: 21.37%; vertical-align: middle;">&#160;</td>
                  <td rowspan="1" style="width: 6.48%; vertical-align: middle; text-align: center;">&#160;</td>
                  <td rowspan="1" style="width: 7.27%; vertical-align: middle; text-align: center;">&#160;</td>
                  <td rowspan="1" style="width: 7.39%; vertical-align: middle; text-align: center;">&#160;</td>
                </tr>
                <tr>
                  <td style="width: 2.11%; vertical-align: top;">
                    <div> 2.<br>
                    </div>
                  </td>
                  <td colspan="2" rowspan="1" style="width: 1.93%; vertical-align: top;">
                    <div style="line-height: 1.25;">
                      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; text-align: justify;">To approve the amended terms of compensation for Adi Mor, the Company&#8217;s Co-Founder, Chief Scientific Officer, and Class III Director.</div>
                    </div>
                  </td>
                  <td style="width: 6.48%; vertical-align: top; text-align: center;">
                    <div style="line-height: 1.25;">&#160;&#9744;</div>
                  </td>
                  <td style="width: 7.27%; vertical-align: top; text-align: center;">
                    <div style="line-height: 1.25;">&#160;&#9744;</div>
                  </td>
                  <td style="width: 7.39%; vertical-align: top; text-align: center;">
                    <div style="line-height: 1.25;">&#160;&#9744;</div>
                  </td>
                </tr>
                <tr>
                  <td style="width: 2.11%; vertical-align: top;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td colspan="2" style="width: 23.3%; vertical-align: middle;">&#160;</td>
                  <td style="width: 6.48%; vertical-align: top;">&#160;</td>
                  <td style="width: 7.27%; vertical-align: top;">&#160;</td>
                  <td style="width: 7.39%; vertical-align: top;">&#160;</td>
                </tr>
                <tr>
                  <td style="width: 2.11%; vertical-align: top;">3.<br>
                  </td>
                  <td colspan="2" style="width: 23.3%; vertical-align: top;">
                    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; text-align: justify;">To approve additional equity grants to certain of the Company's directors and certain changes to the Company&#8217;s director compensation
                      package, all in compliance with the Company's Compensation Policy.</div>
                  </td>
                  <td style="width: 6.48%; vertical-align: top; text-align: center;">&#160;&#9744;</td>
                  <td style="width: 7.27%; vertical-align: top; text-align: center;">&#160;&#9744;</td>
                  <td style="width: 7.39%; vertical-align: top; text-align: center;">&#160;&#9744;</td>
                </tr>
                <tr>
                  <td style="width: 2.11%; vertical-align: middle;">&#160;</td>
                  <td style="width: 1.93%; vertical-align: top;">&#160;</td>
                  <td style="width: 21.37%; vertical-align: top;">&#160;</td>
                  <td style="width: 6.48%; vertical-align: top;">&#160;</td>
                  <td style="width: 7.27%; vertical-align: top;">&#160;</td>
                  <td style="width: 7.39%; vertical-align: middle;">&#160;</td>
                </tr>
                <tr>
                  <td style="width: 2.11%; vertical-align: top;">4. <br>
                  </td>
                  <td colspan="2" rowspan="1" style="width: 1.93%; vertical-align: top;">
                    <div style="text-align: justify; line-height: 1.25;">To ratify the appointment of Somekh Chaikin, a Member Firm of KPMG International, as our independent registered public accounting firm for the year ending December 31, 2022.</div>
                  </td>
                  <td style="width: 6.48%; vertical-align: top; text-align: center;">
                    <div>&#160; &#9744;</div>
                  </td>
                  <td style="width: 7.27%; vertical-align: top; text-align: center;">
                    <div>&#160;&#9744; <br>
                    </div>
                  </td>
                  <td style="width: 7.39%; vertical-align: top; text-align: center;">
                    <div>&#9744;</div>
                  </td>
                </tr>
                <tr>
                  <td style="width: 2.11%; vertical-align: middle;">&#160;</td>
                  <td style="width: 1.93%; vertical-align: middle;">&#160;</td>
                  <td style="width: 21.37%; vertical-align: middle;">&#160;</td>
                  <td style="width: 6.48%; vertical-align: middle;">&#160;</td>
                  <td style="width: 7.27%; vertical-align: middle;">&#160;</td>
                  <td style="width: 7.39%; vertical-align: middle;">&#160;</td>
                </tr>
                <tr>
                  <td style="width: 2.11%; vertical-align: middle;">&#160;</td>
                  <td style="width: 1.93%; vertical-align: middle;">&#160;</td>
                  <td style="width: 21.37%; vertical-align: middle;">&#160;</td>
                  <td style="width: 6.48%; vertical-align: middle;">&#160;</td>
                  <td style="width: 7.27%; vertical-align: middle;">&#160;</td>
                  <td style="width: 7.39%; vertical-align: middle;">&#160;</td>
                </tr>
                <tr>
                  <td style="width: 2.11%; vertical-align: top;">&#160;</td>
                  <td colspan="2" style="width: 23.3%; vertical-align: top;">&#160;</td>
                  <td style="width: 6.48%; vertical-align: top;">&#160;</td>
                  <td style="width: 7.27%; vertical-align: top;">&#160;</td>
                  <td style="width: 7.39%; vertical-align: top;">&#160;</td>
                </tr>
                <tr>
                  <td style="width: 2.11%; vertical-align: top;">&#160;</td>
                  <td colspan="2" style="width: 23.3%; vertical-align: top;">&#160;</td>
                  <td style="width: 6.48%; vertical-align: top;">&#160;</td>
                  <td style="width: 7.27%; vertical-align: top;">&#160;</td>
                  <td style="width: 7.39%; vertical-align: top;">&#160;</td>
                </tr>
                <tr>
                  <td style="width: 2.11%; vertical-align: top;">&#160;</td>
                  <td colspan="2" style="width: 23.3%; vertical-align: top;">&#160;</td>
                  <td style="width: 6.48%; vertical-align: top;">&#160;</td>
                  <td style="width: 7.27%; vertical-align: top;">&#160;</td>
                  <td style="width: 7.39%; vertical-align: top;">&#160;</td>
                </tr>
                <tr>
                  <td style="width: 2.11%; vertical-align: top;">&#160;</td>
                  <td colspan="2" style="width: 23.3%; vertical-align: top;">&#160;</td>
                  <td style="width: 6.48%; vertical-align: top;">&#160;</td>
                  <td style="width: 7.27%; vertical-align: top;">&#160;</td>
                  <td style="width: 7.39%; vertical-align: top;">&#160;</td>
                </tr>
                <tr>
                  <td colspan="2" style="width: 2.29%; vertical-align: top;">&#160;</td>
                  <td style="width: 49.22%; vertical-align: top;" colspan="5">&#160;</td>
                  <td style="width: 2.48%; vertical-align: top;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 6.48%; vertical-align: top;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 11.62%; vertical-align: top;">
                    <div style="line-height: 1.25; font-weight: bold;">EVENT&#160;#</div>
                  </td>
                  <td style="width: 1.48%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 23.8%; vertical-align: top;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 1.04%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 1.57%; vertical-align: top;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                </tr>
                <tr>
                  <td colspan="2" style="width: 2.29%; vertical-align: top;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 49.22%; vertical-align: top;" colspan="5">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 2.48%; vertical-align: top;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 6.48%; vertical-align: top;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 11.62%; vertical-align: top;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 1.48%; vertical-align: top;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 23.8%; vertical-align: top;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 1.04%; vertical-align: top;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 1.57%; vertical-align: top;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                </tr>
                <tr>
                  <td colspan="2" style="width: 2.29%; vertical-align: top;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 49.22%; vertical-align: top;" colspan="5">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 2.48%; vertical-align: top;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 6.48%; vertical-align: top;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 11.62%; vertical-align: top;">
                    <div style="line-height: 1.25; font-weight: bold;">CLIENT&#160;#</div>
                    <div style="line-height: 1.25;"><font style="line-height: 1.25;">&#160;</font></div>
                  </td>
                  <td style="width: 1.48%; vertical-align: top;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 23.8%; vertical-align: top;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 1.04%; vertical-align: top;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 1.57%; vertical-align: top;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                </tr>
                <tr>
                  <td colspan="2" style="width: 2.29%; vertical-align: top; background-color: rgb(0, 0, 0); padding-bottom: 2px;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 49.22%; vertical-align: top; padding-bottom: 2px;" colspan="5">
                    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">&#160;Authorized Signatures - This section must be</div>
                  </td>
                  <td style="width: 2.48%; vertical-align: top; background-color: rgb(0, 0, 0); padding-bottom: 2px;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 6.48%; vertical-align: top; padding-bottom: 2px;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 11.62%; vertical-align: top; padding-bottom: 2px;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 1.48%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 23.8%; vertical-align: top; padding-bottom: 2px;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 1.04%; vertical-align: top; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 1.57%; vertical-align: top; padding-bottom: 2px;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                </tr>
                <tr>
                  <td colspan="2" style="width: 2.29%; vertical-align: top;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 49.22%; vertical-align: top;" colspan="5">
                    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">&#160;completed for your instructions to be executed.</div>
                  </td>
                  <td style="width: 2.48%; vertical-align: top;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 6.48%; vertical-align: top;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 11.62%; vertical-align: top;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 1.48%; vertical-align: top;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 23.8%; vertical-align: top;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 1.04%; vertical-align: top;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 1.57%; vertical-align: top;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                </tr>
                <tr>
                  <td colspan="2" style="width: 2.29%; vertical-align: top;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 49.22%; vertical-align: top;" colspan="5">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 2.48%; vertical-align: top;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 6.48%; vertical-align: top;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 11.62%; vertical-align: top;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 1.48%; vertical-align: top;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 23.8%; vertical-align: top;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 1.04%; vertical-align: top;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 1.57%; vertical-align: top;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                </tr>
                <tr>
                  <td colspan="2" style="width: 2.29%; vertical-align: top;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 29.59%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 7.27%; vertical-align: top;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 21.33%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);" colspan="4">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 39.52%; vertical-align: top;" colspan="5">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                </tr>
                <tr>
                  <td colspan="2" style="width: 2.29%; vertical-align: top;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 29.59%; vertical-align: top;" colspan="2">
                    <div style="text-align: center; line-height: 1.25;">Please Sign Here</div>
                  </td>
                  <td style="width: 7.27%; vertical-align: top;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 21.33%; vertical-align: top;" colspan="4">
                    <div style="text-align: center; line-height: 1.25;">Please Date Above</div>
                  </td>
                  <td style="width: 39.52%; vertical-align: top;" colspan="5">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                </tr>
                <tr>
                  <td colspan="2" style="width: 2.29%; vertical-align: top;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 29.59%; vertical-align: top;" colspan="2">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 7.27%; vertical-align: top;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 21.33%; vertical-align: top;" colspan="4">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 39.52%; vertical-align: top;" colspan="5">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                </tr>
                <tr>
                  <td colspan="2" style="width: 2.29%; vertical-align: top;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 29.59%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 7.27%; vertical-align: top;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 21.33%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);" colspan="4">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 39.52%; vertical-align: top;" colspan="5">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                </tr>
                <tr>
                  <td colspan="2" style="width: 2.29%; vertical-align: top;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 29.59%; vertical-align: top;" colspan="2">
                    <div style="text-align: center; line-height: 1.25;">Please Sign Here</div>
                  </td>
                  <td style="width: 7.27%; vertical-align: top;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 21.33%; vertical-align: top;" colspan="4">
                    <div style="text-align: center; line-height: 1.25;">Please Date Above</div>
                  </td>
                  <td style="width: 39.52%; vertical-align: top;" colspan="5">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                </tr>

            </table>
            <div style="line-height: 1.25;">&#160;&#160;</div>
            <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
              <div id="DSPFPageBreak" style="page-break-after: always;">
                <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
            </div>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 1.99%; vertical-align: top;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 2.01%; vertical-align: top;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 52.94%; vertical-align: top; font-family: 'Times New Roman',Times,serif; text-align: center;">
                    <div style="font-weight: bold;">Chemomab Therapeutics Ltd.</div>
                    <div style="font-weight: bold;">&#160;</div>
                    <div style="font-weight: bold;">Instructions to The Bank of New York Mellon, as Depositary</div>
                    <div style="font-weight: bold;"> (Must be received prior to 12:00 p.m. EST on May 31, 2022)</div>
                  </td>
                  <td style="width: 40.06%; vertical-align: top;">
                    <div style="text-align: justify; line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 3%; vertical-align: top;">
                    <div style="text-align: justify; line-height: 1.25;">&#160;</div>
                  </td>
                </tr>
                <tr>
                  <td style="width: 1.99%; vertical-align: top;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 2.01%; vertical-align: top;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 52.94%; vertical-align: top;">
                    <div style="text-align: justify; line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 40.06%; vertical-align: top;">
                    <div style="text-align: justify; line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 3%; vertical-align: top;">
                    <div style="text-align: justify; line-height: 1.25;">&#160;</div>
                  </td>
                </tr>
                <tr>
                  <td style="width: 1.99%; vertical-align: top;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 2.01%; vertical-align: top;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 52.94%; vertical-align: top;">
                    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">
                      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">The undersigned registered owner of American Depositary Shares hereby requests and instructs The Bank of New York Mellon, as Depositary, to endeavor, in so
                        far as practicable, to vote or cause to be voted the amount of Shares or other Deposited Securities represented by such Shares of <font style="font-weight: bold;">Chemomab Therapeutics Ltd. </font>registered in the name of the
                        undersigned on the books of the Depositary as of the close of business on <font style="font-weight: bold;">April 28, 2022 </font>at the <font style="font-weight: bold;">Annual General Meeting </font>of the Shareholders of <font style="font-weight: bold;">Chemomab Therapeutics Ltd. </font>to be held on <font style="font-weight: bold;">June 7, 2022 </font>or any postponement or adjournment thereof in respect of the resolutions specified on the reverse.</div>
                    </div>
                    <div style="line-height: 1.25;">&#160;
                      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">NOTES:</div>
                      <div style="text-indent: -9pt; margin-left: 9pt; line-height: 1.25; font-weight: bold;">1. Please direct the Depositary how it is to vote by placing an &#8220;X&#8221; in the appropriate box opposite each agenda item.</div>
                    </div>
                  </td>
                  <td style="width: 40.06%; vertical-align: middle; text-align: center;">
                    <div style="line-height: 1.25;">
                      <div><br>
                      </div>
                      <div><img src="sc4.jpg"></div>
                    </div>
                  </td>
                  <td style="width: 3%; vertical-align: top;">
                    <div style="text-align: justify; line-height: 1.25;">&#160;</div>
                  </td>
                </tr>

            </table>
            <br>
          </div>
        </div>
        <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
          <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
      </div>
      <br>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <br>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>image0.jpg
<TEXT>
begin 644 image0.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 0@ !<# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
>*** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image1.jpg
<TEXT>
begin 644 image1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 0V!W\# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'@Q0L:].E=O7//<<0HHHJ"@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@!",BHI(5;UJ:BBX%,VBD8YIZ6RKTS
M5FBJYF*Q$D85LU+114C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **CDE"#K4!O4'4U2BV*Y:R,XI:SS?1EL@T\7\9[TW3:%S%VBJZ7<;=
MZF5PW2I::&FF.HHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ I">*:[A5JG-=JH()/2JC%L5RGJ-P
M5) ;I6+)J#=-U-U6[&X\FN=DNQO/)KTJ5+0PG(W3J) ^]2KJ!S]ZN9>Y&[J:
M5+D;QR<5M["XKG:6]X2W#5LVMP"H^;FN%MKSY@,GBNALKP%1G.:RK8>R*3.K
M4[ES2U3M9PR]:N5YDE9V-DPHHHJ1A1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %!HJ*9PB&FE<3*=[,%R,_K7.7UX0W
MWS^=6M4O@"1_6N3O]04''Y\UZ-&EH928S4;PL?O'\ZPY)SG.3^=)=7ZLQX_6
MJ/F;CG^M>A2@8MEDSMUS^M.2=AW_ %JD>:3=CO7<J5Q-FU;71#CYC^=;UG=M
M\O)_.N*CF*UL65^% !_G4U:-T7 ]$TZY)53FNCA?<@KS_3M07"_XUUNGWH;
M)KPL71:=S>+-BBD!R,BEKSBPHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^E6*P8PHHHI %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MZ5RS11)11168!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MFCB%)DM'/J-O7%/1N^:66,J<9JJ[[3C->G#WD26BV>>.*@FD## ZU'YW&,U
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%5S$\IE6EF4YQT]JUHEVBG! .@IU)RN4D%%%%2,**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 0R/C/(JE)=8D +"H-1NQ#N(:N=N-3PY^>
MFAH[&"?>.HJT#D5Q^GZJ'/WZZ6TN1(,;L\4V&Y<HHHJ1!1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 (
M5!'-020*V:L44TVA-%(6Z@XQ2M;J".*M[1G-!7-7SL7*0I;JO:I@H%+14-MC
M2"BBBD,**** "BBB@ HHJ*64*III7$VD(\NW-5'NB&ZU2O+W:#R:S&O\MDDU
MUTZ%T2Y(Z W1]:%NSGK7/?;?<TZ.]!/)-7[ CF.I27('-3 Y%8,-Z" N36G;
MW(; KFG2<3523+E%("#2UB,**** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MUX1X:;$HY[U[KX1?*)5=!=3TJW_U0Q4M0VW^I'TJ:LB@HHHH **** "BBB@
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MT7FK2AU)ZUS@U5,X\P?G5J#48F(^<=/6E8#;HJM;W".OWJLT@"BBB@ HHHH
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M252Z 50%& ,4M%%8@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M]\UOZ?JNT#Y_UJ)+49[SI&HAU&36_&X=<UY)H.K#C+]O6O1=*OUEB0;AS46
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M4.N1V]*]0M8Q'" *Y#PG9^6$)'0>E=J!@8J)C0M%%%9C"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@#+U_']ERY]*^:_&7S3/BOI/7_\ D&2#U%?.'C%?
MWK>]:P(D>?V__'X.>]>W^ WVVL.,5XK&H6Y##UKUKP=>B*UBR:U9-STS5=2,
M5J,$=*\WUW6GVL PY)K6\0ZR!;XSVKS'4]2:5F )J;#OH5]3U.1Y#\V/I6/)
M>/)TI)O,EDXS^526]A-(._OQ4NUREL51,^[.!4ZW;+Z5=.DR[>AY]JHW%E*@
MZ'\JF^H=11J3JXQ6]I>MR1L,$<UQ[HZ9SG\JDM[MHVY)J@9]">#=8:5ER17K
M-C/YT"GCI7S7X(UHK,H8FO=- U99H4&>M*2 ZJBD!R 1WI:R*"BBB@ HHHH
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MQC.:UM&T]G=>#^580?S+I0/6O0O"]EYY& QS6Z8'I'@?3C%+$VW]*]@B&(U
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MQ6^(Y"3ZUX3K8W7SGWKH3$P\/Q W*CW]*^@O ,.U1_A7A7AV(FZ4GU]*^A/
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M9#9S7C&L'%Y)UQGK7M'BV,[3QBO$M<8BX?\ WJT0K%C0IL7T8R>M?2/@"3=
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M%0,**** &OC8<UY#X\'[UQ[UZ[+_ *LUY#X]^\_'/UK2 'A^M\77<UJ>%O\
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MKP'@1P].M>":)_KA]*]X\"YQ#CUK.>P'KB_='TI:1?N#Z4M<I04444 %%%%
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M>HYKV+P5=8=1DYI]"'>Y] V#JT*XZXJY6%H4_F(HR>E;M9O<L****0!1110
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M]76A!HP/2.MY+!=V>*OVME\W:MJF($S.L-%5<$1UTMI8K"OW0*FAMPBCBK
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MF7@2\W[,_P!WUKTQ3N4$=ZSEN-;"T445(PHHHH **** "BBB@ HHHH ****
M"BBB@ HHHH S=<_Y!DGTKYO\;C$GXU](:[_R#)/I7S;XU.93]:N)$CSU,_:1
MQ^M>R^ @#%!QWKQF/_CZ'3KZU['X"/R0_7BK0CW32_\ 4#CM6A6=I?\ J5^E
M:-9RW+CL%%%%2,**** "L[5!^YYK1K,U;B'K51W \+^(?1J\>E_X^OQKU_XA
MGY7(Q^=>/O\ \?.?>M6R6>F>""0\0]Q7T;I Q8Q\?PU\Y>"!^\B([$5]&:.0
M;*,#^[4SV&C1JIJ7_'C)]*MU6O\ _CSD^E9K<'L?.OQ'7]X,CJ:\NMFVW2]A
MFO5?B0H$F,=_6O)AQ< CL:ZX;&9ZYX2PZQ@CBO6]*LUDC'R=J\;\'3?)$??U
MKW#P^?,C7MQ5SE:()DC:0AY\L4PZ,A'^KKH@HQ1L%<CF7:YSHT5,_P"J'%-;
M14Z>6*Z38*3RU]*FXN4Y5M%7/^JJ2/1U7_EF*Z4PJ:!$H-"921B#25V_ZL5#
M)HR$Y\O)KH]@QTH**>U*^HSF!HRY_P!73AHJD\QBND$:BE$:CM3YA6.=_L90
M.(Q1_8RXQY8KHM@HV#%#8&78::ENV0F.]:U(!@8I:D8=JYGQ&?\ 1G..@]:Z
M8]*Y;Q*?W#CVK6EN)GSEXW.9)!C^(UP4*CS ,9KN?&YQ))GNQKA(C^\R*Z6(
M]H^&2XD3 XSZU]"V8Q;KQVKYX^&!R\?UKZ&L3FW6L:NP(LT445SE!1110 44
M44 <AXS_ ./2OGOQ.,22''?UKZ#\:'_0^E?/?BC[\GXUI$AG+61)N1GKFO8O
M!>?,08[>M>,V)Q<CZU[-X-X=#CL*M CVS3?]2O':K]9VF?ZA/I6C64]RPHHH
MJ0"BBB@"*?\ U9XKR/QT/F?TKURX_P!4:\C\==7-:P0'A^L\7!YZ]JT_"H'V
MU>/UK-U@#[0QK1\+'_35QV(IM"/H#PJH CXYQZUWR_=%>?\ A7K%G'2N_3[M
M1(8R?_5FO,/&)/SUZ=<_ZHUY?XQ!PYK2D3(\(\1-_IS?6K'AVX*2* <<U3\2
MX^VN3C\ZJZ-.5G4>]:2)/I+P5<%RO/85Z0IRH->/^ ;G?*OL/6O783F,5S2*
MB24445)04444 %%%% !1110 5#<_ZAJFJ"\XMF^E-;@SR_Q:^$/TKQ7Q+@AB
M/6O7O&$V$/TKQK7Y-P(XZUNB#-TF/-P.,\^M>T^!X1^[RO<=Z\>T*/=<+GUK
MVKP8H4(..HIR>@NI[';@"WC Z8I9AF)N,TEO_P >\?THN#B$FN=;FAYSXR.V
M%@.*^??%!S-US7OOC+F"0FO /$W^NXQ75T)(]#QYJX'ZU[UX$;,<5>!:&<R"
MO>? A^2'W-3/8:/7$^XOTI::GW%^E.KF&%%%% !1110 U_N&O*/B+DV,F>>M
M>KR?ZMOI7E/Q&Q]CDZ=^]7 3/FW4!B^?ZUU_@;)OXQ[UR.H?\?KD>M=;X%YU
M"+ZUU="3Z=\-C%L.,<5OU@^&\?9Q]*WJY);EA1114@%%%% !7/>)_P#CV_"N
MAKG_ !,,VQ[\54=P/FGQIC[3,<<Y]:X>U&9QQWKM_&O_ !]S#CK7#VW%P![U
MV=#-GJW@P ]N/K7M_AK&Q>.*\.\&G%>W^&?]6M*?P@CK*@N@3"<>E3CI3)AF
M-OI7$:'EWB]/W$A YYKY_P!>^6\DX[U]&>+(<V\OXU\Y^)5VWDGUXJT3U%T"
MX*W:X..:^A_ 4Y=.M?,VC2[;U<>M?0W@&<"/C^=:="CUY?NBEJ.!MT*GVJ2L
M& 4444 %%%% !1110 4444 %%%-<X0GVH YCQ)<81ES7@?C.0N9<]":]B\6W
M8C8BO#?%4V]I"?6NVFO=,V<&I_>_C7K/PQS]K7'J*\D3F7\:]=^&(_TM?J*)
M; ?2%K_QZQ_[M35#:?\ 'K'_ +M35QLT04R7_5-]*?3)?]4WTI >.^-@-\N!
MW]:\/UH8N"*]P\:X+S?6O$-<&)FK5;$LDT.8I)^->U>";O)0 _K7A&FRA6_&
MO7/ ]Q^^7ZU0=3WBR8M;J2<U9JCI1W62U>K%[E!1112 **** "BBB@ HHI#P
M#0!S'B*Y,9(SVYKPSQG=DRD9[U[!XNEV%C[>M>!^*[C=,V?7UKJI&;.3E.Z8
MD>M2+&2.1^M5H\O/CMFM:.W^7'%=L=B&?:-+24M>.C<****8#67<*KO; _PB
MK5%4I- 9RV>#T%6H[<)V%3 8I:;FV 4445 !1110 4444 %%%% !1110 444
M4 %%%% !1110 5C:K;>:I&!S6S4%S'O4GTK2G+EE<B:NCS75M,*Y.U:XZ^M=
MKG@5ZKJUMG(]/:N"U2U_>,!Z^E>SAZAFT<=(NU^0*="26!XP*M7$'[TTQ8MC
M5ZL))H430M9<'K6I!J01MI-8F[RTX/.*K27A5L@T.%T#.M.K[&QFH[G5=W?K
M7+?V@7 ;-31W1EP2:R]D-,U9[@-'NK'EDYZU/YW&W/6JD_6M=D7%B!O,.T?C
M6O96Y<A< UAQ']X,']*Z_2(-VW_"N.LQO4DBTW# [5KK=%L=B_=7/TJ&ULMV
M,_RKIM-MPO:O-K3L@2-*VBV1+P.E3T@&!BEKS&[NY84444@"BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** *.HP^;%CBO)?%FF?NYB%&,FO8
MYQF,UP7BJS/V60GK]*N+$SYAUV$QWK#CK5;2[CR[M![UL>*8=E])GU]*YZS8
M+<J3V-4]R6?0W@:]VF/GJ*]AL)A+ .:^>O!^H[7C&>U>V^'[\21!2>HJ6@1T
M=%%%06%%%% !1110 4444 %%%% !1110 4444 %%%% &=K?_ "#)?H:^;?&X
M_>FOI'7#_P 2R3Z5\W>-F'FGFK@1(\[7B<'CK7L'@(_NX3[UX^G-QC/4UZ]X
M$; A&>]:"/=]+_U2_2M*LS26S"O/:M.LI;EK8****D84444 %9NJC]T:TJS=
M5.(3SUJH[@>$_$7!#@ 5X^P_TG''6O7_ (B'ASFO(2<W8/J:T8CTWP2,/$,#
MDBOHC1O^/*/_ ':^?/! !:,D]Q7T)HYS9I]*B0&C5>^&;1_I5BH+SFU<>U2M
MQG@7Q$AW-G KR"6,I/VZU[;X^BW'_P"M7C-^FR4G/>NR!!VWA2X"^6,U[CX8
MO 5 SUZ5\[^';K9L.:]I\)7^YE!;/-$]B4>IJ<J#2U%;MNA4^U2UQO<U0444
M4@"BBB@ HHHH **** "BBB@ HHHH .U<QXC7-NYP,[:Z>N<\0G%L_/:MJ/Q"
M9\V>.4Q))D#[QK@8%_>8XZUZ'X\/S2<_Q&O/(&PX.>]=#$>S_#)=DB=.M?0E
MF,0*?:OGGX8MF6,Y[U]#639MU^E8U=AHLT445SC"BBB@ HHHH X_QK_QYU\^
M>)_]9)TKZ$\:_P#'G7S[XG_UDG/K6J)L<C8J3<C@=:]G\&#<\?3@"O&K$[;D
M<]Z]H\%'#Q\]A5BMJ>S::,0)TZ5?JGI^# OTJY6,MRD%%%%2,**** (YAF,U
MY%XZ_P!8XKUZ7[A->1>._O2'-:TP/#M;.+C%:?A; O%; ZBLO6_^/GKWK4\+
MG_3%&<\U<@/?O"HXB..U=^OW:X#PH_$0SVKOU^Z*RD V1=ZD5YSXOM\AS@5Z
M0WW37$>+(,1,<U=%V9+/FWQ7'LO'R!6#IK[;E<GO73^,5Q>R5R%JVVX!ST-:
M2)/H'P"^UU^@KVBT;,"_2O!/ %Y^]7+=!7N.E7'F0*"<\5A(J)HT445!0444
M4 %%%% !12'H:%Y% "U6OO\ CU>K-4M3DV6;\]J:W!GCOC24*K<UXYK<G+<]
MZ]3\;W'RL<UY%J4OF.5]#709FEX<3?,AXKVSPA#_ *OIU%>/>%(LS+[U[?X5
M@*!.>A%1)AU/3(?]2GTI+@9A(IT7^J7Z4VX.(6/I62W-#SGQ?&/)DKY_\4Q[
M9C7T'XM;]PYS7S_XI.9CS76MB2GH@PZ\#FO>? 8!2'..M>#:*W[Y1GWKWOP$
M?DBY[U$]@/6%^Z/I2TB_='TI:YB@HHHH **** &R?<->4_$;FR?CUKU9_N&O
M*/B/Q9/SZUI 4MCYNU _Z:_UKK? Q_XF,>.F:Y'4#_ITGUKKO W_ !_Q\YYK
MI7PDH^GO#>/LZ_2M^N?\--FV7GM705R2W+"BBBI **** "N>\3'%O^%=#7/>
M)O\ CWJH?$!\U>-!_I,QXSFN%A_X^1TZUWGC0_Z3-[FN#A_X^5Y[UVO8A'J?
M@KYC_*O<O#/*J.*\.\%\?CTKW'PSD 5,_@&CJZ0C(Q2]J*XBCD/%ED?LCM@8
M(-?,OBV$+=S=!SQ7U;XF3?I[#M@U\O>,X?\ 2YN>_I5K81QNFMMO%^M>^^ +
MD%:\ M!B]3G^*O:/ MUL[]35H#WZQE#PK5NL+2+P,B@GK6X#D9%9R0Q:***D
M HHHH **** "BBB@ J.<XA8^U256O7VVS\\XIK<#R?QI?;9'!/>O%=>NO-+C
M->E^/;W9<.-W>O(=1F\QF.>]=L-C-F?"H\T<#K7K7PVPMTIXZBO*+<_O!]:]
M;^' _P!*4>XIU%H-'T3:'-K&?]FIZAM/^/6,>BU-7"]RPILG,3?2G4V3_5M]
M*0'CWC0 RS# ZUXCX@'[X\"O<O&8^:4Y[UX?XA^^3GM71%71+,BR?$O:O5_
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MJ:$CZ&TZ\,\8)-:5<3X>U#?&HW5VB'<@-921:'4445(PHHHH **** "BBB@
MHHJ-Y0E #R<"@'(S6?)>#.-U68)]X'I0!8HHHH S=<_Y!LGTKYO\:K^])]Z^
MD-<_Y!LGTKYP\;D^:?KS5P(D><K\MR#S7L/@*+='"Q'4UX\F6N0/?FO9_ /$
M4(QW]:MAT/;M)0K"#[5I51TWB 9&.*O5D]RPHHHI %%%% !6=JJYA^E:-9NK
M-B'ZTUN!X1\01G<.:\B?B[[]:]<^(1(WG^M>12$FZR?7UK9 >I>"#\\8]Q7T
M)I Q9H?:OG;P.<O%G^\*^B='.;-/I6<P-&HIQF%A[5+39!E"*E;@>2^,[02<
MD$\5XCKUL$9C@U]%>*[0E?N\8YKP[Q5:B-9#MQSS79 B1SFE2LC*,GK7JO@Z
M];SXQD\FO'+><QR<>M>A>"KXF[C&X\&JDM!'TKI[;K5#[5;K)T2??;(,_P -
M:U<4U9EH****D84444 %%%% !113)) G4T /HJC)>!.]2VUR)5%.S LT444@
M"N;\0_\ 'L_7I725S'B0_P"C./;UK:C\0F?./CD@R..>IK@(E_>CK7>^-_\
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M^<GL:[+P0V;^(^]=3>@SZ;\._P#'N/I6[6#X<(-N,>E;U<4MQA1112 ****
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M+-%%%9#"BBB@ HHHH **** "DQ2T4 )@48%+10 4444 %%%% !1110 4444
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MR#Y.<^E>V^&K0&),J,_2O.?#6G%9/3GTKV+P_;E84'3\*I2)M<;J>FK]E<[
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M=8M5E@.<TT!XE=Z6IG8^6>OI6WX<T\+<*2A'/I6U/I@,Q&#BM/2=.$<H)IW
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M*RI;'>?N\ULTFT9SBA: 95OIZ@_=Z5J(@1<"E  Z"EH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D;[II:1ONF@#B
MO%&?F/L:\KNB6G8>]>J>*!][Z&O++@8N&X[FO>P:]TYY$D"G:*FR5X I(5'E
MYIQ&3FO;I;&<AP/%0/(0:E[5 X%;Q1DR2-R<5(V>O>H8QTJ8CC_Z]#W,FQ@.
M3BG<CBD5>2<=:=MXZ4A1W!6Q3R2141ZU(G(I,W0UNE(GR\\CO1)WXJ+=VKFK
M(I,N)=,.M3KJ+GC'ZUD/+L[5$+D[C_*N.VNI29MO=L3UJ&6X;!%58VW+DTUF
M%7!:DO<BF&XYYI]NN * NX=*D1=IKT()6"Q+S52Z7>O/;TJX,5%*@ZTVBD9D
M$>+CO76:,I$D?7K7/1Q?O<UTVC+\Z\5Y^*BK%H]$T3(4#VYK>K"T8?**W:^9
MQ'QFT-@HHHK L**** &O]P_2N \43'RWS^-=]+_JF^E>:^)W&QL_C6E/<3/"
MO&3%KMR?6N1B3=R<UU7BQMUVP]ZYZUC]170D2R=$VC//2DED)7::L,N$Z51?
MENE58@@D& <5HZ$Y6Y'U&:H2@;,XJUHV//S[BI:*CL?2G@.Y9;2,UZ7$^^,&
MO)? L@^RQ_XUZK9G]P*YYHM%BBBBLQA1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M04?2I:**Q;N,****0!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 &**** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *0D"HIIA&N<
MUFW.J+&.IXJXP;$V:GF#.,T\$$9%<P-84MU(K0@U167K5.FQ<QL453@O%D?;
MFKE9M6*"BBBD 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %,D<(A)["GUF:M<"&V;/'%5%78&'JVN)%D
M;AQ[UR5_XE7D;U_.L/Q1K"QL_/<]ZX"[UH,^=WZUW0BK$,]*7Q&H_B'YU=M_
M$Z CYQ],UXY_;*^OZU-%K8!'^-%D2>^Z7X@625?F'6NUM;M9E!'I7SWX?UE7
MGC&>_K7L6B7R-"G?('>L)P15SK <C-+44#;D'%2US,L**** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH)P,T %-WBH)9=N?
MUJOYXS0!H Y%+5:*7./K5D=* "BBB@ HHHH **** "BBB@ HHHH ***1CA:
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MR39&?I30&5YI,IYK1@8L!]*PQ+^];I6S9L"H.1TJE8"^GW:=35Z4ZH ****
M*E[G9QZ5C12YGZ]ZU=1EV)CVK!MY!]H)]ZI ;X;]WU%1;R).O2FK*/+SQTJ/
MS TV.*3 UT^X*=4<+;HQ[5)2 **** "FO]PTZHYFPA% %/>5/6IXI.:H2RC=
M4UO(&/XU?03-*BD7[HI:@84444 %9DC_ +QAD>U:3'"FLF1E,AQC\J +2CY,
M@BJDLO[S%6U8>7CC\JRIW N#TH V+1]P^M6JS]/<$5H4V 4R4X0T^HIS^[/T
MI(##D8^:3GO6G:\@=*RI''FGZUI6<F0.*H9H"EI!TXI:D04444 %)WI:C:3#
M8]Z )**0'(S2T %(#39&VKFFHX)H$2T444#"D/2EI&^Z?I0!C7TG[S&>E-MG
MRP%07S_O?QI;-P&!-/J(WH_NU)4,+9 J:D""BBB@8QVQBF Y;@TDK &FQ/\
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MY!KL?"USBYB&[O7!5T*1]%>%I=\:]:ZNN'\'RA@G)KN*Y)[FB"BBBH&%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M'.:X*SN:GOO@O(1..U>@#I7 >#!A5KOATKFD5$6BBBI*"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'TE.1WK<EQY;9K#F^61CQ0!J1,!']*YV_&Z]SCCO6HLOR=15&:/S)L\9II7
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH *0'-+30W\Z '4444 %%%% "'I6/=[O,..F:UWSM.*SKA00>
M>G3B@!+,G/2M)<X'-4K-<=?PJ_0!!<C"9XK(C8^> ?6MF892LA!_I0^M- ;$
M(P@J2FI]P8IU( K.U,GRS]*T:I:C_JC]#30'*0G]^W3KZ5T%F3M4UA6PS<L#
MZ^E=)9(=@]/I0!<B^[SUJ6D"XI:& 4444@,37"-O'I7"RR,LQQZUWFLC<IY[
M>E<4(2UR1_2F@+$$S%0#Q6G:NS.,U5AM6&TD' ]JN0+B4<=Z8'56G^H%3U#:
M_P"I%35+ **** *=\Y6,XKG#(S7 ^M=%?_ZLU@K'_I(Q_*J0&JJ!HJP+N0QS
MD=LUU")^ZX_E7/:C%^]/'0TP-K2)-T !/2M2L#3)-D04GFMR-MPZYI,!]%%%
M2!%<'$9Q7/W#$.V>U=!/G;6%<IF0X[T 11NS-[5<A@W%21UIMO#D#T^E:T,0
M$8P>GM0 Z",(O%2T@&!BEH *K7@S WTJS4%UDQ'Z4 <3(,79^M=3IN?+7TQ7
M/R)_I7XUT^GKB!?I57 NT445(!1110 C?=-8DC8NFSV-;9Z&L&8@71YQS0!M
M6Y!C!J6JUF<Q=<U9H H7TFT8%-LSG&?Y4V[Y<\]_2G6G'>GT T:***0!2'H:
M6D/0T <[J1_?&K.GXXYJIJ9(E/UJYIG)7F@1LCI1110,**** *5S]ZHE/S#I
M4UUUZU6B8&3KWH%U--/N"G4U/N#G-.H&1S?=K+F^^<^M:LHRE9\Z<\?RIH5A
MD'#@=OI6HGW16=$"".?TK03I0,?1112 **** "BBB@!" 156X3:IQ5NHIE)7
MB@3.?GE*MCO5W3+DL2.U5+Y/WAXYIUB"K'G H&=".1FBF1$%!SFGT %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110!'.-T+#VKS?Q3;!HWX/2O2G&4(KEM?L3)$YVYXJXDM79\W^)+4AF
MPIZFN/EC*]C7L6OZ.69ALSR:X34-(920%Q6UPY3DU)P>M.4,[ 8/6M5=,?/"
M5<MM)8L#LZU-[B:#1;<M.N0W6O8?#-H%6,X-<=HFBD2(=O.:];\.Z7MB4E/Q
MI7)1U&C1[%!P>E;55+.'RQ@CM5NLY.[-%L%%%%2,**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MRX!% &==Q@MDU7A&/6IKE\M@411@\@=^: +]NQZ'-6=_L:BABP <5(03_#0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D(R"*6B@"
MM]G()(Z]:408YJQ10!&B^M2444 %%%% %>Y3<M06L!C?(J\PR*:BX/>@!]%%
M% !1110 4444 %%%% !1110 QDW9SWI40(*=10 4444 %%%% !1110 4444
M%(_W32T4 9P@W2M[^U7HP0H!H5-K$T^@ HHHH **** "FLNX4ZB@"'RR,@4S
M;M-6:0J#3N V->]/HHI %%%% !1110 A&:6BB@ HHHH **** "BBB@ HHHH
M*0C(Q2T4 5WBR?\ ZU1&UYS5VB@"E]EXI4M<,*N44 (!@8I:** "BBB@!&&X
M8JK);9)-6Z* *2VN&!_I5M%VKC.:=10 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
/ %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image2.jpg
<TEXT>
begin 644 image2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 0V!W\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D8X
M4GTI:S;^[\I'&[H#32NP.:\0ZFT3/AA7GNK:_(-VUQ5WQ9J1\QOGKS74;YF+
M?-74HDW->7Q),K_ZP5:T_P 22[U)<<FO.[BZ8OD-4]A=MOQN/6FX@>^:%KCR
M2*"PYKTK3IO-MQD@U\ZZ!J;"5/G/!KV?P[J)DM@2_..*QG$=SKZ*9"^^,$T^
ML1A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 A&5(KFM;L]T;G;V-=
M-52]M_.B;ITIIV$SY\\5Z=EW!3BO.KVQ6/< N*]T\4Z6^9,*,5Y=J^G2#/RB
MNF+(.$>'Y\=JFMX06 *YK1EL7S]T5-96,QE4;!UK22T U-%T\/,F4S7L?A;2
M]J+F/C%<-X>TR1IT^4=J]J\.Z:8[=6(' KG;L,W+"(16RJ!BK5(H"J *6L66
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !2$9&*6B@#E/$.F>>"0/TKSS4_#Q9B=I_*O:)H%F'S5FSZ%
M#)GKS6T:@K'@\WAA_,)R1_P&K-AX:(<9'Z5[ WAN,GM^5.A\.Q(<XK251,BQ
MR>B:)Y<B87H?2O2;.(16ZJ/2J]MID<&"*O@8&*YY.Y20M%%%24%%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 )M'I1M%+10 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !112$T !('6F><OK56ZG5!]X"LPWH4GYA[<UM&DY*Y/,;OG)Z
MT"93WKG3?J3@,/SI\=^I.-P_.K^KNPN8Z$.#WIU9$5XC=Q^=:$,JLO45E*FX
ME)W)Z***S&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% "$XJO+<*BYS3)IL9K#O-0*9!S6].DY&,Y,;JM
M\@SS6!)?K@G=45_J&<@YK!EOSDUZ5*EI8SN;0U#YLYIT5^0_6N>-YWYI\=Z!
MUSS74J5T',=E;7Z\9-;MC>*<<UY[;:AENAK>TZ_W-CFN:K0NC2,COHI1(*EK
M$L;S<!6TK!E!'>O)J0<&:W%HHHK,84444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !3)#A#3ZI7\QBB)XJHJ[L)F;?7(53
MS^M<KJ5_EB<_K4FJZAP0#TKD[Z^+%LD9KUJ-/0PF275V78GM68Y//)YJ)KDL
M^,C% ;=7;33,]1X8XQ2%]O6D'!IC<GM7HT:2MJ(L07'S<$\5OV%WMP<]:Y8?
M*_:KT%R4(Y%34H(J+/0["[P!SUKJ["X\V/!KS"ROSM6NQTB^^4<UXF,P^ET;
M*1U=%102^8N<U+7CM6=C4****0!1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MHZ#/85ZQIP_T8>]<M1Z%(N4445B,**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MW11160PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4R096GTA
MY%"!G+ZM%E6XK@M8A(W=<UZ1J48*M7"ZM'G<<5[F#GH835CB6R).>U3QR?)P
M:CN5VN>E0QL5)!Q7M4C,TTD.T ]ZE"Y-4$<_+R*OQ$$5TR5E<+C6&&ZTUFS@
M<^].G^5<\574Y85FV9M$OEY&>U-=,#/K5A1E:KS9!QVJHL$BLS[6Q[U;MU,A
M K-ESY@]ZT[ $E>*JI+W36&INV5B7=1BNILM).T$ UGZ/"6=.E=U:6P6(<"O
MG<;B7%V-U$JV6G>6,G-:D<804X #H*6O%G4<GJ58:RY7%8^H6._) .*VJBEC
M#CFG3FX.Z)E&YYYJ>EX).":YRZL,9X->CZE;9)'%<U>6?RL2!FO?PN)NE<RY
M3A6MRKD8/!J2.UW2 C/%;-Q9_," ,FI;6R.X<#%=LZRL%AVEZ=F0$KUKO='L
M1'$..M9&G6@!' KK;*()$..U>+C:U]$:Q1:0;5 ]*=117DEA1110 4444 %5
M[R+S(6QUQ5BFR#=&P]J:=F!YOK>G[V?@\UY[K.B;T8X.17LFI6H;<>,UR&JV
M (/ Y%;MW(9XCJ>CF,%L$8K*BLB6P<\UZ/KVG 1G ]ZYNVT\[^1WK2+T$&BZ
M*7D7(.:])T30_G3"GBL[P_IPPI*\UZ5HU@%V_**BX&UHUAY,2L<\"ML=*B@C
M$<8%2UA)W9:04445(PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@#,O8@R&N/UF!1NX'Y5W\J!D-<OJMJ"&XKT,)5L[$31Y?>6X5R?Z5F2J
M%; /Z5UFHVV-W'3I7+WL95^,\5]#0DVC%HCC;GKP*O12>G:LL$J>]6HY,>M=
MG-=&;+L[92H8C@C/:E+;AWH3D]ZQDP+2M\IY]ZCE(*_2DSC')I#^/X4G.VP[
M%<H"X)Z5L:=$/E.._I5"*$M(%YP373:99YVC!XK&K6T-8(Z30X5,BUV,:A4
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 0C(Q
M61J,.5)"UL57ND#1FM*<N60FCSO4K;<&VCD&N0U"V(E)Q]*]+O;;;N.T5RFI
M6@R<KUKZ##UM#)HXMHMI/'':FKP>E:MS;\D8J@$^;I7>IZ&31)'Z8^E2D<C
MID?K4K< >]3*06&G[PI\8S+C'%1[OFQZU>LX<R*<#K6,IE6+=G:DD''.:Z[2
MK0Y!QS5;3K'* [176Z;9;%#;1TQ7FXBO9&D2S90[1RN*OTU%"KBG5Y$Y<SN:
M(****D84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 48HHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH ***1ONGZ4 8NK76R,G(Z5Q]SJ^SC
M<,YK1\3W;1H<''.*\KU76723)?C-" ](T[5AN^\*Z[3K\2*HR.E>$Z-KK/(5
M+]37I>AZ@6"?-GBKL!Z$#D9I:KV<HEA!JQ4, HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH ***:[;%S0 ,X49)JI/<*%)W5GWVIK'N';OS7.W6N*-
MP#=?>NFE1;(E(O:C=C=]X_G6;]JYQO//O6-=:JKMU_6JPU!2<?UKU:='0RYC
MH?/X(W'CWI8KG#YW'\ZY\7^.*5[\(/\ Z]6Z-Q7.OAO &'S?K6M:W8Q][]:\
M[35U'&1^=:EIK X&?UK*IAKHM,]&@E##K4]<A9:N"0 ?UKH;:[$BCWKRZM!Q
M9HF7J* <BBN<H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "D9@HR:1V"KFL;4=32)<9'OS5*-Q,MW-ZJ?Q8K
MD]7U7EOG_6L[5?$21YY'YUPNI^)4:1B6&/K6JC81IZKJ>0WSG\ZXZ]U%N?WA
M_.J5[K@=6^;GTS7/W.H[SG/ZU5^@%NZU!]Q_>-CZU"+YMO\ K&_.L6XN S\&
MFK/VJDM";FK+?N!]]OSIL%\X?.]OSK*W%NU+G;R12:'<ZFRU)@Z_O#^==]H>
MJ$(H,A_.O';>YVN*ZC3-86+&2,#WI,I'OVB:F @/F=?>NLM-067 W?K7A&E>
M)HT YS^-=CIGB52ZY8>_-)Q3&>KJX;I3JYO3=76;;@CWYKH8Y!(N16+C8!]%
M%%2!B>(CBT;D]*^;?&UPRWLGS'J:^D/$O%F?<5\Q^.B/[0D],G/-6B6<O'=-
MYR?,>OK7L_@*4M&OS''>O"[<_OUSZ\5[9X _U*DCTI,9[?I0S'G)K3K*T9CY
M-:M)C"BBBD 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %-D_U;?2
MG4R7_5-]* /,_&,I"-R>M>(:]<$2G#$<^M>Q>-G8(W'?FO"]?E)F./6CJ!<\
M-SEK@Y8\'UKV+P_+\L?)S@5XGX8/[_W/6O:/#BDB/\*U0'JNDY-OGFM&L_21
M_HP)ZFM"LWN 4444@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*M2H9284444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4V3_5M
M]*=39/\ 5M]* /)O'1Q#)P.M>#ZS\TK9'>OH#QO%OC<5X1X@3RY.3WZXH:L
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M44BG*@^M+7GB"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQ%^%7JQEN6M@HHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I
M&^X?I2TC\(Q]J /-_&,68G_2O!O$B9D9<9.:]R\9W.V)^G6O!/$%P3,Q&.O%
M4P'^&T*W0 []:]N\-*<1XSVKQ#PQ(6N.:]R\+_=B_"K0'J%H,6Z_2IZ@M/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MG71:-XEW$#/ZUX^)G!SNQ6]HMZR.N7[TK"/H?1-9#LISU]Z[RQNUE3(Q^=>
MZ/K?E[<M7H6C^)%"!2U9R07/3,YHKG[#6UGP,UNQR"1-PJ 02L5C)%<)K>IB
M*5@>WO7<7)Q;N?:O'O%U_P"7-(,UM20-DJZW^\&T\9]:Z[P]J7G2J">OO7B4
M&K'SL9[UZ/X/O/-N(QFJDM 1ZUVHI$.4!]J6N<84V3_5M]*=37^XWTH \L\;
MIF&3BO!->4K(<#G-?0/C,[HV/%>$^(EQ(3QUK6UP*GAH[9CGO7MOA>3B+TXK
MQ/P\/](KVCPQTC QVII6(OJ>NV!!M5Q5JJ>G?\>JU<K)[E(**:[A!DUGW&JQ
MPC&>:0S2HKG6\0H >>E$?B&-N,T["N=%16(FLKUS5C^U4(&#S3Y6,TZ*I17R
MOWJXK!ER*35@%HHHI %%%% $4YQ$:X/Q%/@M7:W\NV!@.M>;>()29&!->A@J
M;;,JC.;O)-S%JH G=3YI&W&DA4M7OTZ9S=0*XJ,#YL9JS+&0,U5 .[GK71"F
M ]0<U8$>8\U%$"35M5.,'I6K5A(S)1ASFGPRE#3KF,AR3WJML;=C)KEJQN3<
M[/2+_"+G/-=WI-X'13SFO*+&5DQ[>]=SHEZ0J@_SKRL31NC2#L=^AW*#3JH6
MEP64 U?KQ)1<78[$[A1114C"BBB@ HHHH ***K7$^Q<YII-L3=A+B<(#7/:A
M>##=:DO;UN<']:YG4+QL-S]>:]/#8=[F39GZS=[D;&>.*Y*4[_SK3U*Y9E..
ME9,)+'ZU[,*=D0]636D!9PN>M=GHMFP*_P"%<]IEJ6E!YSFO0-'LL(I.:YL3
M-1B-(Z32XMD"Y]*T:@M8]D0%3U\]4=Y-F\=@HJ&>X$"Y-95UK:Q#&!GZU 7-
MK<*-P]:YAO$2GA0#^-(FOAF &/SIQ5R>8ZC.:6LRTU#S2 1C/O6D#D9H:L4G
M<&&Y2*Q+W3C(6(_E6Y360-UJH3<6,XYM**MN]?:M+3;!D<'^E;#VH9N.E/BB
M\LUM*M>($JC:N*6BBN8 HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH 9*=J$UP?BV\6.%@<G KL]1<QVQ(KRSQ=>DHXSDXK6F(\G\0
MZ@#-)C/4UQID\VX!SR:T]<G9IY/J:S;"W:6=2<U;$=[X3L3(P_#M7M_AK3F5
M%]O:O,?!-@69>N?2O<=#M?)AY]*4GH"-2!"B#/I4M%%8%!1110 4444 %%%%
M !1110 4444 %%%% !1110!D:_\ \>9^E?.GC9O]/DY[FOHGQ#N-FV!P!7S=
MXW8_;WQZGO6U/8EG _\ +VO^]7O?PXA/V=#[5X+$NZ[7.>M?0GPW&+5![4V3
M<]8LDVQC-,O[D0+DFF"Z6"/G^=<UKNLC# 8X]ZBSN4F5=1U=06.[M7.7/B!$
M!&3^=8.L:V02!_.N7N]78J3_ %IV [4>(U#=36I::^LB=3Q7D2ZH^_./UK6L
M=9=%Q_6D%SU9-?5>YYKJ-#U%9\?-DFO$$U@L03T!]:[;P]KAC1>GMS5<MQGL
M"L".#3JP=+U3[0%SW]ZWATK.2L,****D HHHH **** "BBFNX1230 I.!FL+
M5[]80>>AIU_K:1(0H&?K7 Z]KYD=L8Q]:: M7FMJI;YN^:YZZ\1('(R>OK7-
MWVLMEN/UKF[O4I"Q^OK6B ]"7Q(F0.?6KJ>(UP,9KR9=3EW#_&K\>KLH&?YT
M["/58?$2YQD]:V[#649U^8^M>-P:LV0?ZUT6EZX?- X_.IL(]WT^\6>(<U?K
M@-"UOY -H)QZUV%G?BX0$@ _6DXC+]% .114#"BBB@ JK=R;%)YZ5:K*U6;;
M&0*NFKR YS5-36)RN3US60NM+OZGK6+XEU(QR/CKGUKEDUD[Q]?6NF423W#0
M+\7"\$]*Z*O,_!FHL^TD<?6O0VNU2/>1^M<THZC$O9UBB(/IFN"U75UC=AD\
M&MC7=:"1N ![<UY)K>N.9W 'MUIQ5A,Z&X\2*K8R>*IOXE1CCG\ZX&YU5RW3
M]:JC4GSP/UJAGJ-MXA7..?SKH;'6U<KS7B]OJCAN>WO71Z=K3;EQ_.HD@/>-
M(O1,F,UL5YAH&N_,H'X\UZ!97RW$8/'(I<KM<9?HHI&.U2:D 9@HR:P=5U 1
MHW/>C4-8\K<H Q]:X;6==W!^G7UJ^6PA^H:VB;LDUBQ^(4WD9/7UKD]6UEOF
MQ_.L&/57WG(Z^]1(#U0:^I7&3S[TJ>(5)QD\>]>:C5G Y_G2IJ[;LCUYYHB!
M['8ZVL@')XKJK#41)MYZUXEI>M$%0?QYKNM'U?+)GI]:U2&>H1MN7-/K,TV\
M$L84]:TQTK-JS ****0!1110 4444 %%(QVC)JA=7ZQ!AQP/6FE<!]]=+$G6
MN=O=4123G%4=6UWENG'O7&ZCKA)Z#\ZNPC=O-;4,V6KFK[Q,B.>2:YZ^UEV9
ML#]:Y+4-4D,IR/UH2$STJ'Q0CX&3^=7$\0K)@EC^=>20ZH_^35^+5G'0?K3L
M,]BMM;0E<,:Z73]40E1NZUXG8ZTP"Y_G756&N,NTG&?K3MH![-:72R8&:T <
MBO.=*UTL%R><^M=E8Z@)4&?QYJ'$9J44@.1D4M0 4444 %%%-=MJD^E $-U(
M(XB<XKD;W5%65LDUJZM>LD+<?K7F.K:NXG;C]:Z80T$SLX-35Y%^;O74Z9<"
M6,<UX_I^JEB">OUKT#0-1/EC(_6B4-!(ZVXE5(B2<5RFK:J%4C/2K>KZH(H6
MX'3UKSC6M;X<' /IFLU&PR]=:\H?DGBJC>(TZ\\^]<%=ZRQF(_/FJ4FJO_DT
M-:B/15\1J6QDC/O6O8ZXK' )KQ]=5<2<]?K6WI^KN&QCG'K4]0/:]/U-693F
MNIM9A(O7->+Z;KI#*.X]Z[_1-;\S (!&/6G:X=3LJ*CAE$J;A4E9E!378*A)
MJ*:Y6'K_ #K$U#7 D3  ?G0A7,?Q%JJ0N^":X^;Q"H;J<51\5ZV6D8 #GWKA
M9]5?.<=>G-:Q5Q7/2(_$"XQDU(VO(%SG]:\QAU>3.,?K5AM79E(_K4M:BN>F
MV7B%-XY-=CI>IJZ YZUX+9:NV\''3WKO-$UPE0/;UJDBCUZUNQ(<5>KBM*U,
MLPSQZ<UV%O*)8@U*:ZC):***S **** "BBB@ IKL%4DTX]*Q=7U,6\3KWQZU
M45=@9.O:FD:L<G@UYCJ^OCSC@GTK0\4ZZWE-MQGZUY5?:K(TK=OQK?ELA&QJ
M.L!@Q!/2N9N-2W$YR:@GN&E[]?>JRVSN>]3<".6X+-T-0F-I,G!K4CTAY,8S
MTYK2MM"9B!\V*T2NAG+/ X[=O2I[5VA.3FNGE\/L,\M^59ESH[Q''S4/1$M%
MFRU;RR,Y&*Z?3?$BAN&->>RQRPD]>*6TO)$DQVK*0K'OWAW7A+*O)ZUZKI5P
M)K93GM7S+X9U9DN%!Z9]:]Q\-ZSFV53UQZU%AG97I_T5_I7@GCFZ"7,HKVNY
MO/,LWP,?+ZU\]?$&=A=S8K6FM!/<Y"&^"SCKUKU?P%>;[J,<]:\)AG?S@>>O
MK7L'PXD+74>?YU4]@1]$1',2_2GU#:Y^SKGKBIJY66%(WW3]*6D?[C?2@#S;
MQDF(G],UX3XD4[S[9KW?QDQ\IP?PKP7Q&S&4CW]:W2N!2\/MMN:]H\,O@Q-S
MVKQGP\A:X/7@U[3X:A.R(D<#%:<IG+N>M:=_QZ*:MU0TYMMHOM[U#?:JD 91
MC(]ZYG%W+3T)=0NECB)SC%<-J^L+%GDU)K&OLT1  _.O.->UMFSCG\:M(1KW
M/B55?&34=OXD4L.O7UKSJXU)VR?ZTRVU&0'YCWXYIBN>Q0:^C <FM"+75;N:
M\GM]6<<8_6M6WUD@Y_K5) >LV&KJQ7D]:[&TF$L*D'M7B%AKIW*  .?6O0]$
MUTM"BG'YUG)%G:454M;L3\5;K, I"<#-+10!S5[=NT#$D5P&MS;I&!(KIKJZ
MS$1FN.U5\R'FOH\'1LSEG(PI#\QSBKMJ@P*ID GK^E:5FH*@UZJ5C&^H3*-G
M:J.!]ZM.Y557%4<#=C-;4]K@Q8>*M@<55BQN(S5K( ZT3W$F0S1A^N*J^6,]
M*N,PR!2,JX_^M6<HW'9%<,8RM=#I5VRX^85STVT'K5FPN=C#GI7)6INQ2/3]
M,O&9ER1741-NC'TKSK2;O#J<UV]G=JR*,UX&,HM.Z-X31HT4T.I[TN:\\W%H
MI-PI-Z^M 7'4A.*"P SFH9)U ZTTFQ-C+B;8.M86H7S -AATJS?W:A3S7+ZE
M=\'FO2PM"[U,VRO=W[X;YA7.WMXS!L,.:?>7."0#UK%GFR6&:]RE243)LAN)
MV;*G'/6ELUW8&!51B2>36IID88*3_*M9Z(E;G4Z%;JQ7Y:]%TVV58%XKC?#T
M W@9ZUZ#;QA(E ->!F%36QNHDJC P*4]**@N)EBC;)[9KRC38YGQ#J;0A@&
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MQR:L:GJ+R2N QP>*PG229_:LVK"8K7KEU&1R>:F\QM_48IB6#L<XZ>U7$L7
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M^;*W)/-0V4 ED (-,9#)+P,\UOZ18E[B,!>M920SIM!T#[1M^0\CTKMK?PB
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MSN:-D?!%=%X=GV2QC.*J"+L?0<>L[+)1OQQZUS>NZUF%AO\ UK%;4!]E7+<
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M6K#1-I_A\21@^6?RK63PM\NXQ''TKMM#TW<JC9P:ZG^RQY./+R*QE8#PV_\
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MK7<:'X>:0J0!6-X?L3/<(<=QVKVCPSHN0I]/:N28#=#T%HU&0.U=?:::(PO
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MZ=N=N!6'JVCE[=L 9KMR,BH)[<2)C^E4F#1\^>(_#S;V8J,XKS/5=/\ (E;
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M&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !3)/\
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M',+9J6H+LX@;Z5E'<H\X\6#]VQ/K7SYXG8_;6_6OH+Q6P^SOTKY[\2X^V/\
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M.O3K7K_PX(-Y'ZXYJZNP(^A;?_4K]*EJ*W_U*_2I:\U[F@4V3_5M]*=39/\
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ML@/;TKIZQ_#\/E62]:V*Q104444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !3)?]4U/IDO^J;Z4(#S+QIS$>?6OG;Q",ZDV/6O
MHCQL?W)QGO7SWK@W:DPYZUJB+%_P_$#-&<]QVKZ4\"*!8#'7%?//AV',T9([
MBOH_P8H6Q'TI,:.IHHHK,H**** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@#&\0*#:')[5\X>-A_IS_ %-?2&OC-H?I7SAXV!-Y*>>":UIF<SSR10)
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M#=-FO>?%(Q"PYZFO"/$ W79'->A%:">Y2TF!7G'U]*]W\"6J>3'TZ^E>,:'
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M?6MTQ&SH";A&/Z5[QX&A*1KSV%>'>'$+>7M&:]X\%AA$O'.!2D]!H[>BBBL
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M:$![5;N'B&/2I:I6#9B'TJ[6;W&@HHHI#"BBB@ HHHH **** "BBB@ HHHH
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M?+:LQ_\ K5UTZ[74#F!IPW=!5Z#35^48&:TQ9-NZ?I5R&W(-:SQ&@6&VM@B
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MJ]#C.4%1/882X\MLUYEXP^Y+CISBO391F-AZBO./%T+>3)CT-51)D> >)O\
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MA!P*\C$5N@[$ZC:H%+117 6%%%% !1110 4444 %%%% !1110 4444 %%%%
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M5XKHQ'VOMUKVSP6PVJ3CC%- SV#3L_95JW533_\ CV!JW6+W+"BBBD 4444
M,E_U;?2O+O%^?+D^E>HR_P"K;Z5Y;XMQLEZ<"M:8(\*\1$B9N.<U-X5!^U+U
MZBH_$)'G-[&I?"AQ=+TZUH(][\([L*.V*]%C^Y7G?A #8OTKT2+[@K.IL,<W
M*FN*\46Y>"3CG'-=M7.>)8!]DD;'8T4WJ)GS+XQC*R'CJU<; Q648KT/QK:_
MO&&.=U>='Y) H['FM61Y'LOPXN")4YYS7T!83B2%03SBOF/P+?&&2/IQ7ONA
MZEYNS)%920UN=712 Y -+6184444 %%%% !1110 55U!MMLWTJR3@9K"UN_\
MN!E!'%-(3/'?&=SB>3GK7D^KNSN<^OK7=>+KXR7$@XKSF]EWOS6B(.B\,QE]
MN,\FO;_!ENR&/BO(O!5J) I([U[UX6LECC0X[4WL!VJ_='TJ.X)$+8J0=!3)
M_P#4M]*R6YH>=>*LF%B1S7SWXH!^VM]>:^A?%6/(DZ=Z^>?$Q_TZ3VKM6Q)#
MH:_O%/OS7T+X _X]H_K7SSHA_>8..M?0GP_.;>,<<5E/8$>H#[HI:1?NCZ4M
M<Q04444 %%%% #7^X?I7DGQ+)VM[?X5ZV_W&^E>2?$GA'!Z__6JX;B9\[:H3
M]N:NC\);O/C-<[JF/MQZ5TOA-?WJ'WKL6PCZ@\)'.DIGKBN@K \)X.DQD>E;
M]<4]R@HHHJ0"BBB@ K"\3@G3GQZ5NUA^)AG3GZ=*J.XGL?-?CK/F,>XS7GR9
M\P5Z#X[&96/3K7GR_P"M%=70A'JG@?)B3C]:]LT ?<KQ3P/@PQCV%>U:"<,@
MIRV'$[%?NBEI%^Z*6N(LR=;MO-M7/M7S!\0K9DOY"!P*^JM1 -G)GTKYR^(E
MHKS2X'<_SJXZDL\CB++)TYKV7X<WI1HQGT[UY#)$(IC[$UZ!X*O#"R,".,5M
M$I;'TKI5UYB*,]JV*X#P]JC,5&1S7=0R^8N:RG$"6BBBLP"BBB@ HHHH ***
M* "JFH2>7:,?:K=<[XAOO+@9013BKL3/)?'>H%7?GJ,=:\<U&Y9I6/\ 6N]\
M<WS-*PR.E>;3-DY..IKO@M" M\M*I/K7L/PY0_;8\C%>0V@!E7ZU[)\/0/M<
M=*HM ZGO]M_J%^E2U%;?ZA?I4M<+W- ILG^K;Z4ZFO\ <;Z4@/+O&:DQOQWX
MKP7Q "LA..<U[_XTPT+;?6O!?$8_?M]:Z(D,YN"1A(?K7>>%;@_:8AGN*\_0
MX<XQUXKK?#,Y2YBZ=16O+H)GU-X8DW:;&/:MVN%\)ZH3;1J2.F*[B-]Z!O6N
M6<;,I,=1114%!1110 4444 %(YPA-+4-RX2%N>U-;@SRCXA7! DP>:\*UF<M
MN [FO7?B#=_-)R.0:\3U&7=(:Z8NQFR[HD!E?;CC/!KOK/2V>!2!VKE/"4"R
ML,XZUZ_IFDH]LIQVK6,B6>PTM%%><E8V"BBBJ **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@".6,.N,5B7VFAB?E'Y5OTR2,
M.*TIU'%BLC@[_3,J?E''M7-W=CAFPO0>E>G7EJ&!XKF[O3QE\*?RKU</B%U(
M:/.[F H,8P2*SS:$M]:Z^]TUB_"M^55ETQ@>5;\J]6-=&;3.;-F?2D6#:W3]
M*ZH:8?[C?E4#Z4Q.0K?E2=<$8:0G(XZUH06A+#/\JT(=+?(.UNOI6K:::V[E
M3[<5A.LBK%:STW>XX&/I75V%CM0<#CVI+&P*[>#G-;\%MM ZUY^(Q *XZT@V
MH,BKH&!2*,"G5Y<I.3N:I!1114C"BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ K)UV#S;%^.U:U5K]-]HX]J<=Q,^<?%=@1/(VP=3
M7EU]"8[CGUKW_P 4:8SR2D*>_:O&]>L7CE;Y3U]*V:$BGI-[Y4JC=BO4_"^K
M<J"]>,(6A;'(.:['P_J'ER)\W0\\TPL?2&@:@)0IW=JZM3N4&O(?#&KKO0;N
MP[UZC8WJ30KS6<T.Y>HHZBBLQA1110 4444 %%%% !14<DJQ#+'%8UUJR(IY
MII7 T9[A4;ENG:K$,@= 0>M</<:TK2 !\?4UNZ3J"S%1NR#[U30&_1114 8O
MB%<VA.>U?./C@?Z7(<]SVKZ.\1$_9"/:OG#QP3]KD//4UM#8B1Y_&!]I7ZU[
MI\/DW11CVKPM"?M"=>M>[?#PXA0\YQ3Z@SV;3EVVX%7:I:>V8:NUE+<I;!11
M14C"BBB@ K'UPXA//45L5CZVN8#]*J.X'A'C<#][[DUY1'Q<GGOZ5ZOXXZ2_
M4]:\E4'[7WZUH]Q'IW@8_P"E)SW%?1VEC_0(SGM7S;X&YO8SSU%?2.D@C3X\
M^E3,9>HHHK,#@/&=OYJN?Z5X9XHM#&K''3)KZ-\1V?FQG )]:\2\:6)0.<'!
MS7;2>AF[7/+;5_*F//6O1?"5X!=Q*6KS60&*X;KUKI/#5VT=ZF2>M;/5 ?57
MA^826R\]JVZX/PIJR/'$N[G;CK7=(X= P.<UP5%9EH=11168PHHHH **** "
MBD9MHR:RM2U-+<<&FE<#1DD"]^E.C<,N<UQ=QKRY/S?K6EI.L)* N[]:IQT
MZ6BHXI1(,@U)4 !Z5RWB!OD<>U=0>AKE/$(;8V*VH[B9\Z>/0/M3\]2:X* ?
MO1]:[SQZ#]J?.>IK@HO]:O7J*ZA'MGPSP"G->_:=_P >BUX!\,APAY[5[]IO
M_'HM85]BBY1117, 4444 %%%% '#>/,"U8^U?/.NC+NV>IZ5]#>/P6M3C/2O
MG?6S^\DSGK6\-B'N8^C8^U]>]>T^"SD*"?2O%M'_ ./KOUKV;P5SM'/:A >R
MZ8?]& J]5/31BU7Z5<K&6Y84444@"BBB@!DO^K;Z5Y;XM "2\YX]*]2E_P!6
MWTKRWQ?_ *N7KTXK6F"/"_$0'FD9ZFK'A9!]H7GO5;Q%GSFZ]:L^%&/GJ,'J
M*U ]\\(@;%/M7H47^K%>?>$\_)C/2O08_P#5BLJ@#ZS-;@,UB^.PK3JK?KNM
M''/2HB[,#YW\<VI&]L8(/I7DL\>R7)YKW7QU9ED<@'K7BFHQM%-T-;WN9=3;
M\-70AD7YL<U[EX3OQ*T0+9Z5\YZ5<;)>2>O%>O>#]1*F'!Y%2T/J?0$1S&N#
MGBGUFZ3>":U3)Y(K2SGI6+5F:!1112 **** "BBD)P* (KEPD+$FO/O$>H@(
M_P U==K=Z(;8@'M7COB/4]S2?/\ K5I:"9YWXFO,W#G=GVKD3^\F49SFKVM7
M#2W3C)]JIV-O(]PIP>O%4B&>K_#^R)5<C/3M7O>B6GE6Z$@=*\E^'=G^[4D'
MM7MMJ@2V11V%$WH$=635%<?ZEJEJ*X_U#?2LUN:'G7BOB)A]:^>/%'%XPSWK
MZ$\59\MLYKY[\3C_ $U^O%=R6A)#HG^L&.>:^A/ !"VZ'UKY[T7/G+C/6OH7
MP ,VZ<'CUK&>P'J*_='TI:1?NCZ4M<Q04444 %%%% #7^X?I7D?Q*&49B>?_
M *U>N/\ <;Z5Y%\2ON-U_P BKAN2SYXU,?Z<W/>NK\)*#+&,]ZY6_P "_;.:
MZOPB?W\9YZBNOH"/IOPI@:5&H],UOUA>%L?V5&1Z5NUQSW*"BBBI **** "L
M/Q-_R#GY[5N5A^)O^0=)_NU4-Q/8^:_'?^N8$^M>?+S+UKT'QU\TC=<Y->?+
MGS1C-=1"/5/!&/)C->V:" 60YKQ'P03Y:]<5[?H/\'6G+8(G7C[HI:1?NBEK
MB-"&Z3?;.OM7AOCK3BTDAV]?:O=I!N0BO.?%NF^:KMM)X]*N(F?-6J6ODSMQ
MBM3P[=>4ZKNQ5SQ+8E)Y,*:YRQ=H9>_6MX@>Y^%]2#2J-_2O6=*N!)"#G-?.
MGAG4<3+\WZU[)X>U0&-06XP.]*2NAG=T5%;R"6(,.]2US/0 HHHH **** "B
MBD)P,F@""[F$,)8G%>>>)M1 1AOKJ->O@D+ -V]:\@\2ZD6W+N).3WK6"U$S
M@/&%UYL[ /GBN08Y/)]ZWM:W3R%N36 48$Y!XKMB27+$#S5^M>Q_#T?Z;& :
M\=L<><O6O8OA]_Q^1D9I5=AGOT(Q"H]JDJ. DPKGTJ2O.904U_N-]*=39/\
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M !1BEK*4FP2"BBBI&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MKS^RU'8>OZUT5CJ60"3^M<];#-;%*1TM%5H+D.O-6>M<#33U*"BBBD 4444
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M?L\9]:^=M'D*W*X'?FOH7P!(7MD![=*S;T$CU9/N+]*6D3[B_2EKF*"BBB@
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M]<UZU\.;<I>QG&*B4KC1]%VW^H7Z5-4-J,6Z?2IJQ&%-D_U;?2G4V3_5-]*
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MXY(S&?RKOM!T$KLRA_*M33M)Q@F/-==I6GA.3'BBXV3Z79>2B@C&*V*15"C
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MOK5V,T>[6/B*([?WAKJ+#54GP-U?/>B^)&>8+DUZCH6KEV0<YR*SDC6+L>E
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M=<QX5N#+8ID]JZ>L)*S+3N%%%%2,**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *3 -+10 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4F!2T4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@!#T-"YQS2T4 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %13_ZLU+4<P)3 IQW$]C@]>5C&^<_
ME7!3 B8_6O1]?4^4_'UKSRX!\\GWKZ'"O0YYC1G%(YI2<#--/->O29DR)JB
M.:G(SQ3=I)KH3)8*#4V>*9C')I6Z=ZEZF#W$;FD&: ?>G(#3*BA<'TJ.4$C
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M_P!D5ZQI_P#J*X#PA8XM4X/W:]$MDV1 5E4V*)J***Q&%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MAA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%,= P.:?10)JY@7MB2&R.M<CJ>GX;!4UZ/+$KCD5@:G9*P)P*[:-5F;BCS&]
MM=I(VGZUEG<,G'%=I?6.2>!6*^GC<1CBO1IU3+E,;<<[N::2Q'(K3:QP<<8H
M^P5VQK"L9:(2_0\UL6%L78#::EM=/W#.T9!K?L+$+M..IJ*E?0I1U+>FV9&P
MX-=EI\.Q 2*SK&T 51QBMV) B "O%Q5;FT-DB2BBBN$L**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M \G/-8\[XE.?6M6P8&+'>M+: :0Z44B]*6LP"BBB@ I-W.*6H@XWT 2T444
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M[9I1O[FO;M4;;8R'VKYT\:W!^T3?6M(;D3=CSW5G,LI/!K.0'-7+AMYSSUJ
M<&O1HF3D2H/D[5%*#CC%.+$<4]06%=4K-"17MR8Y 3W.*[WPK<%+A<MVKAV4
MH<_TKH?#,["Y49-<-70L^F_"$N^U7GM74UQ7@=R;)1S7:UPSW-(;!1114E!1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M!KU#PI:\K\IZ>E9RU!(]:\*(5A2NR'2N>\-P;( <'%=%64RXA1114%!1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M L'!"DY]ZU[#'FY["HULBJ [3^53P*%D4<YS5= .JM_]2*EJ*W.8AZ8J6LV
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MCN?2KEJI"\TZ=-V/6I$7:M #J*** "HU4[R>U244 %%%% !1110 4R;_ %3
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
J**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>image3.jpg
<TEXT>
begin 644 image3.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 0J NH# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
F*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image4.jpg
<TEXT>
begin 644 image4.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 0J Q$# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
@@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image5.jpg
<TEXT>
begin 644 image5.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 0>!VP# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHI,T +129HS0 M%)FC- "T4F:,T +129H
MS0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1124 %&:2FDT +FDW4PM3"U $NZC?4!>F^90!8WT;ZK>91YE %G?2[ZJ>93
MA)0!:W4N:KAZD#4 2YI:8#3Q0 M%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %)2TAH ::833C3#0!&QJ)FI[U ] "%Z:7IC&HF:@"8
MR4GF56+TF^@"UYGO3E>JF^I%:@"ZK5,K530U84T 65-2BH%-3+0 ^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "DI:3- #33&%24TT
M 5W%0.*M-5=Q0!5>JSFK4E4I30 POS2;JA9N:0-0!8#5,AJH&JQ&: +D9JTE
M4XS5I#0!96IUJNE3J: )**0&EH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "FDT$U [XH D+BDWCUJF\V.]1_:/>@#0WTA<51$_O09_>@"RSCUJ
M!W%0//[U7>X]Z ))7%4)GI9)_>JDDF: !GYI U0LW- :@"TK58C:J >IDDH
MU(WJTCBLE):G6?WH UED%3+(/6LA;CWJ5;GWH UA(/6G!Q6:MQ[U,LV>] %W
M=3LU562I5:@":BF@TZ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M ***2@ S1FDS1F@!U%)2T %%%% !124F:8"TM,S2YH =124M( HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *3-%)FF M+3<TM "T444@"BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "DHI,T +
MFEIN:6@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH ***3- "T4W=2;J 'T4S?2;Z )**CWTF^@"6BH]]+
MNH ?13-U+F@!U%)FEH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BDI": &N>*HSR8JU(W%95U)@&@"O-<8
M/6JWVGGK56YGY/-4_M'/6@#96Y]Z<;CCK60D_O3S-QUH NR7/O55[GWJK)-Q
MUJH\_O0!?:XSWIAES6>)O>I%?- %K=2[JA#4[- $P>G"2J^ZDWT 7!-[T\7'
MO6<9*;YU &J+GWIPNO>L?S_>E$_O0!OQW/O5R*?/>N=AG]ZT8)NG- &['+FK
M*/63%+5^)Z -!#4@J"-N*E!H =129HS0 M%)FEH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BDS2;J '44S=2YH =129HS0 M%
M)FDS0 ZBFYI<T +129I: "BBB@!*:33C3#0 F: :::!0!(*=313A0 M%%% #
M33:<:8:I &:<*CIXIL!XI::*7-0 M%)FDS0 ZBFYI<T +129HS0 M%-S1NH
M=13-U+F@!U%)FEH ***0T (:;2FFFJ0"YI13*<*& ^EI!2U(!1110 4444 %
M%%% !1129H 6BFYHW4 .HIFZEW4 .HI,TM !1110 4444 %%%% !1110 4E+
M2&@!I--S2M3#0 X&GBHA4@H ?1249H 6BDS29H =13<T9H =13<T9H =13<T
MN: %HHHH **** "BBDS0 M%)FC- "T4W-&: '44F:,T +129HS0 M%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MJ9*!+S0!=#4\&JJ/FK"F@"2BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZNHCUJ9+\>M '0I-5F.3-<]%>@GK6C;W.['- &TAS4PJG ^15M: '4AI:0T
M--,)IS4PT *#3Q48IZT /%+2"EH **** "BBB@ HHHH **** "BBB@ HHHH
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M0^E--J?2@"EYC4OF-5G[,?2D^SGTH CCE;-;%E*<BLU8"#TJ_;+M- '3V4W
MK:AN!CK7+VTNT"KRW>T=: .C6Z7UIXNU]:Y=M1Q_%41U4 _>H Z_[8OK2_;%
M]:XX:L/[U/&K#^]0!V NU]:<+E?6N235 ?XJL)J(/\5 '4"<>M/$H/>N>COL
M]ZN176>] &R'S3\U1BES5I6H DIC]*=FF/TH I3M67/)UK0N3UK&N7ZT 5Y9
M*IR/3Y7JJ[T -<\TVD)YH% "@5*@I@J5: )D%3<8J%33]W% "/5=ZE9J@8T
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !2&EI#0!$YXJI*]6)3Q6?.^* *MU)P:YS4#D&MFYDX-8
M=X<YH YR[3+&HK>')Z5<G3)J2UAR1Q0!>LK;('%;L%I\HXJ"P@X'%=#;VWRC
MB@#/%I[4[[)[5L"V'I2_9_:@#&^R>U)]D]JV_L_M2?9_:@#$-G[5&;+VK?\
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MXH U(:OQ5G0FM"(T 6UZ4ZF+TI] !1110 4444 %%%% !1110 4444 %%%%
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M#\AH Y#6'P&KSW6)>6KNM;? :O.-9EY:@#F=0EY/-<U>/G-:]]+DFL&Z?.:
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M3&Z5)3&Z4 9MUT-8-Z.#6]<]ZPKWH: .3U4?*:\\UO\ BKT/5ONFO/-;_BH
M\_U/[YK&;[U;.I_>-8S=: $%+2"EH ;WJ[9_ZQ?K5/O5VS'[Q?K0!Z#X<^\E
M>P^'/NI7C_AP?,E>P>'?NI0!W]I]P5=[52M/N"KO:@"M/]TUS>I]&KI)_NFN
M:U/HU '%:I_%7&:GWKLM4/WJXS4SUH X[4NIKF+K[YKI]2ZFN8NOO&@"GWJ1
M.M1]ZD7K0!<@K7M>U9$%:]J>E '1Z;]Y:[W1.JUP&G'YEKOM#ZK0!Z/H_1:Z
MB'[M<OH_1:ZB'[M $U%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MGO4ZRY[UST%UGO6C#/G'- &IOHS559?>I!)0!-1BF!Q4BD4 -V4NRI1B@XH
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M- '+:J?E->>ZV?O5W^JGY37GVMG[U '!:G]XUBOUK9U/[QK&?K0 E.IHI10
MO>K]F/G7ZU1%:%F/G7ZT =_X='S)7K_AW[J5Y%X='S)7KWA[[J4 =[:?<%7>
MU4[3[@JYVH K3_=-<SJ?1JZ:X^Z:YC5.C4 <3JI^]7%ZF>M=EJI^]7%ZD>M
M'):EU-<Q=??-=+J/4US5U]XT 5.].4U&>M.4T 7H#6M:GI6- :UK4]* .ETX
M_,M=]H9Y6O/M-/S+7?Z$>5H ]*T?HM=3#]VN6T;[JUU$/W10!/1110 4444
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MCC'S4 =NEZ/6IUO5]:XQ-3_VJF75!_>H [);Q?6ITO%]:XM=4']ZIDU4?WJ
M.T6[7'6E-VOK7(KJH_O4_P#M0?WJ .F:Z7UI!=+GK7,?VD#_ !4]-0YZT =;
M%<KZU;2=:Y*'4/>K\=_[T ="9EJ,RBL@7N>]+]K]Z -3>*<'%90N?>I%N?>@
M#5#+06%9XN/>G?:/>@"V6%1.14'G>](9,T (XJ KS4Q.:;B@!T8YJ_"<5305
M:CXH T(FZ5?B:LN)JT(30!H)TJ6H(ZGH **** "BBB@ HHHH **** "BBB@
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MEEKFV;]_70Z0?F6@#N],'"UT4*\5@:4.%KI(1Q0!(!3Q1BEH **** "BBB@
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M@#E[^[^9N:P;B?<3S4M].=[5EO)DT *?F:M*RAW$<5FQ\M6_IJ D4 ;5E9Y
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MTX_,M=[H9Y6O/]./S+7?:&>5H ])T?HM=/%]VN8T?HM=/%]V@!YIN*D(IN*
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M*,T +13<TM "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1110 AII-*:830 N:4&H\TX4 2"EIHIU !1110 4444 %%%% !1110 4444
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MZ5H4> M '<:>G[I:U @Q5&P'[L5I+TH J7$8VGBN-U]!M:NWG'RFN,U\?*U
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M@8OV7CI4$EISTKIULLKTJ-['GI2'8YV&T^<<5T>FV^".*2.QPW2MBSMMI'%
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M!]%(*6@"-NE9>H#]VU:S=*R]0'[MJ /-?$8X>O(]>^^U>O>)!\KUY%KWWVH
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M;WJP9?EZU@QW6.]3F\^7K2&B'4WR&KA]3.6-=-J%UD'FN2OWW,: 95LQF?\
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MU--.IIH 8:2E-)0 X4\4P4\4 .HHHH **** "DI:2@!I%-Q3Z3% " 4X44M
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MMFX[UC7?0T <KJWW6KSG7?XJ]&U;[K5YSKO\5 'GFJ??-8K=:V=4^^:QCUH
M>M./2FK3CTH C:K-I_K!]:JFK5I_K!]: /0?#GWDKV'P[]U*\>\.?>2O8?#G
MW4H [^T^X/I5H]*JVGW!5SM0!3N/NFN8U/HU=1<?=-<MJO1J .)U5OO5QFHO
MUKKM6/WJXS43UH Y?4&ZUS=T?F-=!J!ZUSMR?FH J-UI!UH/6@=: +<'6M>U
M'2LBWZUM6@Z4 =#IH^9:] T(<K7!::/F6N_T,<K2L!Z-H_W5KJ(?NBN8T?[J
MUU$/W13 FHHHH **** "BBB@ IM*332:: ,T9I**8#Z6F TZD M%%(:0#2:C
M+4YJA8T .W4]35?/-2H: )Q12+3J &$4F*?BC% " 4X48HH 6BBB@ HHHH *
M**2@ I*":;F@!]%-S3J %HHHH 0TTTZD- $9IM/(J,T *6XJA>O^[:K+M@5F
M7TG[MJ .+UY_E:O-=6?YVKT#7I>&KS359?G:@!^F-^\%>D^'SPM>7:7)^\%>
MF>'6X6@#T2RYA%%RF0:6PYA%3S)D4 <O?Q9!KC=8BP&KT.\@R#Q7&ZU!@-Q0
M!Y5K2X+5Q5Y_K#7?:]'AFK@KT?O30!57K4Z577K5F.@"914JBF(*F44 &*::
MEQQ4;4 ,SS4J&H">:FBY- %R/-7X <U4@3-:EM#DCB@"];(3BM>"(XJO9V^<
M<5MP6O'2@"%4Q4@P*G>+:*IROMH LJXIXD6LDW0!ZT@O!ZT ;0E6E\U:Q?MH
M]:0WP]: -HS+4;3K6*VH#UJ-M0![T :SSBJTDU9IO<]Z8;G/>@"W))GO520D
MTH?=3Q'NH H2*3562)CZUN?9<]J7[ 3VH YT0-GO5ZVA8$5K#3#_ ':L1Z>5
M[4 16\9 %6RG%2QV^WM4OE<4 9LL=56B.:V6@SVJ![?VH S F*?G J>2/;52
M5L4 5KI^#7.WQSFMFYDZUB79SFF-&%<#YJJD<U?G7FJK)1<HB JS"*AQS5F
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M21P9/2@+%98":F6U8UIV]F6[5JP:86'W:!'-?8V]Z7[*WO77?V0?[M(=)/\
M=H Y'[.WO33"WO75MI1_NU ^F$?PT <R8F]Z;Y+'UKH&TX_W:%TXGM0!S_V5
MCZTTV9QTKJDTPG^&E?2R%^[0!QSVQ':H3%BNFN+#;GBLJ:WVGI0!GJE6$6E\
MO%2*M #2.*K2U;8<53FH 9&WS5UNAR89>:X]3\U=+H\F&6@#UWP_/@+S7H6G
MW'R+S7E.AW& O-=]IUU\J\T =E%+D59#9%8UK/G'-:<;9% $=QT-8UWT-;$_
M0UCW?0T <KJWW6KSG7?XJ]&U;[K5YSKO\5 'GFJ??-8Q'-;.I_?-96/FH %6
MG%>*E1*>T?% %)AS5FT_U@^M1R+S4MJ/W@^M '?^'/O)7L/AS[J5X]X=^\E>
MP^'/NI0!W]I]P5=[52M/N"KO:@"K<?=-<MJHX:NJN/NFN9U->&H X#5E^]7%
M:BO6N]U6/[U<9J4?6@#B=0'6N<N?O5U.I)UKF+H?,: *)ZT+UH/6A>M %VVZ
MUMV8Z5BVW:MNS'2@#I--'S+7?:(.5KA--'S+7>Z(.5H ]$TCHM=/%]T5S&D=
M%KIHONT 344W-&: '4M,S3J  FFEJ&-0LU $A:DW5#OH#4P)LT9I@-+FF \&
MG!JAW4!J0$^:6HE-/%(!K5 PJPPJ)EH A YJ5*;MYJ110!(M24Q:?0 4F*6B
M@ HI**0KAFEI**+C%HHHHN 4E+333 :33,TXTR@!X-/%1"GB@!XI:2EH *2E
MHH 814+U8(J"2@"I*W%8U^_R-6M-TK%OP=AH X37GX:O-M58[VKTG6XV(:O/
M-3MV+GB@"MI1_>"O3_#C<+7FNFP,L@XKT;0#M"YH ]-TX_NA6@P!%8FGW $0
MYK1^U+CK0!%=1@@UQVN1##5UMQ<I@\UR>MS*5;F@#ROQ"GS-7GE^O[TUZ1K^
M&9L5Y_?1$RF@#*4<U9C%(L)S4Z1&@!R"IU%-5,5*.*  CBH7J8FJ\C4 0D\U
M9@Y-4RW-6[8\B@#8M4SBMRSBY%8UH1Q7061&10!N6, XXK>@@&WI638NO%;L
M,B[: *-W'M!KG+Y]I-=+>N"#BN4U$DDXH RI;D@GFH?M1]:AG#;C5;:] %XW
M9]:B>\/K54J]1.KT 6'O3ZU']M.>M4W22F".3- &FMT3WJ=)R>]9D<;U<B1J
M ->W;)%:MNF:R+92,5M6I QF@#0AMP>U7XK('M45LR\5L6S)Q0!773QCI2-9
M!>U;2&/;4,Q3% &&\ 7M47EU>F*YJKN&: &>5FF/",=*LJPI7*[: ,2YCP#6
M)=<9KHKL @U@W<9.: ,2=JS)^<UK30M6?+$:"D9,J<U5=*TY8ZIR)BD,IXYJ
MQ .:B8<U-!UIDLUK4=*Z"Q'(KG[5AQ6[9R $4".RTML%:[+3IL <UP.GW &.
M:Z>RO  .: .RCN..M.-S[U@)?C'6E-^/6@#;:Y]ZA>Z]ZQFOQZU"]\/6@#9^
MU\]:M6]SDCFN6^W<]:NVMZ,CF@#LX)LKUJ*_?]R:SK6\&T<TM[=CR3S0!Q/B
M-_E:O+-8?YVKT;Q%< JW->7ZM)F1J *]MRXKJ=-AW <5RUCRXKN-'BR%H W;
M"VX'%=)90XQQ5*Q@&T5N6\6,4 7K88 JX#Q5>(8%3YH&!J%ZE)J%S0(J3"J;
MCFKDE57JD P"IXZB J9*&!<@ZUKVW:LF#K6M;=JD#6@Z59'2JT'2K(Z4 +11
M10 4444 %%%% !1110 4444 %,:GTTT 0..*R=0'[MJV'Z5DZ@/W;4 >;>(A
MP]>3:[]YJ];\1CY7KR77?O-0!RA'SU?MA5'^.M&U% &C$ORU(5HB^[3FZ4TP
M",?-72:./F6N;0C=71Z.WS+5"/2M"Z+7?V'^K%<!H)X6N_L/]6*EC-,=*@G^
MZ:G'2H9_NFD!QNO#Y6KR3Q&OS/7KVNCY6KRCQ%'R]!2/,;]?WK533@UJ:A$?
M-:LTK@TBB97P*&DJ'=BHW>D YY*KO)3'>H&>J(9(STT')J(M3X^30(U+1<XK
MHK"#..*Q=/3)%=?IEMG;Q2*1L:7;?,O%=[HT.-O%<YIEI]WBNUTN#&.*!LZC
M3UP@J[)]VJ]FN%%3R]*:),RZ/!KF-6;Y&KH[L\&N7U5OE:J&>?:Z?O5YWJ@^
M<UZ%KA^]7GVI_?-2QF(PYI0M./6G@4"9&5XJ%AS5IAQ4#CF@DEM/]8/K7H/A
MS[R5Y_:_ZP?6O0/#GWDH ]@\._=2O0+3[@KS_P ._=2N_M?N"@"YVJK<GY#5
M@GBJ=TWR&@#EM7? :N U>7EJ[;69.&KSO69>6IHI',ZA-R>:YJ\ER36M?S<F
MN>NI.30P*<C9:IH%R:J9R]:=E'N(I"+D$&1TJU]E]JNV=J6 XK1^PG'2@1SK
M6_M4D-OEAQ6N]D<]*?!9G>.*12)+"RW$<5U%EIFX#Y:ATNRY7BNTTZP&!Q0#
M,5=(X^[36TG_ &:[9;!<=*8]@OI3).$DTK_9JE-I?^S7?2V ]*H3V ]* .#D
MTW_9I8]-Y^[75R6 ]*6*P&>E '/Q:7Q]VG3:7A/NUUT-@,=*+BP'EGB@#S/4
M+#;GBN8O;?!/%>EZK9@ \5Q>HVV">* .5:+!I-E:,EN<]*B^SG'2@"@Z\52F
M%:\D!QTK.N(R* ,\?>K=TQ\,*PV&&K3L9,$4 >C:/<8"\UW.FW?"\UY?IESC
M;S79Z9=_=YH ]'L)\XYKH+=LK7&:7<9V\UUEF^5% %B;I6/>=#6O,>*Q[P\&
M@#EM6^ZU>=:[_%7HFK'Y6KSG73]Z@#S[4_\ 6&LQ1\U:>I?ZPUFI]Z@"W$O%
M2LG%-BQBIFQB@#/E7FEMO]8/K3INM);_ .L'UH [WP[]Y*]@\.?=2O'_  []
MY*]@\.?=2@#O[3[@J[VJE:?<%7>U %>?[IKGM17@UT,WW36!J'0T <7J:?>K
MC=4C^]7;ZECYJXW5,?-3 X35%^]7*7@^<UU^JX^:N1O/OFD!G-UI5ZT'K0HH
M NVW45NV?:L*VZBMNT/(I,#J--^\M=YHAY6O/]/D *UVVCW !7FD!Z;I+#"U
MTD3C;7%Z7>* O-=!'?+MZU0&N7%-\P5EF_7UI/MZ^M &N'%.WUCB_7UI_P!O
M7UH T7D%5WE%4GOU]:J27Z^M &EYHSUIZRCUK#^WKGK4J7Z^M &ZL@I2XK)6
M^7'6E-\N.M,#2,@I!**R3?KZT+?*3UI ;:/4ZM6/%=J>]78[@$=: +M-(J-9
M :D!S0 FVG 4M+0 "G4E% "T44AH 2BBDJ26%.IM+2&A:***"A:2EI*L0PTP
MBI"*0B@!E.%)10 \&E!J,&G@T /HI*6@!#43BIJ8PH H2KQ65>194UN.F:IS
MPY!XH X+5;/<&XKB[_3"6/RUZM>66[/%<_=Z4"3\M 'G]MI^QAQ73:</* J=
M].V'[M1$>50!T5O?;$ZU*VJ #[U<F]\4'6J4VJD?Q4 ==/JPQ]ZN?U+4 X/-
M<_-JY_O50EU$O_%0!'JC^86KE;FWW.>*Z&5_,-56MMQZ4 <^+7GI3Q;X[5LF
MT]J:UM@=* ,@Q8J%N*TYH<=JS)QC- $#O5:1Z)7Y-5F8T /W<U:MWY%9V>:L
MPM@T =!:RXQ6W:W&,<URT$N,5HPW..] '9VMX!CFM:+4!CK7!Q7^.]78M2/]
MZ@#K9KK>.M95POF56AO-_>M"%?,Q0!D26A)Z5']A/I73K9!ATI_]GCTH Y7[
M ?2D.G$_PUUHTX>E3)I@/\- '%?V63_#0-)/]VN^32 ?X:?_ &.,?=H X$:8
M1_#4@L2O:NT?2@/X:JRZ>%'2D58YI8MG:ITEV=ZLW4.S/%8MS-L)YH!FY#?
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M>7%>@:(G"UP.E#+K7HVA)PM,#L;&/Y!6Q$E4;%/D6M1%IV D08%/)H IC&I
M1FJ!WH=JKL]4D .U5VI[-41- #Q4R"H5JQ&*5P+< YK6MNU9< YK5MNU(#4A
MZ59'2J\/2K H 6BBB@ HHHH **** "BBB@ HHHH *::=330!$_2LK4/]6U:S
M]*RM0_U;4 >;^(_NO7DFO?>:O6_$?W7KR37OO-0!RO\ '6C:]JSOXZOVQZ4
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M&@HHI:+#"BBBJ 2D(IU(: &&F&I#3"* &BG@TRES0!*#2YJ+=3@: 'T$44M
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MUW>E X6D!VEA*3BNELFR!7+:>.E=/9#@4 ;4?W:>>E,B^[4AZ4 ,- H(I0*
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MFJ1:(U2I1%3T6K2QTF)E/R:C:*M$QU$\=(DSS'2A:L,E,*T ,'%.#8IIIA-
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M**Y+0UPJUV$ ^45)(.M1>7S5HK3=E $:I4RB@+3P* %HHHH ,4444 +1110
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MPCX%=)9K@"L:RCP!6]:KTI :47W:DQ38^E24 1XI0*=BC%  *=24M !1110
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ME,7I3Z "BBB@ HHHH ****5P"BBB@ HHHI@%%%% !1110 4444 )3"*DI,4
M1[: *?BEQ0 @%.HHH **** &D4S;4F*,4 1[:<!3L48H !2T44 %%%% !111
M0 4QNE.ICGB@"C<M@&L.[FP3S6M>-P:YR]<Y- $#W'S=:<DN368SG?5F!B30
M!IIS3C#N[4V#FK\: T 9C6.[M4#Z8#_#72)"I'2GM;+CI0!QDNF@?PU2FT\>
ME=I-;+Z5FSVZ^E '$W-AUXK'N+'GI7<75N.>*Q;F!<GB@#D7L>>E-%C[5OO
M,]*! /2@#"^P>U0R67M72F 8Z56FA'I0!RTMICM6=<6^.U=1<1CGBL:[48-
M'+W4>,UE2-M:MN^ YK N3AJ8%N"ZVGK6S;:EMQ\U<D)2#UJ9;EAWH [=-8('
MWJD_MD_WJXD7C>M/%X_K0!VG]KD_Q4X:@7[UQ\=TQ/6M&WF8XYI@=$LN_O4J
M5GV[$@5HQCBI G2E<_+0O2FR?=H R;WH:YN]ZFNDO.AKG+L<FFBD9+#FE44]
MEYI56J!CE%6$J-5J0"@@G1J?NJ$4[-2QBDTPT[---(!,T;Z:349- $V^EW5
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MTY5J0KS3E6G<&(%IV*D"TI%%Q$=%.Q334@%(324AICL(:C-.--H'8!UJ513
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MMD?WJ .R^UKZT?:U]:XW^V!_>I1K _O4 =E]J7UI?M2^M<>-7']ZG?VL/[U
M'6_:E]:3[6OK7(G5Q_>IAU@?WJ .Q^UKZT?:U]:XW^V!_>H_M@?WJ .R^UK_
M 'J/M:_WJXW^V!_>H_M@?WJ .R^UKZT?:U]:XW^V!_>H_M@?WJ .R^UKZT?:
MU]:XW^V!_>H_M@?WJ .R^UKZT?:U]:XW^V!_>H_M@?WJ .R^UKZT?:U_O5QO
M]L#^]1_; _O4 =E]K7^]1]K7^]7&_P!L#^]1_; _O4 =E]K7UH^UKZUQO]L#
M^]1_; _O4 =E]K7UH^UKZUQO]L#^]1_; _O4 =E]K7UH^UKZUQO]L#^]1_;
M_O4 =E]K7^]2_:U]:XW^V!_>I?[7']Z@#L?M:^M)]K7UKC_[7']ZC^V!_>H
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M/=+C- %!Y,&G)-SUJK.V#422<T ;44U61)Q63%)5M).* +9?-,8YJ,-3L\4
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MG^W#_>IPUL_WJX+^T&]:>+]O6@#O/[;/]ZD.MG^]7$"_;UIIOSZT =N=;/\
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M!QALF]*C-DWI7;'1S_=IO]C'^[3 XL63>E2"R;TKL/[&/]VG#1S_ ': ./\
ML9]*0V3>E=G_ &.?[M']C'^[2 XDV+>E--DWI7<?V*?[M1MHQ_NTP.+^QGTJ
M>&U.1Q74'2"#]VGQZ60?NU5P,VTMCQQ7064!XXJ2VTT@CBMNUL,8XJ6!9TZ(
MC;77:<F *Q[*TQCBNDLH< 4@-:W'RBK:U!"N *L 4 .HHI#0 N:3--)HS0 ^
MEI@-.% "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4TTZFF@!AIN:4TV@!XIXJ,5(* %II%/I,4 5I5XK*N8^M;,@
MXK/G3- '/7$76J$D>*W9XO:LZ:*@#*88IJGFIY4Q5?'- %N(U<0UGQ&KB/0!
M.>E1M1OIA:@!III-!----#0N:>K5#2YIC+2R4_S:J;Z-]22RT9O>F^=[U5+&
MD!-4A%P/FI NZJL9JY'3*0TVX;M436(;M6BF*F4+Z4AF$^E@_P -5WTD?W:Z
MD(N.E-:)?2D!Q[Z2/[M5)=*']VNU>!?2JLMLOI3&<--IG^S6;<:=@'Y:[N:U
M7TK+N;08/%40SSR]L<9XKG;RVQGBO1;ZRR#Q7,WUAG/%(:.&GA(SQ5"6,UUE
MQIQYXK-FTX^E)C9S+H<TL<TT*2I'*Z),FR558@.NX-@^HRJG![@'M6O)IS9Z
M55>Q([5))3(B%NC*\AF+L'0H H7 VD-G)).[(P,8')SPBM4[6Q':H_*(I@.5
MJ>&J/;BEI /+4W=3<TE4BD/W4N:C%/ H8,4U&34A'%0O4B$W5/$<U!-*LL@9
M(4A 55VH6()  +<DG)(R>V2< # $]L,D4P-"WCR170Z;!\XXK*LX<D5U&F6_
MS+Q2$==H46"M>BZ4N$6N(T6'!6N\TU<**:*1HM]VLZY/6M&3[M9ER>M#!F?*
M>:JN:FE;FJS&A$C&-,)I6-,)JA"YJ13S4&:D0\T 6XZN1+56$9K1A2F!;@7I
M6I M4H$Z5HPK4L9:0<5*!34'%25("4M%% !1110 4444 %%%% "&FD4^DQ0!
M"ZY%5)8<]JT"*8R9H Q)K7/:J$UCGM72-$/2H'@'I0!R4VGYSQ5*331G[M=A
M);#TJLUJ/2@#DCI8_NT?V2/[M=7]D7TIWV1?2J0'(_V2/[M)_9 _NUV'V-?2
MC[&OI0P./_LD?W:/[)']VNO^QKZ4?8U]*0'(_P!DC^[2_P!DC^[77?8U]*/L
MB_W:H#DAI0_NTO\ 9?\ LUU?V1?2C[(/2I8')G2A_=IITD?W:Z[[(OI1]D']
MVD!QQTD?W:8=)_V:[(V:^E1FS7TH X_^RAG[M.&DC^[76?8QGI3Q9KZ4 <F-
M)']VG?V2/[M=:+-?2G?9%]* .0_LD?W:3^R1_=KL/LB^E'V1?2@#D/[)']VC
M^R1_=KK_ +(OI1]D7TH XXZ2/[M,.E?[-=D;-?2HS9KZ4 <?_90_NTX:3_LU
MUGV,>E/%FOI0!R@TD?W:/[)']VNO%FOI2_9%]* ./_LD?W:4:2/[M=?]D7TI
M19KZ4 <D-(']VG_V0/[M=:+-?2GBT7TH XXZ2/[M-.E#^[79&T7TJ,VB^E '
M(?V5_LTX:2/[M=7]D'I4BVB^E ')?V0/[M(=(']VNQ^R+Z4AM%]* .+.DC^[
M2#21_=KL39KZ4T6:^E ')C2!_=I_]D#^[76K:+Z4_P"R+CI0!QQTD?W::=*'
M]VNQ-HN.E,-HOI0!R']E?[-/&DC^[75BT7TIZVB^E ')?V0/[M(=(']VNQ^R
M+Z4AM%]* .+.DC^[3?[)']VNR-FOI3?LB^E ''_V2/[M']DC^[78?9%]*/LB
M_P!V@#C3I(_NTPZ4/[M=B;-?2F&S7TH Y :4/[M2#21_=KJQ9KZ4\6:^E ')
M_P!DC^[2_P!DC^[77BT7TH^QKZ4 <?\ V2/[M']DC^[78?9%]*/LB^E '(?V
M2,?=I/[)']VNP^QKZ4&T7TH XTZ2/[M1G2A_=KLC9KZ4PV:^E '(C2A_=IXT
MD?W:ZL6:^E2"S7TH Y+^R1_=I?[)']VNO^R+Z4?8U]* ./\ [)']VC^R1_=K
ML/LB^E'V1?2@#C_[)']VE_LD?W:Z_P"QK_=H^R+Z4 <A_90_NTO]E?[-=;]C
M7TI?LB^E ')C2A_=IPTD?W:ZP6B^E2"T7TH Y#^R!_=I#I(_NUV/V1?2F-:+
MZ4 <<=*']VD_LK_9KKS:+Z4GV1?2@#D/[)']VC^R1_=KKOL:_P!VE^R+Z4 <
MA_90_NTO]E?[-=;]C7TI?LB^E ')C21_=IXTD?W:ZL6B^E2"T7TH Y#^R!_=
MIITD?W:[(VB^E,-HOI0!QQTH?W:3^RO]FNN-HOI1]D7TH Y#^R1_=H_LD?W:
MZ[[(O]VE^R+_ ': .0_LD?W:7^RO]FNM^QKZ4?9%]*AC.4&DC^[3AI(_NUU@
MM%]*>+1?2D!R']D#^[2'21_=KL3:+Z4PVB^E4A''G2A_=I/[*_V:ZXVB^E)]
MD7TJ@.1_LD?W:/[)']VNO^R+_=H^R+_=H Y'^RA_=H_LK_9KKOLB^E'V1?2@
M#D?[)']VC^R1_=KKOLB^E+]D7^[5(#D/[)']VC^RA_=KKOLB_P!VC[(OI0P.
M2&E#^[3QI(_NUU0M%]*D6T7TJ0.3_L@?W:B?21_=KM/LB^E1R6:_W: .%?2N
M?NU&NF8/W:[*2S&>E0?8QGI3 P8=.QVK1@LL=JTX[4#M5N.W [4@*UO:XQQ6
MM;Q8Q210@=JN1IB@":,<5+35%/H 2FFG&FF@!AI,TIIM #Q3Q3!3Q0 ZBBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MD-+2&@!A%-Q4F*3% " 4\4F*44 +1110 QQQ525,U<-1,N: ,J6*LZ>*MV2.
MJ%Q%0!ST\=4F7!K8N(ZS9$P30!"IQ4HDQ4#<5&7Q0!=$E+NJFLE3*U $V:0T
MF:2@ I,T&FFF.XNZC=41-*#3L(E'-/"TB#-3JM  @Q4Z-BH\8II;%*XRZLN*
MD6<#O6:9<4TSX[T#-@7 ]:D$P/>L,7/O5B*?/>F!K;@:8X!J&.3-39S3&5)8
M\U0G@SGBM9ES4+Q9ID,YFYL]V>*Q;G3=V?EKN'M=W:JSZ>&[4F"//)M()_AJ
ME+HQ_NUZ2VE _P -0/I _NU(SR^;1C_=K,N-**Y^6O5Y]'&#\M85]I0 /RT"
M/,+BP*YXK.DML=J[N^T_&>*P+JTQGBG81S,D>*KMUK5N8<$\5FR)S18"*EQ2
MA34@2@M#56I%6G*E2JE ,A*\57D%7V3BJLJT6)(KRY^UW"R^1!!MBCBVP)M4
M[$5-Q']YMNYCW8D]ZL6:Y(JEMYK4T],L*0SH=.@SCBNNTVV^[Q6'I4&=O%=I
MIMMPO% [&[I4.-O%=C8KA17/:=#C'%=):C"B@18E/RUD73=:TYFXK'NFY- B
MA*W-0$TZ1N:BS3L &F&G4QJ8[#":DB/-0,>:DA/S4KB-:V&<5K6Z5F68SBMR
MV3@47 LPITJ]$M11)5I%I 2KTIU(*6D 4444 %%%% !1110 4444 %%%% !2
M4M)0 TBHV6IJ810!5=*A,=6V6HRM %<1T\1U*%IX6F!#Y8I/+]JL;:-M,"OY
M7M1Y7M5C;1MI 5_+]J/+JQMHVT[@5O+]J/+]JL[:-E)@5O+]J7RZL;:-M("J
M8_:F&+VJ[LII2@"GY7M3A%[59\NEV4 5Q'3O+]JL!*-M %?RZ/+JQMHVT 5_
M+H\NK&VC;0!5,7M3#%[5<*4A2@"GY7M3A%[59\NEV4 0".E\NK&RC;0!7\N@
M1U8VT;: (A'3ME2A:7;0! 8Z88ZM;::5H K>73A'4VVG!: (ME(8ZGVT;: *
MICI/+JSMI-M $0CIVRI0M+MH @,=,,=62M)MH K".GB.I=M."T 1;*0QU/MH
MVT 53'2>75G;2;: *_ETGEU9VT;: *AB]J88O:KI2F^70!4$7M3Q%[58\NG!
M* *XCI?+]JL;*-M %?RZ/+JQMHVT 5_+]J0QU9VT;* *AB]J88O:KI2F^70!
M4$7M3Q%5CRZ<$H @\NCR_:K&VC;0!7\NCRZL;:-M %?RZ/+JQMHVT 5O+]J/
M+]JL[:-M $ CIXCJ4+3MM $.P4TQU8VTA6@"J8Z3R_:K.VC;0!6\OVI?+JQM
MHVT 5O+]J/+]JL[:-M $ CIXCJ4+3MM $)04PQU9VTA6@"J8_:D\OVJSMHVT
M 5O+]J/+JSMHVT 5O*]J3RO:K6VC;2 KB.I!'4H6G;:5@(/+IICJSMI"M- 5
M#'[4>7[59VT;:8%;R_:E\NK&VC;0!6\OVH\OVJSMHVT 5O+]J7RZL;:-M4!7
M,=)Y?M5G;1MH K"/VIXCJ;;3@M2!%L%,>/VJSMIK+0!G/%[5%Y//2M%HZ9Y7
M- %18?:IUCJ81T\)0 U$J=12!:D H <*6D%+0 4TTZDH C(I,4_%&* $ IXI
M *44 +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 F*,4M% "8I:** "BBB@!*0BG44 0,E4YX^M:)%59ES0!A
M7$76LN:/K703QUFSP]>* ,*52*IOD&M>>+VK.ECYH @4G-6$:H=N#3U.* +(
M:G9J -3P: 'TPT\4A%- 1&A>M/*T!>:H1/'5E<8JLG%2AJ3&2,>*@=J>S5"Q
MJ0(W<U SFI6J%EIH:$$AS5N"0Y%4PO-6(N*H9K0OQ5Q6R*S(FQ5M)*0RWUHV
MBHE>I U.Y#)!&#3Q"IJ(28IPF [TF!+]G0T?9$/:D6<>M3+*#4@49[)-IXKG
MM0L5P>*ZV0@K6/>1ALTT!Y[J-CUXKF;VQ//%>C7MINSQ6#=Z?G/%4A'FUW9'
MGBL>:S;=TKT6ZTO.?EK*FTDY^[3 XK[(V>E/6U;TKJ6TLC^&F'3B/X:12.=6
MV/I4JVY]*V_L/M2_8O:D-F&T!QTJC/"?2NGDM..E9]Q:]>*9)SGE'=6QID)W
M+Q49MOFZ5L:9;<KQ4@CI]'M_N\5V^G6V%7BN?T:VX7BNVL;?"#BF47;2/:!6
MO"0!5")=HJP),"DQ,EG?@UCW+=:N32^]9L[Y--"*;GYJ:*5NM*HIC2#%1N*L
MA:8Z4F44F'-20#YJ<R<U+ GS5)+-:R7I706J<"L6R7I706J\"@1;1:F I%%/
M% "BEHHH **** "BBB@ HHHH **** "BBB@ HHHH *:13J2@",BF[:D(I,4
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M ?1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4E+10 F*3%.I,4P#%%+12 **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH C--Q4A%-Q0  4\4@%.% "TM%% !1110 E--/IIH B-)3R*;B@!13Q3*7-
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MTT&E% "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4E+10 E%+10 E!I:* &D4W%/HQ0 W%.HQ10 QA4#IFK1%,*T
M 43%0(O:KFRCRZ *HBI?+JULHV4 5?+H\NK6RC90!5\NCRZM;*-E %;RZ7RZ
ML;*7;0! $IP6I=M+MH 8%IX%+BEQ0 @IU)2T %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4F*6B@!,48I:* $Q1BEHH 3%&*6B@!,48I:*
M $Q1BEHH 3%+110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
..4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>sc2.jpg
<TEXT>
begin 644 sc2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  <%!08%! <&!08(!P<("A$+"@D)
M"A4/$ P1&!4:&1@5&!<;'B<A&QTE'1<8(BXB)2@I*RPK&B O,R\J,B<J*RK_
MVP!# 0<(" H)"A0+"Q0J'!@<*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ
M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BK_P  1" !9 -T# 2(  A$! Q$!_\0
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MBGT+ 4GVF#_GM'_WV*\GN=!TG5O'/BF75-.MKN1+V)$:9-Q5?L\9P/;-2?\
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M?!_C1_Q5'_0G77_@?!_C0!=S1FJ7_%4?]"==?^!\'^-'_%4?]"==?^!\'^-
M%W-&:I?\51_T)UU_X'P?XT?\51_T)UU_X'P?_%4 5/%W_(DZW_UX3?\ H!KT
MS3/^03:?]<$_]!%>8:W8>*]5\/ZAI\7A&XC>ZMGA5FOX"%+*1D_-TYKU*QB:
M'3[>*08=(E5A[@4AD]%%% !1110 4444 %%%% !1110 4444 %%%% !1110
:4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>sc4.jpg
<TEXT>
begin 644 sc4.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  <%!08%! <&!08(!P<("A$+"@D)
M"A4/$ P1&!4:&1@5&!<;'B<A&QTE'1<8(BXB)2@I*RPK&B O,R\J,B<J*RK_
MVP!# 0<(" H)"A0+"Q0J'!@<*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ
M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BK_P  1" #G %@# 2(  A$! Q$!_\0
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M444 %%%% !1110 5BZ_>6VFS6=[/I=]?S1LPB-E 96CR.21D<$5M5F:MK/\
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M1P[C_JP" 1CN"!SGBN,UR^T[3];N--74[V73)-36>XM[72S*5N"X?9Y^<#+
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>sc.jpg
<TEXT>
begin 644 sc.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  <%!08%! <&!08(!P<("A$+"@D)
M"A4/$ P1&!4:&1@5&!<;'B<A&QTE'1<8(BXB)2@I*RPK&B O,R\J,B<J*RK_
MVP!# 0<(" H)"A0+"Q0J'!@<*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ
M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BK_P  1" ); !<# 2(  A$! Q$!_\0
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M!$-X)S8SBT($_EMY1;H&QQ^M>._9=2MO$&EFZN=;GN9KN!VA:<M$&$A$F0.
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>F4#A@.Q]17H5% $<$(M[=(D)*H, L<FBI** /__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
